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Surface plasmon peak shifts observed for the oxidation of various RGD/NLS-
AuNCs incubated in cell culture medium for up to 48 h. (A) Sample 1 (2.56 
Ag:Au) exhibits an 84 nm redshift after 48 h. (B) Sample 2 (2.34 Ag:Au) exhibits 
a 63 nm redshift after 48 h. (C) Sample 3 (1.78 Ag:Au) exhibits a 37 nm redshift 
after 48 h. 
 
Figure 3.21……………………………...…………………………………….………..127 
Apoptosis and necrosis induced in HSC cells by 48 h treatment of 0.1 nM 
RGD/NLS-AuNCs with varying porosity and Ag content (Samples 1-3). All 
nanocage-treated samples have statistically higher levels of apoptotic and necrotic 
cells (p < 0.05) than the untreated cells (control). Remaining data are considered 
statistically significant if p < 0.05, and is indicated by * above bars. 
 
Figure 3.22……………………………...……………………………………………...137 
TEM images of AuNPs synthesized via citrate reduction of HAuCl4. (A) AuNPs 
with diameter of 29 + 4 nm, inset showing size distribution histogram. (B) AuNPs 
with diameter of 14 + 1 nm, inset showing size distribution histogram 
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Figure 3.23………………………………...…………………………………………...143 
Cell cycle analysis of HSC-3 cells after treatment with various AuNPs (0.4 nM, 
24 h) and 5-FU (100 µM, 48 h). Cells that were not treated (white), cells treated 
with AuNPs alone (yellow), cells treated with 5-FU alone (light gray) and cells 
treated with combination of AuNPs and 5-FU (dark gray). Comparison between 
AuNP size: (A) 30 nm NLS-AuNPs versus (B) 15 nm NLS-AuNPs. Comparison 




5-FU efficacy in HSC-3 cells after treatment with various AuNPs (0.4 nM, 24 h) 
and 5-FU (100 µM, 48 h). Control represents cells that were not treated with any 
AuNPs. Cells that were not treated with 5-FU (light gray) and cells that were 
treated with 5-FU (red). 5-FU efficacy defined as % cells in S phase divided by % 
cells in G2/M phase of the cell cycle. 
 
Figure 3.25………………………………………………...………………………..….147 
Cell viability determined by an XTT assay of HSC-3 cells after treatment with 
various AuNPs (0.4 nM, 24 h) and 5-FU (10-500 µM, 48 h). Cells that were only 
treated with 5-FU (control, black) and cells treated with a combination of AuNPs 
and 5-FU (red). Comparison between AuNP size: (A) 30 nm NLS-AuNPs versus 
(B) 15 nm NLS-AuNPs. Comparison between AuNP surface functionalization: 
(A) 30 nm NLS-AuNPs versus (C) 30 nm RGD-AuNPs. Statistical significance 
between cells treated with only 5-FU and cells treated with combination of 
AuNPs and 5-FU is indicated by * (p < 0.05). 
 
Figure 3.26……………...……………………………………………………………...150 
Flow cytometry analysis of HSC-3 cell death after treatment with 0.4 nM NLS-
AuNPs (24 h), 150 µM 5-FU (48 h) or 0.4 nM NLS-AuNPs (24 h) followed by 
150 µM 5-FU (48 h). Right panel shows necrotic cells (red), late apoptotic cells 
(dark blue), early apoptotic cells (light blue) and live cells (green) for cells that 
were untreated (c), treated with 150 µM 5-FU for 48 h (5-FU), treated with 0.4 
nM 30 nm AuNPs for 24 h (Au) and treated with 150 µM 5-FU (48 h) after 24 h 
pre-treatment with 0.4 nM 30 nm NLS-AuNPs (Au + 5-FU). Statistical 
significance with respect to the control is indicated by * (p < 0.05) within the bars 
of the graph. Statistical significance with respect to different treatment groups 
indicated by * (p < 0.05) above graph. 
 
Figure 4.1……………………...…………………………………………………….…162 
UV-Vis spectra of AuNRs (black) as well as the NIR cw laser spectrum (red) 
(with corresponding TEM images, scale bar: 60 nm). (A) 38 x 11 nm AuNRs with 
longitudinal plasmon resonance at 740 nm. (B) 28 x 8 nm AuNRs with 
longitudinal plasmon resonance at 770 nm (C) 14 x 5 nm AuNRs with 
longitudinal plasmon resonance at 755 nm.  
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Figure 4.2…………………………………...………………………………………….166 
Photothermal heat conversion factor determined, per particle, for 17 x 5 nm 
AuNRs (17 nm, blue), 28 x 8 nm AuNRs (28 nm, yellow) and 38 x 11 nm AuNRs 
(38 nm, gray) at increasing NIR laser irradiation time. All initial temperatures 
were 24 + 1 °C. Statistical significance (p< 0.05) indicated by *. 
 
Figure 4.3…………………………...…………………………………………….……168 
Field contour plots for the longitudinal mode of the different AuNRs, with 
particle dimensions indicated and the field decaying to 1.25 at the extremities of 
each plot. (A) The field maximum of the 38 x 10 nm AuNR (calculated at 804 
nm) is 3500. (B) The field maximum of the 25 x 7 nm AuNR (calculated at 761 
nm) is 5220. (C) The field maximum of the 18 x 4 nm AuNR (calculated at 875 
nm) is 5480 
 
Figure 4.4……………………………………………………………………...……….171 
DDA extinction (black dots), absorption (red line) and scattering (green line, and 
shown in inset) spectra for the longitudinal mode of the different AuNRs in water. 
(A) The 38 x 10 nm AuNR has an absorbance:scattering ratio of 63.8. (B) The 25 
x 7 nm AuNR has an absorbance:scattering ratio of 204. (C) The 18 x 4 nm 
AuNR has an absorbance:scattering ratio of 921. 
 
Figure 4.5……………………………...……………………………………………….173 
Temperature change induced by plasmonic photothermal heating of different 
AuNRs (17, 29=8 and 38 nm in length) at different optical densities (0.5 and 1.5) 
and increasing NIR laser irradiation times. All initial temperatures were 24 + 1 
°C. Statistical significance between different sized AuNRs and optical densities at 
2 min laser irradiation (p < 0.5) is indicated by *. 
 
Figure 4.6…………………………………...……………………………………...…..175 
Temperature change of cell culture medium containing different AuNRs. AuNRs 
38 nm in length at OD 0.5 (light gray), AuNRs 28 nm in length at OD 0.5 
(yellow), AuNRs 17 nm in length at OD 0.5 (blue) and AuNRs 38 nm in length at 
OD 1.5 (dark gray) were all exposed to upon NIR laser irradiation at increasing 
lengths of time. All initial temperatures were 32 + 1 °C. . Statistical significance 




Cell viability determined for HSC cells treated with different AuNRs and 
subjected to PPTT via NIR laser irradiation. Cells treated with AuNRs 38 nm in 
length at OD 0.5 shown in light gray, AuNRs 28 nm in length at OD 0.5 shown in 
yellow, AuNRs 17 nm in length at OD 0.5 shown in blue and AuNRs 38 nm in 
length at OD 1.5 shown in dark gray. Statistical significance (p< 0.05) indicated 
by *. Statistical significance with respect to control (no AuNRs) indicated inside 





TEM image (A), size distribution (B), and UV-Vis spectrum (C) of AuNRs about 




Structure of HNSCP peptide conjugated to AuNRs for specific targeting of 
squamous cell carcinoma of the head and neck. Peptide provided by Raftery, E. 
and Sotimehin, A. (Georgia Tech). 
 
Figure 4.10……………………………...………………………………………...……192 
Pharmacokinetic properties, in terms of the blood circulation half-life (t1/2) in 
healthy mice. (A) The t1/2 is 12.8 h for PEG-AuNRs and (B) 8.5 h for HNSCP-
AuNRs, as calculated by fitting the data to a one-phase decay model. Conjugated 
particles were provided by Mackey, M.A. and Ali, M.R.K. (Georgia Tech). 




Biodistribution profile of PEG-AuNRs and HNSCP-AuNRs 24 h following iv 
injection to nude mice bearing Tu212 xenografts. (A) Accumulation of AuNRs in 
brain, heart, lung, kidney and tumor. (B) Uptake of AuNRs by RES (i.e. 
accumulation in the liver and spleen). Conjugated particles were provided by 
Mackey, M.A. and Ali, M.R.K. (Georgia Tech). Biodistribution profile was 
provided by Peng, X. (Emory University). 
 
Figure 4.12………………………………………...………………………………...…195 
Tumor volume measurements with respect to time after treatment of nude mice 
bearing Tu212 xenografts. Control (black) mice (n = 3) were directly injected 
with 100 uL of PBS. Laser control (red) mice (n = 3) were directly injected with 
100 uL of PBS and exposed to NIR radiation (5.8 W/cm
2
, 2 min). HNSCP-AuNR 
control (blue) mice (n = 3) were directly injected with 100 uL of HNSCP-AuNRs, 
such that final concentration in tumor was 2.25 nM. HNSCP-AuNR laser 
treatment (green) mice (n = 6) were directly injected with 100 uL of HNSCP-
AuNRs, such that final concentration in tumor was 2.25 nM and exposed to NIR 
radiation (5.8 W/cm
2
, 2 min). Conjugated particles were provided by Mackey, 
M.A. and Ali, M.R.K. (Georgia Tech). Photothermal treatment and tumor size 




Real time imaging of cancer cells incubated with 0.4 nM cytoplasm targeting gold 
nanoparticles (RGD-AuNPs) (a) and 0.1 nM nuclear targeting gold nanoparticles 






Cell cycle time of cancer cells and normal cells with treatment of AuNPs. The cell 
cycle of cancer cells was extended by about 4 h with treatment of 0.1 nM 
RGD/NLS-AuNPs; but no changes with RGD-AuNPs treatment. The cell cycle 
time of normal cells have no change under both RGD-AuNPs and RGD/NLS-
AuNPs. For cancer cells, 0.4 nM RGD/NLS-AuNPs induced cell cycle arrest, 
which make the whole cell cycle observation unavailable. The cell cycle time here 
is defined from the division of parent cells to the division of 2
nd
 generation cells 
(daughter cells). Four individual cell cases were taken for each data point to 
obtain an average value. The * indicates p < 0.05 and NS indicates not significant. 
 
Figure A.3……………………………………...…………………………………...….203 
Release dynamics of cancer cells (left) and normal cells (right) initially 
synchronized at prometaphase. Cells are synchronized to prometaphase with 
nocodazole and then released in fresh medium. At different time points of release, 
DNA content was measured using flow cytometry. 
 
Figure A.4……………………………………………...……………………………....204 
Apoptosis induced by the presence of AuNPs at the nucleus of cancer cells. Cells 
were incubated with AuNPs for 24 h before analysis. The red box indicates 
sample with subG1 cell population (i.e. apoptotic cells). 
 
Figure A.5………………………………………………………………………….......205 
Cell cycle changes induced by 0.1 and 0.4 nM peptide-conjugated gold 
nanoparticles in HSC cells after 48 h treatment with RGD-AuNSs (A), NLS-
AuNSs (B), RGD-AuNCs (C) and NLS-AuNCs (D). Values expressed as mean + 
standard deviation of three independent experiments. Statistical significance, with 
respect to control, indicated by * (p < 0.05). 
 
Figure A.6………………………...……………………………………………………206 
Raw data obtained from flow cytometry cell cycle analysis for all nanoparticle 
treatments tested in this work. Cell cycle histograms, not filled in, represent the 
raw data, including the subG1 population, indicative of an apoptotic population. 
SubG1 populations appear in HSC cells treated with 0.1 nM RGD-AuNC, 0.4 nM 
RGD-AuNC, 0.4 nM RGD-AuNS, 0.4 nM NLS-AuNS, 0.4 nM RGD/NLS-
AuNS, and the greatest subG1 population in 0.4 nM RGD/NLS-AuNC. Cell cycle 
histograms, filled in, represent how the data was fit, after gating single cells and 
eliminating the subG1 populations, to obtain G0/G1 (green), S (yellow) and G2/M 
(blue) phase populations. 
 
Figure A.7……………………………...…………………………………………...….207 
Peptide-conjugated gold nanoparticle-induced cell death, via apoptosis (A) and 
necrosis (B), in HSC cells after 48 h treatment with RGD-AuNSs, RGD-AuNCs, 
NLS-AuNSs, and NLS-AuNCs. Values expressed as mean + standard deviation 
of three independent experiments. Statistical significance, with respect to control, 





HaCat cell death via apoptosis (left) and necrosis (right) induced by all 
nanoparticle formulations. All nanoparticle formulations induce minimal cell 
death in the HaCat cells compared with the HSC cells. This was expected, as the 
HaCat cells do not overexpress the alpha beta integrins on their surface.
1
 Values 
expressed as mean + standard deviation of three independent experiments. 
Statistical significance, with respect to control, indicated by * (p < 0.05). 
 
Figure A.9……………………………………...……………………………………....208 
ROS generation detected by confocal microscopy for 0.4 nM RGD-AuNCs, 
RGD-AuNSs, NLS-AuNCs, and NLS-AuNSs. DAPI panel (left) shows the nuclei 
of HSC cells stained blue. FITC panel (middle) represents green fluorescence 
indicative of ROS generated inside cells. DAPI/FITC overlay (right) shows the 
combination of both nuclei and ROS. The 0.4 nM RGD-AuNCs and NLS-AuNCs 
display FITC fluorescence, indicating ROS are generated in HSC cells with this 
nanoparticle treatment. Scale bar: 20 µm. 
 
Figure A.10……………………...…………………………………………………..…209 
Uptake analysis of 5-Fluorouracil (5-FU) in HSC-3 cells after cells were pre-
treated with 15 nm NLS-AuNPs (light gray) or 30 nm NLS-AuNPs (dark gray). 5-
FU uptake was determined by measuring the optical density (OD) of cell culture 
medium containing 5-FU, after 48 h treatment, with a Biotek Synergy H4 multi-
mode plate reader. The measured OD was converted to a concentration by 




 (determined by 
measuring various concentrations of 5-FU in cell culture medium). This 
concentration was then subtracted from the treatment concentration initially added 
to cells. Pre-treatment with NLS-AuNPs does not appear to enhance the uptake of 
5-FU by HSC-3 cells. 
 
Figure B.1………………………………………………………………………….…...210 
Field contour plots at the resonance wavelength for the longitudinal mode of (A) a 
38 x 10 nm AuNR at a wavelength of 786.  The field maximum is 5560. (B)A 25 
x 7 nm AuNR at a wavelength of 757 nm.  The field maximum is 5320. (C) An 18 
x 4 nm AuNR at a wavelength of 865 nm,  The field maximum is 5760.  For all 
cases, the particle dimensions are indicated on the axes and the field has decayed 
to a value of 1.25 at the extremities of the plot.  At the resonance condition, there 
is less than 10% difference between the maximum field enhancement values for 
the different sized AuNR, not corresponding to the experimental results. 
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Gold nanoparticles exhibit an array of properties, both intrinsic and extrinsic, that can 
be exploited for their use in cancer therapeutics. Owing to their size and ease with which 
they can be functionalized with various ligands, gold nanoparticles represent a class of 
highly functional biomedically relevant nanostructures. Chapter 1 introduces the reader 
to the synthesis and functionalization of various gold nanostructures. Intrinsic properties 
of these gold nanostructures are also discussed in this chapter, to lead to Chapter 3, 
where the recent exploration of these properties is presented. Extrinsic properties of gold 
nanostructures are also introduced, to prepare the reader for Chapter 4, in which recent 
developments in the exploitation of these properties are presented. Chapter 2 presents 
the reader with a detailed explanation of experimental protocols for the various in vitro 
methods utilized throughout our work.  
Chapter 3 discusses recent developments in the use of gold nanoparticles as intrinsic 
antineoplastic agents, with their ability to cause DNA damage and cytokinesis arrest 
(Chapter 3.1), to suppress tumor growth (Chapter 3.2), to induce apoptosis in a metallic 
composition-dependent manner (Chapter 3.3 and 3.4), as well as their ability to enhance 
sensitivity to chemotherapy by regulation of the cell cycle (Chapter 3.5). 
In Chapter 4, the extrinsic properties of gold nanoparticles are examined, in detail, 
through both theoretical and experimental assessment (Chapter 4.1) for their use as 
photothermal contrast agents in vitro. Based on this assessment, the gold nanoparticles 
are tested in the plasmonic photothermal therapy of head and neck cancer in a mouse 
model (Chapter 4.2).  









, 1971, US President Nixon declared a “War on Cancer,” with the 
signing of the National Cancer Act, which aims to eradicate cancer as a major cause of 
death through increased research to develop more effective treatments and improvements 
in the understanding of cancer biology. One research area that is currently being used to 
achieve this is that of understanding the interactions between materials and 
cellular/molecular components on the most elemental level of biology, also referred to as 
nanotechnology. The heart and soul behind this area of research is US National Cancer 
Institute’s Alliance for Nanotechnology in Cancer. With this program, new 
nanotechnologies are being developed and, through active collaborations between 
researchers, they are being successfully applied in the diagnosis and treatment of 
cancer.[1] Many, in fact, have already been approved or are in the pre-clinical and 
clinical trial stages of development.[2, 3] 
Among the many types of nanotechnologies, gold nanoparticles, in particular, exhibit 
unique properties that can be utilized in this “War on Cancer.” When conjugated with 
specific ligands, they exhibit properties distinctive from both the particle scaffold and 
their parent molecule. Gold nanoparticle conjugates can show increased binding affinity 
and targeting selectivity when functionalized with multiple targeting groups,[4] as well as 
tumor-selective uptake due to their size.[5] These particles can be delivered systemically, 
demonstrating minimum immunogenic responses[6] and long circulatory half-lives.[7] 
They also possess unique optical and electronic properties which can be exploited in 
cancer-selective photothermal therapeutic applications[8-12] or non-invasive diagnostic 
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imaging.[13-16] Their intrinsic size, shape, and surface reactivity can further be used to 
direct and selectively modify cellular processes associated with malignant 
progression.[17-20] Gold nanoparticles represent a versatile, potent, selective, and highly 
multi-functional anti-cancer nanotechnology.  
 
1.1. Gold Nanoparticles: Design and Biocompatibility 
 
1.1.1. Gold Nanoparticle Synthesis 
Common applications of gold nanoparticles involve the use of spherical gold 
nanoparticles in drug delivery and antineoplastic treatment applications. Small (10 nm in 
diameter) gold nanospheres are synthesized from the citrate reduction of aqueous 
chloroauric acid. A representative TEM image of gold nanospheres is shown in Figure 
1.1A. The synthesis of colloidal gold, first observed by Faraday[21] in 1857, generally 
involves the reduction of a metal salt in the presence of a stabilizing agent. Following the 
advent of the transmission electron microscope (TEM), Turkevich later surveyed a 
variety of synthetic methods to obtain gold nanoparticles[22] and in 1973, Frens 
systematically developed methods for synthesizing gold nanospheres of varying diameter 
via the citrate reduction method.[23] The resulting nanoparticle sizes are controlled by 
the stoichiometric ratio of gold to reducing agent, with larger ratios leading to larger 
diameters. In this case, citrate also acts as an anionic capping agent which stabilizes the 
colloidal solution by electrostatic repulsion. 
Gold nanorods, similar to those shown in Figure 1.1B, are synthesized via seed-
mediated growth.[24] In this method, small seeds (3-5 nm in diameter), capped by an 
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amphiphilic, cationic surfactant are synthesized from the reduction of aqueous 
chloroauric acid by borohydride. An aqueous chloroauric acid growth solution, 





 by the addition of ascorbic acid. The seeds are then introduced into the growth 
solution, acting as nucleation sites for the anisotropic reduction of Au
+
 ions onto the 
seeds, forming rod-shaped particles over the next several hours. Although the widths of 
the nanorods formed by this method are fairly constant, lengths can be extended by 
increasing the amount of silver nitrate. Murphy and coworkers and El-Sayed and 
coworkers further adapted and optimized the surfactant-directed method for solution-
phase growth using the seed-mediated method.[25] Later, Murphy and coworkers 
developed a seedless growth method, which produced gold nanorods that were much 
smaller in size (length and width) than those synthesized via see-mediated growth.[26] 
El-Sayed and coworkers further modified this method, by achieving simultaneous seed 
formation and nanorod growth using only sodium borohydide as a reducing agent. This 
method produces the smaller gold nanorods in large scale and high monodispersity.[27] 
Gold nanocages, like those shown in Figure 1.1C, make up another class of 
biomedically-relevant gold nanoparticles. Over the past several years, Xia and coworkers 
have developed a variety of solution-phase techniques for the synthesis of hollow-core 
noble metal nanoparticles, based on the galvanic displacement method.[28, 29] This 
technique relies on the use of a metal nanoparticle template from which atoms are 
displaced for another metal. The precursor nanoparticle is comprised of a less noble 
metal, (e.g. Ag) such that the addition of ions of a more noble metal (e.g. Au, Pt, Pd) will 
spontaneously replace the ions of the precursor nanoparticle. Gold nanocages are 
  4 
 
synthesized by reacting silver nanocubes with Au
3+
 ions. Because the reduction potential 
of gold is more positive (i.e. more energetically favorable) than silver, atoms from the 
silver nanocube are spontaneously oxidized (i.e. displaced) as gold ions are reduced onto 
the precursor nanoparticle surface. In this case, because gold reduction is a three electron 
process and silver oxidation is a one electron process, voids are created in the newly 
formed cuboid structure as three silver atoms are exchanged for one gold atom. 
Displacement proceeds according to the availability of surface sites on the template 
particle, forming a subsequent cage-like gold structure. 
 
 
Figure 1.1. Transmission electron microscopy (TEM) images of common biomedically 
relevant gold nanostructures. (A) Gold nanospheres synthesized via citrate reduction. (B) 
Gold nanorods synthesized via seed-mediated growth. (C) Gold nanocages synthesized 
via galvanic replacement. Scale bar: 100 µm. 
 
 
1.1.2. Gold Nanoparticle Conjugation 
The gold nanoparticle surface represents one of the most stable and easily 
functionalized platforms for molecular conjugation. Au surfaces can be functionalized 
with a variety of organic self-assembled monolayers (SAMs) (e.g. thiolates, dithiolates, 
amines, carboxylates, cyanides, isothiocyanates, phosphines, etc.) to allow stable 
dispersion of particles in both aqueous and organic media. In most cases, ligation is 
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spontaneous at room temperature and occurs over the millisecond to minute time scale 
for commonly used alkanethiols.[30] Packing and reordering of the SAM can occur over 
several hours and place exchange of the monolayer can also be performed to 
functionalize gold nanoparticles with mixed monolayers or fully exchanged SAMs of 
targeting, therapeutic, or stabilizing ligands, as well as heterobifunctional linkers to 
which such molecules can also be appended. Molecular coverages on a gold surface can 




, however in practice, coverages are typically an 
order of magnitude less.[31] Multivalent nanoparticle conjugates exhibit cellular 
interactions distinct from their parent ligands or particles. Similar to antibodies, 
nanoconjugate binding affinity (Kd) can be enhanced by simply increasing the density of 
targeting ligands on the particle, in some cases increasing the affinity up to 4 orders of 
magnitude.[32] The circulatory half-life of hydrophobic drugs can also be significantly 
increased by functionalization with hydrophilic nanoparticles.[7] The intracellular 
transport rate of molecules which passively diffuse into the cell can be enhanced by 
endocytosis of their nanoparticle conjugates,[33] the intracellular localization of drugs 
can be directed by cell-penetrating peptides or nuclear localization sequences,[34] and 
endosomal accumulation or degradation can be circumvented by proton sponge groups or 
photothermal heating[35] of the particle. Targeting selectivity, tumor accumulation, and 
therapeutic response of the nanoparticle conjugate can be further enhanced using multiple 
targeting groups (i.e. multimodal targeting).  
Biocompatibility of gold nanoparticle conjugates is also an important aspect of their 
design. Physiological environments exhibit high ionic and serum concentrations which 
can disrupt and diminish the stabilizing capacity of many nanoparticle ligands. 
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Nanoparticles are considered stably suspended if the working distance of their repulsive 
forces outweighs that of their attractive forces. Attractive forces are generally attributed 
to van der Waals interactions and repulsive forces are generally associated with charge–
charge (i.e. electrostatic) or physical (i.e. steric) separation. Because of the high ionic 
concentration present in both physiologic fluids and cell growth media, electrostatic 
repulsion alone is often insufficient to overcome Debye charge screening and subsequent 
nanoparticle aggregation. Physical separation using hydrophilic polymer ligands is 
common practice and allows stable suspension of the particles in environments of both 
high ionic strength and serum concentration. Poly(ethylene glycol) (PEG) is the most 
common surface ligand used to stabilize nanoparticles, especially in the case of gold 
surfaces via thiol linker. PEG consists of hydrophilic poly(ethylene oxide) repeats and 
can be branched if increased stability and size are needed. Gold nanorods have, for 
example, exhibited circulatory half-lives as high as 17 h in nude mice when 
PEGylated.[7] Other common polymer stabilizers for gold nanoparticles include: 
poly(lysine) (PLL), poly- (styrene sulfonate) (PSS), starches, and poly(vinylpyrrolidone) 
(PVP). Functionalization with such polymers not only increases hydrophilicity, but also 
decreases immunogenic response from the nanoparticles, as well as their recognition and 
subsequent removal by the reticuloendothelial system (RES) through minimizing 
adsorption of proteins and molecules (i.e. opsonins) which initiate phagocytic uptake. 
Together, these strategies serve to maximize circulatory half-life and, thus, tumor 
accumulation by active or passive targeting strategies. 
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1.1.3. Gold Nanoparticle Accumulation, Uptake and Clearance 
One particular advantage of anti-cancer gold nanoparticle conjugates is their size-
selective accumulation at tumor sites due to the enhanced permeability and retention 
(EPR) effect.[36] Malignant cells require larger amounts of nutrients in order to sustain 
their accelerated growth and division. To meet this demand, solid tumors stimulate the 
production of new vasculatures through which increasing amounts of blood can be 
supplied (i.e. angiogenesis). In contrast to normal vessels, the angiogenic neovasculature 
is characterized by a highly disordered endothelium with large gaps that permit the 
penetration of nanosized conjugates. Characteristically diminished lymphatic drainage 
from the tumor interstitium also serves to increase retention of such compounds at the 
tumor site, resulting in both improved penetration and decreased clearance of circulating 
nanoparticle conjugates. These characteristics are demonstrated by the illustration shown 
in Figure 1.2. 
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Figure 1.2. Graphic illustrating enhanced permeability and retention (EPR) effect 
exploited by gold nanoparticle conjugates to achieve selective accumulation at tumor 
sites. Gold nanoparticle conjugates penetrate leaky vasculature of blood vessels and 
diminished lymphatic drainage allows for retention of gold nanoparticle conjugates 
within the tumor interstitium. Adapted from Dreaden, et. al.[37] 
 
The optimal size for EPR of a gold nanoparticle conjugate varies depending on the 
stage, location, and type of cancer, however particles with a hydrodynamic diameter 
(HD) greater than the renal clearance threshold (about 6 nm) and up to 2 mm in HD can 
be expected to exhibit preferential tumor accumulation. Passively[38, 39] (e.g. EPR) and 
actively[38-40] targeted gold nanoparticles, for example, have exhibited as much as 2–
5% and 6–13% tumor accumulation, respectively, from systemically administered 
particles in vivo. Although most gold nanoparticle conjugates are capable of exhibiting 
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some degree of intracellular penetration, particle size, charge, and lipophilicity also play 
critical roles in determining the extent of uptake. Chan and coworkers have studied the 
size and shape dependent uptake of gold nanoparticles by cervical cancer cells (HeLa) 
and found that size dependent internalization peaked at a 50 nm diameter and that the 
uptake of colloidal nanorods decreased with increasing aspect ratio.[41] In another study, 
shown in Figure 1.3, using immunoglobulin G (IgG) antibody gold nanoparticle 
conjugates, they further found that multivalent functionalization of smaller gold 
nanoparticles did not enhance uptake due to their decreased ability to occupy multiple, 
receptor binding sites and that larger particles, although capable of multivalent receptor 
binding, were too large for membrane wrapping (i.e. engulfing) necessary for efficient 
endocytosis.[42] Particles conjugated to antibodies of an epidermal growth factor 
receptor (EGFR) exhibited the greatest uptake into breast cancer cells (SK-BR-3) and 
therapeutic response when 40–50 nm gold nanoparticles were used. 
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Figure 1.3. Size-dependent receptor-mediated endocytosis of IgG-gold nanoparticle 
conjugates by breast cancer cells. (Left) Schematic illustrating that 2 nm particles do not 
bind multiple receptors and therefore are not efficiently internalized by cells, as shown by 
fluorescence images of nanoparticles on surface of cell. (Middle) 40 nm particles do bind 
multiple receptors and are therefore efficiently taken up via endocytosis, as shown in 
fluorescence images. (Right) 70 nm particles also exhibit simultaneous binding to 
multiple receptors, but are too large for efficient internalization by cells, as shown in 
fluorescence images.  In fluorescence images, the nuclei are stained blue and the particles 
are represented by red fluorescence. Scale bar: 10 µm. Adapted from Dreaden, et. al.[37] 
 
Although the optimal particle size for intracellular penetration obviously varies 
depending on the cell size, type, receptor density, metabolic activity, as well as the 
specific targeting strategy employed, this study nonetheless highlights the importance of 
therapeutic nanoparticle conjugate size in determining subsequent transport kinetics and 
treatment efficacy. Cationic zeta potential (i.e. positive surface charge) can also promote 
the uptake of nanoparticle conjugates due to electrostatic attraction with anionic 
phospholipids on the cell surface. In some cases however, this attraction can result in 
significant cytotoxicity due to membrane disruption. The pharmacokinetic clearance of 
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circulating gold nanoparticle conjugates is also of key importance to subsequent 
efficacy.[43] Cationic nanoparticles exhibit high propensity for urinary (renal) clearance, 
due to electrostatic attraction with the net negative charge of the capillaries that separate 
circulating blood from urinary filtrates. Although efficient renal clearance is sometimes 
desirable, cationic nanoparticles can exhibit poor circulatory half-lives due to 
electrostatic attraction with the negatively charged laminar surfaces of the blood vessels. 
Anionic nanoparticles, on the other hand, often exhibit decreased cell penetration. 
Nanoparticle opsonization and phagocytic uptake are typically lowest when particles 
possess a neutral zeta potential and contain hydrophilic polymers which shield 
hydrophobic-hydrophobic and/or electrostatic interactions with antibodies and serum 
proteins.[44]  
Circulating nanoparticles which cannot be filtered by the renal system are captured 
and degraded by Kupffer cells or allowed to proceed to the liver where they are 
metabolized by (or internalized by) hepatocytes and excreted into the bile. Cho et al. have 
recently studied the size-dependent in vivo accumulation and clearance of intravenously 
administered, PEGylated (5 kDa) gold nanoparticles in nude mice.[45] They found that 
larger gold nanoparticles (100 nm versus 4 and 13 nm in diameter) exhibited shorter 
circulatory half-lives and more rapid RES accumulation, accumulating predominantly in 
the liver and spleen, rapidly reaching maximum accumulation at 30 min and persisting 
for 6 months. In contrast, the smaller gold nanoparticles accumulated predominantly in 
the liver, spleen, and lung, reaching peak accumulation at 7 days and persisting up to 6 
months. Very low urinary excretion of the small gold nanoparticles was shown over 1 
day post-injection and only nominal renal clearance of the large particles was observed. 
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Very low biliary excretion was also shown for both large and small particles from 1–4 
weeks, however the majority of the particles remained accumulated in the RES organs. 
Acute toxicity has been observed with the in vivo administration of polymer stabilized 
gold nanoparticles, but long term toxicological investigations, specifically with respect to 
maintenance of RES organ function, is urgently needed in order to accelerate the clinical 
translation of these therapeutic nanotechnologies. 
 
1.2. Intrinsic Properties of Gold Nanoparticle Conjugates 
 
1.2.1. Anti-Proliferative Effects 
Gold nanoparticle conjugates can exhibit intrinsic antineoplastic properties, much like 
chemo- and radio-therapy. The selective regulation of cell growth and division by gold 
nanoparticles can serve as a potent anti-cancer treatment strategy. The extent of tumor 
growth and malignant progression is highly dependent on the formation of new blood 
vessels, angiogenesis, a process primarily mediated by signaling associated with vascular 
permeability factor/vascular endothelial growth factor 165 (VPF/VEGF-165). Selective 
inhibition of VPF/VEGF-165 activity is one method by which angiogenic growth can be 
mitigated in anti-cancer treatments. Mukhopadhyay and coworkers have recently studied 
the effects of spherical gold nanoparticles on VEGF-165-dependent proliferation in 
human umbilical vascular endothelial cells (HUVEC).[20] Their results showed that 
these gold particles significantly inhibited VEGF-165-induced cell proliferation of 
HUVEC cells (5 nm in diameter, citrate-capped, 335–670 nM, 24 h). Using X-ray 
photoelectron spectroscopy (XPS), they found that the gold nanoparticles bound directly 
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to the heparin-binding domain of VEGF-165 through sulfur and/or nitrogen bonds, an 
interaction which significantly inhibits VEGF-165’s ability to associate with cell surface 
receptors necessary for angiogenic signaling and proliferation. Further, they showed that 
gold nanoparticles had no effect on signaling/proliferation associated with a non-heparin 
binding growth factor, VEGF-121. The group later explored the ability of gold 
nanoparticles to inhibit VEGF-165-induced angiogenesis and vascular permeability in 
vivo, observing a significant reduction of angiogenic activity in ovarian tumor-bearing 
nude mice when the gold nanoparticles were intradermally administered (2 x 10 µL of 
670 nM).[19] A significant decrease in vascular permeability was also observed 
following injection of the gold nanoparticle mixture, combined effects which could be 
potentially applied in future anti-cancer treatments. 
 
1.2.2. Cell Cycle Regulation 
Because malignant cells are increasingly sensitive to cell cycle disruption and also 
less capable of repairing such damages, gold nanoparticles can be used as cancer-
selective cytotoxic agents for the selective modulation of the cell cycle. Xing and 
coworkers have explored changes in the cell cycle and sensitization to radiotherapy in a 
radiation-resistant human prostate carcinoma cells line (DU-145) treated with glucose-
capped gold nanoparticles (10.8 nm in diameter) in vitro.[17] The glucose-gold 
nanoparticle conjugates were shown to arrest the prostate cancer cells at the G2/M phase 
of the cell cycle, the phase in which cells are most sensitive to radiation damage (15 nM, 
2 h). Accumulation of the cells in G2/M was shown to result from upregulated expression 
of cyclin E protein, a promoter of the so-called cell cycle ‘‘checkpoint kinase’’, which 
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regulates the transition from G1 to S and accelerates progression through G1 (1.2 fold 
upregulation, 24 h; 1.5 fold upregulation, 48 h). Radiosensitization of prostate cancer 
cells treated with glucose-gold nanoparticle conjugates is expected to increase the 
efficacy of subsequent radiotherapy treatments and to minimize adverse side-effects by 
lowering threshold exposure levels. Because cancer cells are increasingly sensitive to cell 
cycle disruption and DNA damage, gold nanoparticles which induce such effects can be 
selectively delivered to malignant cells or administered at dosages below that necessary 
to damage normal tissues to achieve oncologic effect. 
 
1.3.  Extrinsic Properties of Gold Nanoparticle Conjugates 
 
1.3.1. Optical Properties 
Metallic conductors are characterized by their delocalized free electrons whose 
density can vary in response to an externally applied electromagnetic field. Just as solid 
materials exhibit vibrational modes associated with the collective oscillations of their 
atoms, metallic solids also exhibit collective oscillatory modes of their free electrons (i.e. 
plasmon modes). Free electrons in noble metals exhibit plasmon oscillation frequencies 
in the mid- to far- UV, but the electrons on the nanometer scalen are less restricted and 
can oscillate at near-UV, optical, NIR, and IR wavelengths. Incident electromagnetic 
fields (i.e. photons) can couple with surface plasmon modes of similar frequency, leading 
to their absorption or scattering. Surface plasmon resonance results in the local increase 
of resonant electromagnetic fields over several orders of magnitude. Surface plasmon 
absorption occurs rapidly, dephasing on the femtosecond time scale, dissipating absorbed 
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energy by coupling to adjacent electronic systems or to atomic lattice vibrations. 
Subsequent phonon–phonon relaxation occurs on the picosecond time scale and results in 
highly localized heat generation.[46] The wavelength of a nanoparticle’s surface plasmon 
resonance depends on the metal, as well as its size, shape, and dielectric environment. 
Plasmonic metals include Li, Na, K, Mg, Al, Fe, Cu, Ag, Pt, and Au. Of these, gold is the 
only nanoscale metal which exhibits both inert reactivity and plasmon resonance which is 
red shifted sufficient to avoid significant attenuation by tissues and fluids in physiological 
environments. Increased size can serve to red shift gold’s surface plasmon resonance, but 
with increasing size, absorption also diminishes due to increased scattering, a property 
which can often be disadvantageous. Although the dielectric environment surrounding 
circulating and tissue-accumulated nanoparticles is fairly constant, surface plasmon 
resonance can also red shift significantly with increasing dielectric permittivity and 
refractive index. By synthetically varying the shape of gold nanoparticles, the plasmon 
resonance can be shifted to higher tissue penetration wavelengths.  
 
1.3.2. Photothermal Contrast Agents 
Photothermal therapy (PTT) is a cancer treatment method which, like chemotherapy, 
relies on the selective application or the increasing sensitivity of cancer cells to cytotoxic 
damage-in this case from heat, or hyperthermia. A wide variety of electromagnetic 
radiation sources can be used in these treatments, applied in whole-body procedures or 
focused to specific regions of interest, where it is absorbed and dissipated as heat by 
physiologically relevant molecules, such as melanin and water, or by photothermal 
contrast agents which can be directly applied to solid tumors or intravenously 
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administered and accumulated at malignant sites by active and/or passive targeting. 
Although the methodology has gained some degree of popularity in Europe, it is not yet 
widely applied clinically in the US. Current clinical and preclinical PTT trials using gold 
nanoparticle contrast agents, however, are rapidly progressing (e.g. CytImmune, 
Nanospectra Biosciences). Photothermal therapies involving plasmonic gold 
nanoparticles can be categorized based on the mechanisms by which they achieve cell 
death. Mild temperature increases of 3–6 °C (i.e. hyperthermia) often trigger apoptotic 
pathways and are well known to alter a variety of normal cellular functions, resulting in 
denaturation of proteins/enzymes, induction of heat-shock proteins, metabolic signaling 
disruption, endothelial swelling, microthrombosis, diminished vascular supply, impaired 
receptor recognition, dysfunctional membrane transport, and inhibited nucleotide 
synthesis.[47, 48] In addition, the ability of malignant cells to repair such damages is also 
decreased, compared to normal cells. Larger, more rapid temperature increases, often 
termed ‘‘ablative’’ treatments, occur via necrotic cell death. In these cases, disruption of 
the cellular membrane is often predominant, with subsequent physical destruction of 
organelles also occurring. Gold nanoparticles are currently being explored as contrast 
agents for anti-cancer PTT (i.e. plasmonic photothermal therapy, PPTT) because their 
absorption cross sections and photostabilities are far superior to traditional molecules 
such as indocyanine green. Treatments can include focused and fiber optic-guided laser 
excitation of primary tumors, and can be particularly advantageous in treating tumors in 
areas poorly accessible by surgery. With absorption by physiological fluids and tissues 
(e.g. hemoglobin and water) being minimal in the near-infrared (NIR, 650–900 nm) 
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region, the absorption maxima of therapeutic and diagnostic gold nanoparticles are 
synthetically tuned to this ‘‘NIR window’’  shown in Figure 1.4).[49]  
 
Figure 1.4. Wavelength range (650-900 nm) of the near-infrared (NIR) tissue 
transmission window. (A) Absorption from physiologic components, such as 
oxy/deoxyhemoglobin and water is minimal in this range. (B) This allows for maximum 
NIR laser penetration depths. Photothermal contrast agents are designed to absorb in this 
wavelength range to allow for maximum penetration depth of external radiation through 
biological tissues. Adapted from Dreaden, et.al.[37] 
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Microwatt NIR lasers (FDA class 1) can, for example, efficiently penetrate as much 
as 4 cm through the skull/brain and deep muscle tissue and up to 10 cm through breast 
tissue. Higher power lasers (FDA class 3) have exhibited 7 cm penetration depths through 
muscle and neonatal skull/brain tissue, as well. In PPTT applications, gold nanorod, 
nanoshell, and nanocage absorption is tuned by synthetically varying the aspect ratio, 
shell thickness:core radius, and the extent of galvanic displacement, respectively. PPTT 
using gold nanoparticles was first demonstrated in vitro by Lin and coworkers in 
2003.[50] Here, spherical gold nanoparticles were conjugated with IgG antibodies that 
target CD8 receptors on peripheral blood lymphocyte cells. Using nanosecond pulsed 
visible laser exposure, 95% of cells containing as few as about 500 particles/cell were 
killed, due to apparent membrane disruption. Our lab later demonstrated the use of 
continuous wave visible laser exposure in PPTT of oral squamous cell carcinoma cells 
treated with spherical gold nanoparticle conjugates of EGFR IgG antibodies.[51] Benign 
cells were found to require more than twice the energies required to kill malignant cells 
due to increased antibody–nanoparticle conjugate labeling and PPTT response from the 
cancer cells. Halas and West later applied silica–gold core–shell nanoparticles (gold 
nanoshells) in near-infrared PPTT, correlating in vitro treatment response with in vivo 
efficacy.[52] Breast carcinoma cells specifically labeled with PEGylated gold nanoshells 
were shown to be efficiently destroyed by cw NIR laser exposure (7 min, 35 W/cm
2
, 5 
mm spot size). The nanoshells were later injected into the tumor interstitium of scid mice 
bearing sarcoma xenografts. Using magnetic resonance imaging (MRI), NIR laser 
exposure was directed about the tumor site (< 6 min, 4 W/cm
2
, 5 mm spot size). Based on 
the temperature-dependent MRI frequency shift of protons in the tissues, intratumoral 
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temperature changes were three dimensionally mapped in real time, showing average 
temperature increases of 37.4 + 6.6 °C in nanoshell treated PPTT, which resulted in 
significant coagulation, cell shrinkage, and loss of nuclear staining, as shown by 
histological analysis. NIR PPTT using systemically administered gold nanoshells was 
later demonstrated using a colon cancer model.[53] PEGylated gold nanoshells were 
intravenously injected in carcinoma-bearing nude mice and their tumors were exposed to 
cw NIR laser radiation after 6 h (3 min, 4 W/cm
2
, 5.5 mm spot size). Tumors in 
nanoshell-treated mice were completely ablated after a single PPTT treatment and the 
animals appeared healthy and tumor free 490 days post treatment. In contrast, tumors in 
control animal groups continued to grow, with nearly 50% of the animals dying after 10 
days. El-Sayed and coworkers later demonstrated in vitro NIR PPTT using gold nanorods 
which can more efficiently absorb photons to generate heat.[54] Anti-EGFR conjugates 
of gold nanorods were found by dark-field light scattering microscopy to selectively label 
oral squamous cell carcinoma cells which overexpress EGFR on their cell surface. 
Similar to experiments with gold nanospheres, cw laser NIR PPTT found that malignant 
cells required nearly half the energy necessary to kill nonmalignant cells, due to their 
increased nanoparticle labeling and subsequent membrane disruption from the treatments. 
As seen in Figure 1.5, The group later showed the use of both systemically and locally 
administered gold nanorods in in vivo NIR PPTT .[48]  
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Figure 1.5. In vivo near-infrared (NIR) laser plasmonic photothermal therapy utilizing 
gold nanorod contrast agents. PEGylated gold nanorods were intravenously and locally 
injected in carcinoma-bearing nude mice. (A) NIR imaging indicated significantly 
increased NIR extinction of gold nanorods accumulated at the tumor sites, with direct 
injection showing higher accumulation of AuNRs than tail vein injection. (B) The change 
in tumor volume was determined over the course of two weeks, after single NIR laser 
exposure, and exhibits a significant decrease in tumor volume for the nanorod-treated 
tumors compared with the controls. Adapted from Dreaden, et.al.[37] 
 
 
PEGylated gold nanorods were intravenously or interstitially administered in nude 
mice bearing squamous cell carcinoma tumors. The gold nanorods exhibited efficient 
accumulation and enhanced NIR absorption at the tumor site following administration by 
both methods. After a single cw NIR laser exposure, nanorod treated tumors exhibited 
dramatic growth remission (10 min, 1–2 W/cm
2
, 6 mm spot size). Greater than 57% of 
the directly-injected tumors and 25% of the intravenously-treated tumors were 
completely resorbed after 13 days. Bahatia and coworkers later showed that the intrinsic 
X-ray absorbing properties of gold nanorods (double that of clinical iodine standards) can 
  21 
 
be used to guide NIR PPTT and increase the treatment efficacy.[7] Using X-ray 
computed tomography (CT) and contrast from tumor-accumulated gold nanorods, they 
were able to noninvasively image and three-dimensionally reconstruct tumor xenograft 
margins in nude mice models. Subsequent NIR PPTT achieved complete tumor 
resorption and 100% survival of the nanoparticle treated group (1 min, 0.75 W/cm
2
, 1 cm 
spot size) while tumors in untreated control groups grew uncontrolled with less than 1 
month survival. In 2007, Xia and coworkers first demonstrated the use of gold nanocages 
for contrast in in vitro NIR PPTT.[55] Nanocages conjugated to antibodies of the human 
epidermal growth factor receptor 2 (HER2) were used to selectively target breast cancer 
cells overexpressing HER2 on their cell surface. Cell destruction using pulsed NIR laser 
exposure was observed at a minimum power density of 1.5 W/cm
2
 (5 min, 2 mm spot 
size). Using similarly synthesized hollow-core, spherical gold nanoparticles, Li and 
coworkers have studied in vitro NIR PPTT using anti-EGFR conjugates of the hollow 
gold nanoparticles, as well as their in vivo biodistribution following intravenous 
administration[40] Squamous cell carcinoma cells, overexpressing EGFR, were found to 
be selectively labeled and photothermally destroyed using cw NIR laser exposure (5 min, 
40 W/cm
2
, 2 mm spot size). Intravenous administration in tumor bearing nude mice 
resulted in predominant RES organ (i.e. liver, spleen, and kidney) accumulation. Tumor 
accumulation was found to be as high as 6.5% of the initial dose with predominant 
perivascular localization. Targeted NIR PPTT of melanoma tumors using hollow gold 
nanoparticles was further studied in animal models by the same group using an agonist 
ligand of a melanocortin type-1 receptor, overexpressed by melanoma cells.[38] 
Biodistribution studies following 24 h of intravenous circulation found significantly 
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enhanced tumor accumulation by the active targeting strategy (13% versus 5%). 
Histological analysis following NIR laser exposure (1 min, 0.5 W/cm
2
, 1 cm spot size) 
determined a significantly enhanced necrotic response from nanoparticle treated tumors 
(66% versus 8% in control). Positron emission tomographic (PET) imaging also indicated 
dramatically decreased metabolic activity in nanoparticle treated tissues, but not in sham 
or control tumors. Xia and Wang have further demonstrated that the NIR absorption 
properties of nanocages and other plasmonic gold nanoparticles can be used to 
noninvasively image tumors for surgical or PPTT guidance, as well as to assess the stage 
and location of primary melanoma tumors in vivo by photoacoustic tomographic 
imaging.[56] Also using a ligand of the melanocortin type-1 receptor, they showed that 
systemically administered nanocages can be preferentially targeted to melanoma tumors, 
allowing about 40% enhanced imaging contrast and actively targeted tumor 
accumulation. 
Determining the optimal gold nanostructure for NIR PPTT can be highly subjective 
due to the numerous ways in which such analyses can be performed. Structures can be 
compared based on their absorption cross sections, absorption efficiencies, or thermal 
transduction efficiencies on a per particle, per unit gold, per unit mass, or per unit 
extinction basis. Gold nanorods have been shown to exhibit much larger and narrower 
NIR absorption cross sections and efficiencies than either nanoshells or nanocages.[57, 
58] Experiments comparing NIR thermal transduction from solutions of equivalent 
optical density (i.e. extinction) found gold nanorods and AuS2–Au nanoshells to be much 
more efficient photothermal contrast agents than SiO2–Au nanoshells.[58] Per unit mass 
gold, nanorods have exhibited 1/3 the spectral bandwidth, about 3-fold higher extinction 
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cross section, and 6 times greater heating capability than SiO2–Au nanoshells in NIR 
laser photothermal experiments.[7]  
 
1.4. Conclusions and Future Outlook 
Gold nanoparticles present tremendous opportunities for the design of next-
generation, multimodal anti-cancer treatment strategies. Due to their multivalency and 
functional versatility, these particle conjugates can exhibit increased targeting selectivity, 
augmented binding affinity, long circulatory half-life, high biocompatibility, rapid 
transport kinetics, and size-enhanced tumor uptake. The optical and electronic properties 
of gold nanoparticles can further provide high contrast in photothermal therapeutic 
treatments. The intrinsic biomolecular interactions of gold nanoparticles can additionally 
provide cancer-selective cytotoxic activity. Together, these properties comprise a highly 
multifunctional platform on which increasingly selective and potent oncologic treatment 
methods can be designed. These new nanotechnologies will ultimately aid in fighting the 
“War on Cancer,” now and in the future. 
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DETAILED EXPERIMENTAL METHODS 
 
 
2.1. Methods of Gold Nanoparticle Design 
 
2.1.1. Gold Nanospheres 
 Spherical gold nanoparticles are synthesized via citrate reduction of HAuCl4, as 
developed by Frens[1] Briefly, 50 mL of a 0.01% (w/v) HAuCl4 aqueous solution is 
brought to a boil, while stirring, followed by addition of a trisodium citrate aqueous 
solution. For gold nanospheres with about a 30 nm diameter and a surface plasmon 
resonance at about 530 nm (shown in Figure 2.1A), 1 mL of 1% (w/v) trisodium citrate is 
added to the HAuCl4 solution, while for those 15 nm in diameter and a surface plasmon 
resonance at about 520 nm (shown in Figure 2.1B), 1 mL of 2% trisodium citrate (w/v) is 
added. Reaction completion is determined by the color changing from clear to a deep 
red/purple. The AuNSs are then purified by centrifugation at 6000 rpm for 15 min and 
redispersed in water. 
  
  31 
 
 
Figure 2.1. Gold nanospheres synthesized via citrate reduction of HAuCl4. TEM images 
(left), size distribution histograms (middle) and UV-Vis spectrum (right) of 30 nm 
AuNSs (A) and 15 nm AuNSs (B). 
 
2.1.2. Gold Nanocages 
Gold nanocages (AuNCs), with a wall length of about 40 nm, are synthesized via 
galvanic replacement reaction with silver nanocubes as a template, where silver atoms of 
a silver nanocube template are oxidized by Au
3+
, which is subsequently reduced and 
deposited onto the surface of the template.[2] The silver nanocube template is prepared 
by a previously reported method.[3] Briefly, 70 mL of ethylene glycol (EG) is heated to 
150˚C for 1 h, followed by the addition of polyvinyl pyrrolidone (PVP, MW 55,000; 0.82 
g dissolved in 5 mL EG). While still at 150˚C, 0.7 mL of a 3 mM sodium sulfide solution 
(in EG) is added, followed by slow injection of 4 mL of a silver nitrate solution (0.48 g 
dissolved in 10 mL EG). [4, 5] The reaction is allowed to proceed to completion (10-15 
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min) resulting in the reduction of silver ions to silver nanocubes. The silver nanocubes 
are purified by adding a 1:2 acetone/water mixture at a volume two times that of the 
nanocube solution, centrifuging at 14,000 rpm for 5 min and redispersing the precipitate 
in 200 mL of DI water. The silver nanocube solution is brought to a boil under reflux, 
after which a 10 mg/L hydrogen tetrachloroaurate (HAuCl4) solution is slowly injected 
and the UV-Vis spectrum of the solution is monitored until the absorption maximum red-
shifts from ca. 440 nm (silver nanocubes) to ca. 600 nm. Once the initial peak shift is 
observed, a 1 mg/L HAuCl4·3H2O solution is added drop wise until the peak redshifts 
and remains constant at desired the wavelength. Addition of the dilute HAuCl4 solution 
causes a decrease in silver content (remaining silver on the inner cavity of the AuNC) due 
to the replacement of silver atoms with gold atoms.[4] Figure 2.2 displays the UV-Vis 
spectra for various AuNCs (A-C) after increasing addition of HAuCl4. The TEM images, 
as well as the schematic show the structure of these AuNCs. The AuNCs are then purified 
by centrifugation at 14,000 rpm for 5 min and redispersed in water. 
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Figure 2.2. Gold nanocages synthesized via galvanic replacement. UV-Vis spectra (left), 
schematic (middle) and TEM images (right) of AuNCs with about a 40 nm wall length 
and increasing addition of Au salt (from A to C). 
 
 
2.1.3. Gold Nanorods 
2.1.3.1. Seed-Mediated Growth Method 
 Relatively large gold nanorods (AuNRs) are synthesized via the seed-mediated 
growth method.[6] A schematic representation of this method is shown in Figure 2.3. 
Briefly, a seed solution consisting of 7.5 mL of 0.2 M CTAB, 2.5 mL of 1.0 mM HAuCl4 
and 600 uL 0.01 M NaBH4 is prepared, followed by a growth solution containing 100 mL 
of 1.0 mM HAuCl4, 100 mL of 0.2 M CTAB, 5 mL of 4.0 mM silver nitrate and 1.4 mL 
of 78.8 mM ascorbic acid. A 240 uL volume of the seed solution is added to the growth 
solution, producing AuNRs approximately 38 nm in length and 11 nm in width, as 
displayed in Figure 2.4. The surface plasmon resonance (SPR) of these AuNRs is around 
740 nm. These CTAB-stabilized AuNRs are purified by centrifugation at 14,000 rpm for 
5 min and redispersed in DI water.  
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Figure 2.3. Schematic representation of AuNR synthesis via seed-mediated growth. The 
three main steps involved are the preparation of a seed solution (A), preparation of a 
growth solution (B) and growth of AuNRs by the addition of the seed to growth solution 
(C). 




Figure 2.4. TEM image (top) of 38 x 11 nm AuNRs synthesized by seed-mediated 
growth. UV-Vis spectrum (bottom) showing these AuNRs have a surface plasmon 
resonance around 740 nm. Scale bar: 60 nm. 
 
2.1.3.2. Seedless Growth Method 
 Relatively small AuNRs are synthesized by a seedless growth method.[7] A 
schematic representation of this method is shown in Figure 2.5. In this method, the 
growth solution is kept at an acidic pH and sodium borohydride is added instead of a seed 
solution, for simultaneous seed formation and AuNR growth. To obtain AuNRs 
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approximately 28 nm in length and 8 nm in width, shown in Figure 2.6, 300 μL of 0.01 M 
NaBH4 was prepared and added to an acidic growth solution containing 160 μL of 37% 
HCl, 100 mL of 1.0 mM HAuCl4, 100 mL of 0.2 M CTAB, 5 mL of 4.0 mM silver nitrate 
and 1.4 mL of 78.8 mM ascorbic acid. The SPR of these AuNRs is around 770 nm. These 
CTAB-stabilized AuNRs were also purified by centrifugation at 14,000 rpm for 5 min 
and redispersed in DI H2O. 
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Figure 2.5. Schematic representation of AuNR synthesis via seedless growth. The two 
main steps involved are the preparation of a growth solution (A) and growth of AuNRs 
by the addition of sodium borohydride to the growth solution (B). 
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Figure 2.6. TEM image (top) of 28 x 8 nm AuNRs synthesized by seedless growth. UV-
Vis spectrum (bottom) showing these AuNRs have a surface plasmon resonance around 
770 nm. Scale bar: 60 nm. 
 
2.1.4. Gold Nanoparticle Functionalization 
Gold nanoparticles can be easily functionalized with sulfhydryl (SH) containing 
ligands through a gold-sulfur (Au-S) covalent bond. Formation of the Au-S bond occurs 
through creation of a thiyl radical via deprotonation of the SH group. The Au-S covalent 
bond is very strong, having a bond strength of around 44 kcal/mol (184 kJ/mol).[8] The 
presence of sulfhydryl groups on many different biocompatible molecules, including 
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polymers and peptides, allows for the facile attachment of biologically relevant 
compounds to the gold nanoparticle surface, as discussed below. 
2.1.4.1. Conjugation with polyethylene glycol 
Gold nanoparticles, of all types, are stabilized with thiol-terminated methoxy 
polyethylene glycol (mPEG-SH, MW 5000, Laysan Bio, Inc.) through a Au-S bond. This 
is done in order to prevent nonspecific adsorption of proteins to the particles in a 
physiological environment. A 1 mM aqueous solution of mPEG-SH is added to AuNPs at 
10
4
 molar excess, and left overnight. Particles are then purified by centrifugation and 
resuspended in water. 
2.1.4.2. Conjugation with peptides 
After PEGylation gold nanoparticles are further conjugated with custom peptides 
purchased from GenScript USA, Inc. Specifically, an RGD (CGPDGRDGRDGRDGR) 
peptide and an NLS (CGGGPKKKRKVGG) peptide, both with C-terminal amidation, 
were used in this work. Conjugation of peptides was achieved by addition of a 5 mM 
aqueous solution of peptide to the PEG-coated nanoparticles at 1x10
4
 molar excess of 
NLS peptides and 8x10
3
 molar excess of RGD peptides for 24 h, after which the peptide 
conjugated nanoparticles were centrifuged and redispersed in water. The hydrodynamic 
diameter of the peptide-conjugated gold nanoparticles was determined using dynamic 
light scattering (DLS). Further confirmation that the nanoparticle surface was modified 
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2.2. Cell Biology and Imaging Methods 
 
2.2.1. Cell Culture 
Human oral squamous cell carcinoma (HSC-3) cells were utilized in this work as the 
malignant cell line and human keratinocytes (HaCat) were utilized in this work as the 
non-malignant (healthy) cell line. Both cell lines were maintained in Dulbecco’s 
Modification of Eagle’s Medium (DMEM, Mediatech, Cat# 10-013-CV), supplemented 
with 10% v/v fetal bovine serum (FBS, Mediatech, Cat# 35-010-CV) and 1% v/v 
antibiotic-antimycotic solution (Mediatech, Cat# 30-004-CI). Cells were grown in a 
37˚C, 5% CO2 humidified incubator.  
 
2.2.2 Intracellular Localization and Nanoparticle Uptake 
2.2.2.1. Dark Field Imaging of Fixed cells 
Cells are grown on 18 mm diameter glass coverslips (in bottom of well in 12-well 
tissue culture plate) overnight and incubated with gold nanoparticle solutions in culture 
medium for desired treatment time. After incubation, coverslips are rinsed with PBS 
buffer and fixed with 500 µL of 4% paraformaldehyde for 15 min. The coverslip is then 
placed on another coverslip containing a small drop of glycerin, and sealed with nail 
polish. Dark field images are taken using an inverted Olympus IX70 microscope utilizing 
a dark field condenser (U-DCW). A 100x/1.35 oil Iris objective (UPLANAPO) is used to 
collect the scattered light from the samples to produce the dark field images. 
For I2/KI etching, cells are grown on 18 mm diameter glass coverslips (in bottom of 
well in 12-well plate) and incubated with gold nanoparticle solutions in culture medium 
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for desired treatment time. The nanoparticle-containing medium was removed and the 
cells are washed with PBS buffer. In order to remove nanoparticles that have not been 
internalized by the cells, a previously developed etching method is used.[9] Briefly, 1 mL 
of an aqueous solution containing a 1:6 molar ratio mixture of I2 (0.34 mM) and KI is 
added to the cells and removed after 5 min. The coverslips are then washed with 
deionized water and placed on another coverslip containing a small drop of glycerin, 
followed by sealing with nail polish. The cells are then fixed with 500 µL 4% 
paraformaldehyde for 15 min and dark field light scattering images are taken. 
2.2.2.2. Live-Cell Dark Field Imaging 
 A homemade setup was modified based on an inverted Olympus IX70 
microscope.[10] The incident white light emitted from the Fiber-Lite MI-150 Illuminator 
(Dolan-Jenner Industries) is delivered with an optical fiber and is focused into a tiny spot 
on the focal plane of the microscope objective by a condenser lens at the end of the 
optical fiber. The angle of the illuminating light is adjusted to prevent the incident 
illuminating light from entering the light collection cone of the microscope objective. A 
schematic representation of the setup is shown in Figure 2.7. The sample, nanoparticle-
treated cells grown in the 35 mm culture plate, is placed in the homemade environmental 
mini cell chamber, which is mounted on the stage of the microscope. The environmental 
parameters inside the chamber, such as temperature, carbon dioxide concentration, and 
humidity, are well controlled. A long working distance 40x objective is used to collect 
only the scattered illuminating light from the sample. The dark field pictures are taken 
using the Nikon D200 digital camera automatically with an interval time of 2 min. 
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Figure 2.7. Schematic representing the homemade setup for live-cell dark field imaging 
of cells treated with gold nanoparticles.A dark field light scattering imaging microscope 
with a side-illumination arrangement is combined with an environmental cell incubation 
chamber for real time studies of live cells. 
 
2.2.2.3. Nuclear Localization with Confocal Imaging 
The nuclear-targeting of fluorescently-labeled gold nanoparticles can be visualized 
using confocal imaging. A simple way to fluorescently-label the gold nanoparticles, is to 
conjugate them with a FITC-PEG-SH (Nanocs, Inc. Cat. No. PG1-FC-5k) instead of 
PEG, prior to peptide conjugation (see Section 2.1.4). After nanoparticle 
functionalization with a FITC-PEG and peptides, cells are prepared for confocal imaging. 
Briefly, cells are grown on 18 mm diameter glass coverslips (in bottom of well in 12-well 
tissue culture plate) overnight and incubated with FITC-AuNP-containing culture 
medium for desired treatment time. After desired treatment time, the nanoparticle-
containing media is removed and the cells are washed with PBS. Cells are then fixed with 
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500 µL of 4% paraformaldehyde for 15 min. In order to visualize the cell nuclei with 
confocal imaging, the nuclei must also be fluorescently-labeled. Therefore, the 
paraformaldehyde is removed, coverslips are washed with PBS, and 500 µL of 120 nM 
DAPI (4’6-Diamidino-2-phenylindole) (Life Technologies, Inc. Cat. No. C1306) is 
added. The plate is swirled gently for ~ 1 min, to allow for homogeneous staining of the 
cells on the coverslip, after which, the coverslip is rinsed with water 3 times. The 
coverslip is then placed on a microscope slide containing a small drop of 30% glycerin, 
sealed with nail polish and stored at 4°C until analysis. Fluorescence images are taken by 
multiphoton confocal microscopy using the Zeiss LSM 510 NLS META with 785 
(DAPI) and 488 nm (FITC) excitation sources (IBB Core Facilities, Georgia Tech, 
contact Andrew Shaw). 
2.2.2.4. Spectrophotometric Measurements of Relative Uptake 
The relative uptake of nanoparticles can be spectrophotometrically measured. Cells 
are plated in a 96-well tissue culture plate and allowed to grow for 24 h. The culture 
media is then removed and replaced with 100 µL of culture medium containing gold 
nanoparticles. Figure 2.8 shows an example of the plate configuration. 
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Figure 2.8. Example of 96-well plate configuration when treating cells for uptake. Wells 
1/A-H contain cells and are loaded with 100 µL of cell culture medium containing 
nanoparticle A (A+). Wells 2/A-H contain cells and are loaded with 100 µL of cell 
culture medium containing gold nanoparticle B (B+). Wells 3/A-H contain cells and are 
loaded with 100 uL of cell culture medium containing gold nanoparticle C (C+). Wells 4-
6/A-H do not contain cells and are loaded with 100 µL of cell culture medium containing 
gold nanoparticles A, B, and C (A-, B-, C-, respectively). 
  
Cells (or wells containing no cells) are then incubated with nanoparticles for desired 
treatment time (e.g 24, 48, 72 h). After desired incubation period with gold nanoparticles, 
75 µL of the gold nanoparticle-containing media is removed and placed into new cell-free 
wells of the 96-well plate. Figure 2.9 shows an example of the plate configuration at this 
step. 
  45 
 
 
Figure 2.9. Example of 96-well plate configuration after transferring gold nanoparticle 
containing medium to new wells. Gray wells represent those that originally contained 
gold nanoparticles. White wells represent the 75 µL of nanoparticle containing 
transferred from the original wells. 
 
The optical density of the nanoparticle containing cell culture medium (wells 7-12/A-
H in Fig. 2.9) is measured with a Biotek Synergy H4 multi-mode plate reader (IBB, 
Georgia Tech, contact Andrew Shaw). In the plate reader software, the settings are set to 
record absorbance of each well at the plasmon absorption wavelengths of each 
nanoparticle tested. After absorbance values (optical densities) are collected, data is 
exported to Microsoft Excel for further analysis. Once the data is exported to Excel, the 
recorded optical densities of wells A+, B+, and C+ are subtracted from the recorded 
optical densities of wells A-, B-, and C-, respectively (i.e. optical density of gold 
nanoparticle containing medium representing zero uptake). These values are then 
converted to an actual number of nanoparticles, or moles, to give the number of 
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nanoparticles taken up cells. The percentage of nanoparticle uptake can then be 
calculated by dividing the number of nanoparticles taken up by number of nanoparticles 
initially added (i.e. the number of nanoparticles present in wells A-, B-, and C-). 
 
2.2.3. Cell Viability Assays 
2.2.3.1. Mitochondrial Activity (XTT) 
Mitochondrial activity (i.e. the mitochondrial respiratory chain) can be used for 
quantitative measurements of viable cells present in cell culture. During cellular 
respiration, the succinate dehydrogenase system is active, rendering succinate 
dehydrogenase activity as an ideal candidate for the measurement of cell viability. XTT 
(2,3-bis[2-methoxy-4-nitro-5-sulfopheny]-2H-tetrazolium-5-carboxyanilide inner salt) is 
a tetrazolium salt that can be cleaved/reduced by succinate dehydrogenase in the presence 
of an electron coupling reagent (PMS (N-methyl dibenzopyrazine methyl sulfate)) in the 
cell. Once cleaved/reduced, a formazan product is formed. This formazan is water-
soluble and orange in color. The formazan can be spectrophotometrically measured at 
450 nm and its absorbance is directly proportional to the number of viable cells present in 
the cell culture.[11-13] 
Cells are plated in a 96-well tissue culture plate and allowed to grow for 24 h.  The 
culture media is then removed and replaced with 100 µL of culture medium containing 
the desired treatment.  Figure 2.10 shows an example of the plate configuration.  
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Figure 2.10. Example of 96-well plate configuration when treating cells for cell viability 
assay. Wells 1/A-H are loaded with 100 µL of cell culture medium (C). Wells 2/A-H are 
loaded with 100 µL of cell culture medium containing lowest concentration of treatment 
(X1). Wells 3-12/A-H are loaded with 100 µL of cell culture medium containing 
increased concentrations of treatment (X2-X12).  
 
Cells are then incubated with treatment for desired treatment time (e.g 24, 48, 72 h). 
Following treatment, the culture media is removed and cells are washed with 100 µL of 
PBS. Immediately following this washing step, the XTT solution is added to each well at 
a volume of 125 µL (a total volume of 12 mL for a 96-well plate). The 12 mL XTT 
solution is composed of 10.8 mL DMEM (without phenol red, supplemented with 10% 
FBS, and 1% antibiotic/antimycotic solution) and 1.2 mL of activated XTT reagent 
(Biotium, Inc. Cat. No. 30007). The activated XTT reagent is composed of 6 µL of the 
electron coupling reagent (activation reagent) and 1.2 mL of the XTT reagent (ratio of 
XTT volume:PMS volume is 200). Upon addition of the XTT solution to the cells, the 
plate is returned to the incubator for 6-12 h. During the incubation period, succinate 
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dehydrogenases, active in viable cells, reduce the XTT (tetrazolium salt) into an orange 
formazan. Figure 2.11 shows an example of what the plate looks like after reduction of 
XTT by viable cells in a control (untreated) sample of cells (column C) as well as that of 
cells treated with increasing concentrations of a cytotoxic agent (columns X1-X8). It is 
clear, by visual inspection of the orange color intensity, that as the concentration of the 
cytotoxic agent is increased, the cell viability is decreased. 
 
 
Figure 2.11. Example of 96-well plate after incubating treated cells with XTT. Wells 
C/A-C contain cells that were not treated with the cytotoxic agent and demonstrate the 
highest intensity of orange color (i.e. formazan produced by reduction of XTT by 
succinate dehydrogenases in viable cells). Wells X1-X8/A-C contain cells that were 
treated with increasing concentrations of the cytotoxic agent and demonstrate a gradual 
decrease in intensity of orange color, which indicates a decrease in the number of viable 
cells present. 
 
In order to quantify the intensity of the orange formazan, the absorbance signal is 
measured spectrophotometrically with a Biotek Synergy H4 multi-mode plate reader 
(IBB Core Facilities, Georgia Tech, contact Andrew Shaw). In the plate reader software, 
the settings are set to record absorbance of each well at 450 and 690 nm, with the 
pathlength correction option selected. With the pathlength correction enabled, the 
microplate reader automatically calculates the pathlength of each sample (instead of 
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assuming 1 cm), thereby correcting the measured absorbance values accordingly. After 
corrected absorbance values are collected, data is exported to Microsoft Excel for further 
analysis. Figure 2.12 shows an example of how the data appears in Excel.  
 
 
Figure 2.12. Example of exported data recorded from Biotek Synergy H4 multi-mode 
plate reader. Top panel contains the corrected absorbance values at 450 nm. Bottom panel 
contains the corrected absorbance values at 690 nm (background).  
 
After data is exported to Excel, the cell viability can be calculated using basic 
mathematical functions, as shown in Figure 2.13. Briefly, all absorbance values are 
averaged (avg) and the standard deviation (sd) is calculated, along with the standard 
deviation squared (sd^2), to be used for further standard deviation calculations. After 
averaging, the background absorbance values (690 nm) are subtracted from the signal 
absorbance values (450 nm) and the standard deviation (sd) is calculated along with the 
relative standard deviation squared (rsd^2). The % cell viability can then be determined 
by dividing the values of each treated sample by the control sample and multiplying by 
100, along with determining the % relative standard deviation (% rsd).  





Figure 2.13. Example of how the cell viability is determined based on the data recorded 
from Biotek Synergy H4 multi-mode plate reader. Control, X1, X4 and X8 represent 
samples shown in Figure 2.xx. In Excel, basic mathematical functions (average, standard 
deviation, etc.) are used to calculate the % cell viability and its % relative standard 
deviation (% rsd). 
 
 
Upon determining the % cell viability and % rsd, the results are graphed using 
OriginPro8. Figure 2.14 displays the cell viability graph for the data and calculated 
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results shown in Figure 2.13. Upon graphing the results, it can be quantitatively 




Figure 2.14. Cell viability graph representing data and results determined by calculations 
shown in Figure 2.13. The % cell viability is plotted as a function of increasing 
concentration of the cytotoxic agent. The error bar represents the % cell viability 
(normalized to the control) + % relative standard deviation (% rsd). 
  
2.2.3.2. ATP Production 
Cell viability can also be quantified by measuring the amount of ATP production in 
cells. The assay utilized for these measurements is the CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega, Inc. Cat. No. G7570). This assay provides a quantitative 
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measurement of the amount of ATP in the cell culture, and can be used as a cell viability 
assay, as the luminescence signal is directly correlated to the number of metabolically 
active cells, based on their ATP production.[14] 
Cells are plated in a white opaque-walled 96-well tissue culture plate and allowed to 
grow for 24 h.  The culture media is then removed and replaced with 100 µL of culture 
medium containing the desired treatment.  Figure 2.10 shows an example of the plate 
configuration. Cells are then incubated with treatment for desired treatment time (e.g 24, 
48, 72 h). Following treatment, the 96-well plate is allowed to equilibrate to room 
temperature (~ 30 min). The culture media is then removed and cells are washed with 100 
µL of PBS. Immediately following this washing step, 100 µL of room temperature 
DMEM (without phenol red, supplemented with 10% FBS, and 1% antibiotic/antimycotic 
solution) is added to the wells, followed by 100 µL of the room temperature CellTiter-
Glo® Reagent is added to the wells. The CellTiter-Glo® Reagent is composed of the 
CellTiter-Glo® Buffer and the CellTiter-Glo® Substrate, mixed according to the 
manufacturer’s protocol. The 96-well plate is then placed on an orbital shaker for 10 min 
to promote cell lysis. The luminescence is then measured with a Biotek Synergy H4 
multi-mode plate reader (IBB Core Facilities, Georgia Tech, Contact Andrew Shaw). In 
the plate reader software, the settings are set to record luminescence. After luminescence 
values are collected, data is exported to Microsoft Excel for further analysis. Once the 
data is exported to Excel, the % ATP production can be calculated. Briefly, the 
luminescence values are averaged and the standard deviation is calculated, along with the 
relative standard deviation (rsd) squared. The % ATP can then be determined by dividing 
the average of each treated sample by that of the control sample and multiplying by 100, 
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along with determining the % rsd. Upon determining the % ATP production and % rsd, 
the results are graphed using OriginPro8. The graph should look similar to that of % cell 
viability, displayed in Figure 2.14. Upon graphing the results, it can be quantitatively 
concluded that by increasing the concentration of the cytotoxic agent, the % ATP 
production by cells decreases. 
 
2.2.4. Flow Cytometry 
2.2.4.1. Cell Cycle Analysis 
 Propidium iodide (PI) is a commonly used fluorescent dye for staining DNA in 
cells. Because it intercalates into the DNA, the fluorescence signal exhibited by PI is 
directly related to the amount of DNA within cells. Utilizing this method of DNA 
staining, fixed cells can be analyzed in terms of their DNA content. Since DNA content 
varies with respect to cell cycle phase, the percentages of cells in each phase of the cell 
cycle can be quantified by flow cytometry analysis of PI stained cells. 
Cells are grown in a 12-well tissue culture plate for 24 h. The culture media is then 
removed and replaced with 500 µL of culture medium containing the desired treatment, 
such that each treatment is administered to two wells.  Figure 2.15 shows an example of 
the plate configuration.  
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Figure 2.15. Example of 12-well plate configuration when treating cells for flow 
cytometry. (C) Wells loaded with 500 µL of cell culture medium. (X1) Wells loaded with 
500 µL of cell culture medium containing lowest concentration of treatment. (X2-X5) 




After desired treatment time, the culture medium is removed, cells are washed with 1 
mL of PBS and then trypsinized by adding 400 µL of trypsin (Trypsin EDTA 1x, 
Mediatech, Cat# 25-031-CI) to each well. When all cells are removed from the plate, 400 
µL of cell culture medium is added to each well and like samples are combined into 15 
mL centrifuge tubes. The cell suspension is then centrifuged at 1500 rpm for 7 min. The 
supernatant is then removed and the cell pellet is redispersed in 600 µL of PBS, followed 
by addition of 2.9 mL of 95% ice cold ethanol, for fixing cells in 80% ethanol. Cells must 
be fixed in order to permeabilize the cell membrane for efficient dye loading of the 
relatively impermeable PI dye. The fixed cells can then be stored at -20°C for up to two 
weeks. 
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The fixed cells are centrifuged at 2000 rpm for 9 min. The supernatant containing the 
ethanol mixture is then removed and the cell pellet is redispered in 750 µL of PBS. 
RNase treatment of cells is achieved by adding 5 uL of 2 mg/mL RNase (Sigma) to the 
cell suspension and incubating at 37˚C for 30 min. RNase treatment is required since PI 
can also bind RNA, which would skew the cell cycle analysis, which is based on DNA 
content only. After RNase treatment, 75 µL of the fluorescent nucleic acid stain, 
propidium iodide (PI, 1 mg/mL) is mixed with the cell suspension and left at room 
temperature for 15 min. After dye-loading, cells are passed through a 40 µm sterile filter 
and analyzed via flow cytometry. Samples consisting of 10,000 cells, in triplicate, are 
analyzed using the BD LSR II (BD Biosciences) with a 488 nm excitation (IBB Core 
Facilities, Georgia Tech, contact Nadia Boduslavsky). Figure 2.16 displays a typical view 
of the flow cytometry software, BD FACSDiva, when using the BD LSR II for cell cycle 
analysis. Using the flow cytometry analysis software, FlowJo, DNA content and 
subsequent cell cycle analyses are carried out.  
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Figure 2.16. Screenshot of BD FACSDiva (software used for flow cytometry analysis) 
displaying settings and typical results for cell cycle analysis via flow cytometry. 
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2.2.4.2. Detection of Apoptosis and Necrosis 
One of the earliest events to takes place during apoptosis is the exposure of 
phosphatidylserine (PS) residues on the outer leaflet of the cell membrane. These PS 
residues have a high affinity for the phospholipid binding protein annexin-V. Therefore, 
by exposing cells to fluorescently labeled annexin-V, apoptosis can be quantified by the 
fluorescence intensity measured using flow cytometry.[15] The apoptotic population can 
be distinguished from the necrotic population with the addition of propidium iodide, 
which binds nucleic acids in cells only once the membrane becomes permeable (i.e. 
necrosis). In order to quantify the amount of apoptosis and necrosis induced in cells by 
various nanoparticle treatments, the ApoTarget
TM
 Annexin-V FITC Apoptosis Kit 
(Invitrogen, Inc. Cat. #PHN1010) was utilized. 
Cells are grown in a 12-well tissue culture plate for 24 h. The culture media is then 
removed and replaced with 500 µL of culture medium containing the desired treatment, 
such that each treatment is administered to two wells.  Figure 2.15 shows an example of 
the plate configuration. After desired treatment time, the culture medium is removed, 
cells are washed with 1 mL of PBS and then trypsinized by adding 400 µL of trypsin 
(Trypsin EDTA 1x, Mediatech, Cat# 25-031-CI) to each well. When all cells are removed 
from the plate, 400 µL of cell culture medium is added to each well and like samples are 
combined into 15 mL centrifuge tubes. The cell suspension is then centrifuged at 1500 
rpm for 7 min. The supernatant is removed and the pellet is redispersed in 500 µL of 1x 
Annexin binding buffer, 2 µL of 100 µg/mL PI and 5 µL of Annexin-V-FITC, followed 
by incubation at room temperature for 15 min after which the remaining volume 1x 
Annexin binding buffer is added (493 uL) and the cells are passed through a 40 µm 
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sterile filter. Cells are analyzed immediately using the BD LSR II (BD Biosciences) with 
a 488 nm excitation on 10,000 cells, in triplicate (IBB Core Facilities, Georgia Tech, 
contact Nadia Boduslavsky). Figure 2.17 displays a typical view of the flow cytometry 
software, BD FACSDiva, when using the BD LSR II for analysis of apoptosis and 
necrosis. Using the flow cytometry analysis software, FlowJo, the FITC and PI intensities 
are gated and percentages of live, early apoptotic, late apoptotic and necrotic cells are 
quantified. 
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Figure 2.17. Screenshot of BD FACSDiva (software used for flow cytometry analysis) 
displaying settings and typical results for analysis of apoptosis and necrosis via flow 
cytometry. 
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2.2.5. Confocal Microscopy 
2.2.5.1. Detection of DNA Double Strand Breaks 
One of the earliest steps in the cellular response to double-strand breaks (DSBs) is the 
phosphorylation of serine-139 of H2AX, a subclass of eukaryotic histone proteins that are 
part of the nucleoprotein structure of chromatin.[16] Using a fluorescently labeled 
antibody specific for the phosphorylated form of H2AX (γ-H2AX) discrete nuclear foci 
can be visualized at the sites of DSBs.[17] For confocal imaging, cells are grown on 18 
mm diameter glass coverslips (in bottom of well in 12-well tissue culture plate) overnight 
and incubated with gold nanoparticle solutions in culture medium for desired treatment 
time. After desired treatment time, cells are fixed in 500 µL of  4% paraformaldehyde for 
15 min, washed in PBS three times, permeabilized for 5 min on ice in 0.2% Triton X-100, 
and blocked  by washing with PBS, containing 1% BSA, three times at room 
temperature. The coverslips are incubated with anti- γ-H2AX antibody (Bethyl 
Laboratories, Inc) for 1 h, washed with PBS, containing 1% BSA, three times, and 
incubated with FITC-conjugated goat anti-rabbit secondary antibody (Bethyl 
Laboratories, Inc) for 1 h at room temperature. Cells are washed with PBS three times 
and the nuclei are stained with DAPI (500 µL, 120 nM) DAPI. The plate is swirled gently 
for ~ 1 min, to allow for homogeneous staining of the cells on the coverslip and rinsed 
with water 3 times. The coverslip is then placed on a microscope slide containing a small 
drop of 30% glycerin, sealed with nail polish and stored at 4°C until analysis. 
Fluorescence images are taken by multiphoton confocal microscopy using the Zeiss LSM 
510 NLS META with 785 (DAPI) and 488 nm (FITC) excitation sources (IBB Core 
Facilities, Georgia Tech, contact Andrew Shaw). 
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2.2.5.2. Detection of Reactive Oxygen Species 
Generation of reactive oxygen species (ROS) is common for some cytotoxic agents. 
In order to detect ROS within cells, a cell permeant compound, 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA), that is converted to a highly 
fluorescent compound, 2’7’-dichlorofluorescein (DCF), in the presence of ROS, is loaded 
into cells. If ROS are indeed present, FITC fluorescence can be visualized by confocal 
microscopy. 
Cells are grown on 18 mm diameter glass coverslips (in bottom of well in 12-well 
tissue culture plate) overnight and incubated with gold nanoparticle solutions in culture 
medium for desired treatment time. After desired treatment time, the culture medium is 
removed and the cells are washed with PBS, after which the cells are stained with a 10 
µM (500 µL) solution of H2DCFDA (6-carboxy-2’,7’-dichlorodihydrofluorescein 
diacetate, Invitrogen, C2938) and left to incubate at 37ºC for 30 min. After dye loading, 
the cells are washed with PBS and fixed with 500 µL of 4% paraformaldehyde for 15 
min, followed by nuclear staining with DAPI (500 µL, 120 nM) and swirling gently for ~ 
1 min, to allow for homogeneous staining of cells on the coverslip. The coverslip is then 
rinsed with water 3 times and placed on a microscope slide containing a small drop of 
30% glycerin. Coverslip is sealed with nail polish and stored at 4°C until analysis. 
Fluorescence images are taken by multiphoton confocal microscopy using the Zeiss LSM 
510 NLS META with 785 (DAPI) and 488 nm (FITC) excitation sources (IBB Core 
Facilities, Georgia Tech, contact Andrew Shaw).  
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INTRINSIC PROPERTIES OF GOLD NANOPARTICLE CONJUGATES 
 
 
3.1. Nuclear Targeting of Gold Nanoparticles in Cancer Cells Induces DNA 
Damage, Causing Cytokinesis Arrest and Apoptosis [1] 
 
 Unique properties of plasmonic gold nanoparticles have been successfully exploited 
for potential use in anticancer drug delivery systems and photothermal cancer treatment, 
both in vitro and in animal models. Here, we report the use of gold nanoparticles alone as 
a cancer treatment. By properly conjugating gold nanoparticles with specific peptides, we 
can selectively transport nanoparticles to the nucleus of cancer cells. Confocal 
microscopy images of DNA double strand breaks show that localization of gold 
nanoparticles at the nucleus of cancer cells damages the DNA. Using gold nanoparticle 
dark field imaging of live cells in real time, the nuclear-targeting gold nanoparticles are 
observed to specifically induce a cytokinesis arrest in cancer cells, where binucleate cell 
formation occurs after mitosis takes place. Flow cytometry results indicate that this 
failure to complete cell division leads to programmed cell death (apoptosis) in cancer 
cells. These results suggest that gold nanoparticles properly bound to nuclear- and 
cancer-targeting ligands can be effective anticancer agents and have implications in 
understanding the interaction between nanomaterials and living systems. 
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3.1.1. Introduction 
 Understanding how nanomaterials affect live cell functions, controlling such effects, 
and using them for disease therapeutics are now the principal aims and most challenging 
aspects of nanobiotechnology and nanomedicine. Gold nanoparticles (AuNPs), nanorods, 
and nanoshells with unique properties [2-5] have been shown to be of potential use in 
anticancer drug delivery systems [6] and photothermal cancer treatment agents.[7-12] 
Although such applications have shown promising potential in cancer treatment, the 
fundamental interactions and effects of nanomaterials in living systems for the most part 
still remain unknown. 
 To address these fundamentals, many studies to assess the effect of introducing 
AuNPs into the cytoplasm of the cell have been done, [13-15] yet little is known about 
the effect of AuNPs at the nucleus of the cell. The cell nucleus functions to maintain all 
processes that occur within the cell, and any disruptions within the nucleus would 
subsequently affect the cell’s DNA, thereby disturbing the highly regulated cell cycle. 
 Here we report the use of nuclear targeting of AuNPs to selectively disturb the 
division of cancer cells by the observation of cytokinesis arrest. Cytokinesis arrest was 
observed by AuNP dark-field imaging of live cells in real time, [16] which showed 
binucleate cell formation at late stages of mitosis, leading to the failure to complete cell 
division. Confocal microscopy and flow cytometry gave evidence that DNA damage and 
programmed cell death (apoptosis), respectively, accompany the observed cytokinesis 
arrest. 
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3.1.2. Experimental Methods 
3.1.2.1. Cell Culture 
 One malignant epithelial cell line, HSC-3 (human oral squamous cell carcinoma), and 
one nonmalignant epithelial cell line, HaCat (human keratinocytes) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech) supplemented with 4.5 g/L 
glucose and sodium pyruvate, 10% v/v fetal bovine serum (FBS, Mediatech) and 1% 
antimycotic solution (Mediatech). Cell cultures were kept at 37°C in a 5% CO2 
humidified incubator. 
3.1.2.2. Nanoparticle Synthesis and Peptide Conjugation 
 Gold nanoparticles (AuNPs) were synthesized via the citrate reduction of HAuCl4 
method developed by Frens.[17] The measured absorption maximum of these particles 
was at 528nm. TEM showed an average particle size of about 30nm (Figure 3.1 A, C).  
  




Figure 3.1. (A) UV-Vis spectrum of AuNPs exhibiting a maximum absorption at 528 
nm. (B) UV-Vis spectrum of RGD/NLS-AuNPs exhibiting a maximum absorption at 532 
nm. (C) TEM image of AuNPs about 30 nm in diameter. 
 
 
 For pegylation necessary to prevent aggregation of AuNPs, a 1 mM solution of 
mPEG-SH 5000 (Laysan Bio, Inc.) in DI water was added to a volume of AuNPs to make 
the concentration of mPEG-SH 10
3
 times that of the AuNPs. The mixture was left to react 
for 2 h, excess mPEG-SH was removed by centrifugation at 6000 rpm for 15 min and the 
particles were dispersed in PBS. For conjugation of peptides to the PEG-AuNPs, a 
previous established method was used.[18] Briefly, for conjugation of RGD peptides to 
the PEG-AuNPs, a 1 mM solution of RGD in DI water was added to a volume of PEG-
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AuNPs to make the concentration of RGD 10
5
 times that of the PEG-AuNPs. The 
mixture was left to react for 48 h, excess RGD peptide was removed by centrifugation at 
6000 rpm for 15 min and particles were dispersed in PBS. For conjugation of RGD and 
NLS peptides to PEG-AuNPs, a 1 mM solution of RGD in DI water and a 1 mM solution 
of NLS in DI water were added to a volume of PEG-AuNPs to make the concentrations 
10
5
 times and 10
6
 times that of the PEG-AuNPs, respectively. The mixture was left to 
react for 48 h, excess RGD and NLS were removed by centrifugation at 6000 rpm for 15 
min and the particles were dispersed in PBS. A redshift of 5 nm was observed upon 
conjugation of peptides to Au (Figure 3.1 B), characteristic of the change in dielectric of 
the surrounding environment of the nanoparticles. Upon conjugation of peptides to 
AuNPs and dispersion in PBS, the peptide-AuNPs were further diluted in DMEM culture 
medium, described above, to concentrations of 0.1 and 0.4 nM. 
3.1.2.3. Dark Field Imaging 
 For fixed cells, cells were cultured on 18 mm diameter glass coverslips coated with 
collagen and incubated with peptide-AuNP solutions in DMEM for 24 h. After 
incubation, coverslips were rinsed with PBS buffer and fixed with 4% paraformaldehyde. 
Dark field images were taken using an inverted Olympus IX70 microscope utilizing a 
dark field condenser (U-DCW). A 100x/1.35 oil Iris objective (UPLANAPO) was used to 
collect the scattered light from the samples to produce the dark field images. 
3.1.2.4. Live Cell Imaging 
 The homemade setup (Figure 3.2) was modified based on an inverted Olympus IX70 
microscope.[16] The incident white light emitted from the Fiber-Lite MI-150 Illuminator 
(Dolan-Jenner Industries) was delivered with an optical fiber and was focused into a tiny 
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spot on the focal plane of the microscope objective by a condenser lens at the end of the 
optical fiber. The angle of the illuminating light was adjusted to prevent the incident 
illuminating light from entering the light collection cone of the microscope objective. The 
sample, cells grown in the 35 mm culture plate, was placed in the homemade 
environmental mini cell chamber, which was mounted on the stage of the microscope. 
The environmental parameters inside the chamber, such as temperature, carbon dioxide 
concentration, and humidity, were well controlled. A long working distance 40x objective 
was used to collect only the scattered illuminating light from the sample. The dark field 
pictures were taken using the Nikon D200 digital camera automatically with an interval 
time of 2 min. 
 
 
Figure 3.2. Schematic setup of real-time light scattering imaging system for live cell 
studies. A dark field light scattering imaging microscope with a side-illumination 
arrangement is combined with an environmental cell incubation chamber for real time 
studies of live cells. 
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3.1.2.5. Cell Synchronization 
 Cells were synchronized in prometaphase via nocodazole block. Briefly, cells were 
grown for 14 h in the presence of 80 ng/mL nocodazole. Mitotic cells, obtained by shake-
off, were released in fresh culture medium containing different concentrations of peptide-
AuNPs. Cells were then harvested at indicated time points, washed three times in PBS, 
and fixed with -20°C ethanol for further analysis. 
3.1.2.6. Flow Cytometry 
 For flow cytometry analysis, all fixed cell suspenstions were centrifuged and the 
pellet was rinsed with PBS. The cells were then treated with 200 µg/mL RNase (Sigma) 
at 37°C for 30 min, followed by DNA staining with propidium iodide (Sigma) at room 
temperature for 15 min. Flow cytometry was done using the BD LSR II (BD Biosciences) 
with a 488 nm excitation laser and fluorescence detection in the PE channel. Cell cycle 
analysis of the data was done using FlowJo (flow cytometry analysis software). For cell 
number counting, the cell samples were run out on the flow cytometer and the single cell 
populations were gated in a PE-A/PE-W window. 
3.1.2.7. Confocal Microscopy DNA Damage Detection 
 One of the earliest steps in the cellular response to double-strand breaks (DSBs) is the 
phosphorylation of serine-139 of H2AX, a subclass of eukaryotic histone proteins that are 
part of the nucleoprotein structure of chromatin.[19] Using a fluorescently labeled 
antibody specific for the phosphorylated form of H2AX (γ-H2AX) discrete nuclear foci 
can be visualized at the sites of DSBs.[20] For confocal imaging, cells on coverslips were 
fixed in 4% paraformaldehyde for 15 min, washed in PBS three times, permeabilized for 
5 min on ice in 0.2% Triton X-100, and blocked  by washing with PBS, containing 1% 
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BSA, three times at room temperature. The coverslips were incubated with anti- γ-H2AX 
antibody (Bethyl Laboratories, Inc) for 1 h, washed with PBS, containing 1% BSA, three 
times, and incubated with FITC-conjugated goat anti-rabbit secondary antibody (Bethyl 
Laboratories, Inc) for 1 h at room temperature. Cells were washed with PBS three times 
and then stained with 4, 6 diamidino-2-phenylindole (DAPI). Fluorescence images were 
captured using a Zeiss LSM 510 NLS META multi-photon excitation confocal 
microscope. 
 
3.1.3. Results and Discussion 
 In order to selectively transport the AuNPs to the cancer cell nucleus, 30 nm AuNPs 
coated with polyethylene glycol (PEG) were bioconjugated with an arginine-glycine-
aspartic acid peptide (RGD) and a nuclear localization signal (NLS) peptide. RGD is 
known to target alpha v beta integrins on the cell surface and enter the cytoplasm via 
receptor-mediated endocytosis.[21] NLS, which has a lysine-lysine-lysine-arginine-lysine 
(KKKRK) sequence, is known to associate with karyopherins (importins) in the 
cytoplasm, after which translocation to the nucleus occurs.[22] AuNPs conjugated with 
RGD only (RGD-AuNPs) exhibit cancer-cell-specific targeting, and AuNPs conjugated 
with RGD and NLS (RGD/NLS-AuNPs) exhibit cancer cell nucleus-specific targeting. In 
this study, human oral squamous cell carcinoma (HSC) having alpha v beta integrins 
overexpressed on the cell surface[23] was used as the cancer cell model, and human 
keratinocytes (HaCat) were used as the normal cell model. The RGD-AuNPs specifically 
target the cytoplasm of cancer cells over that of normal cells, and the RGD/NLS-AuNPs 
specifically target the nuclei of cancer cells over those of the normal cells (Figure 3.3). 




Figure 3.3. Dark field light scattering images of cytoplasm and nuclear targeting AuNPs. 
(A) RGD-AuNPs located in the cytoplasm of cancer cells. (B) RGD/NLS-AuNPs located 
at the nucleus of cancer cells. (C) RGD-AuNPs located in the cytoplasm of normal cells. 
(D) RGD/NLS-AuNPs located at the nucleus of normal cells. The cancer and normal 
cells were incubated in the presence of these AuNPs at a concentration of 0.4 nM for 24 h 
and these images clearly display the efficient uptake of AuNPs in cancer cells compared 
with normal cells. Scale bar: 10 µm. 
 
 
 To look at the effects of the specific nuclear localization of AuNPs in cancer cells, a 
full investigation of the cell cycle was carried out under various conditions. Cell cycle 
arrest was determined by studying the full cell cycle time and the dynamics of cell 
division in the presence of AuNPs by using long-term live-cell gold plasmonic scattering 
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imaging on a homemade setup (Fig. 3.2). Figure 3.4 displays typical snapshots of the 
movies taken of cancer cell division.  
 
 
Figure 3.4. Real-time images of cancer cell division showing an apparent cytokinesis 
arrest (B4) followed by binucleat cell formation (B6, B7) in the presence of 0.4 nM 
nuclear-targeting gold nanoparticles (RGD/NLS-AuNPs). This phenomenon was not 
observed in untreated cancer cells (A1-7) or cancer cells under other conditions (see 
Appendix A, Figure A.1). Red stars indicate the nuclei. Scale bar: 10 µm. 
 
 
 In the absence of AuNPs (Fig 3.4A), cancer cells begin the process of cytokinesis at 
45 min (Fig. 3.4A3). After complete cleavage furrow contraction, daughter cells were 
linked together by a cytoplasmic bridge, which was extended over time with the midbody 
at its center (Fig. 3.4A6). Abscission occurred after 2 h, and the two daughter cells 
separated completely to form independent cells (Fig. 3.4A7). A similar process was 
observed for cells incubated with 0.4 nM RGD-AuNPs (see Appendix A, Figure A.1) and 
0.1 nM RGD/NLS-AuNPs (see Appendix A, Figure A.1), with 0.1 nM RGD/NLS-AuNPs 
extending the full cell cycle time by about 4 h (see Appendix A, Figure A.2). However, 
for cells incubated with 0.4 nM RGD/NLS-AuNPs, complete cell division was not 
observed (Fig. 3.4B). The onset of cytokinesis proceeded with the same kinetics as in the 
untreated cells (Fig 3.4B1-4), but when the cleavage furrow was fully contracted, the 
cytoplasmic bridge did not extend (Fig. 3.4B5-6); instead the contractile ring relaxed, and 
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the daughter cells fused back together to form a binucleate cell (Fig 3.4B7). Cytokinesis 
arrest was not observed in any normal cell groups here. This observation clearly 
demonstrates that a 0.4 nM concentration of AuNPs targeting the nucleus of cancer cells 
causes disruption of cytokinesis, thereby inhibiting these cells from completing cell 
division. 
 Within the present work, cytokinesis arrest was observed only in cancer cells treated 
with 0.4 nM RGD/NLS-AuNPs, suggesting that a disruption within the nucleus is the 
cause. To test this possibility, we investigated DNA double-strand breaks (DSBs) in 
cancer cells incubated with AuNPs. Figure 3.5 shows confocal images of cancer cells in 




Figure 3.5. DNA damage induced in cancer cells by 0.4 nM nuclear-targeting gold 
nanoparticles (RGD/NLS-AuNPs) is indicated by the bright green fluorescence in (C). 
Cancer cells (A) in the absence of AuNPs and (B) with AuNPs in the cytoplasm, no DNA 
damage was observed. Scale bar: 10 µm. 
 
 
 For untreated cells (Fig. 3.5A) and cells with AuNPS present in the cytoplasm (Fig. 
3.5B), no DSBs were observed in the cell nuclei. However, for cells treated with 0.4 nM 
nuclear-targeted AuNPs (RGD/NLS-AuNPs) (Fig. 3.5C), bright green DSB foci were 
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observed in the cell nuclei. DSBs can induce many different defects of cellular function 
and could be one reason for cell cycle disruption, specifically cytokinesis arrest and 
subsequent apoptosis, as observed here. 
 The observations seen with imaging techniques occurred in only a few cases. In 
ordert to prove this phenomenon on a larger scale, flow cytometry was carried out on a 
large number of cells. Both cancer cells and normal cells were first synchronized at 
prometaphase with nocodazole and then released in fresh medium containing different 
concentratiosn of RGD-AuNPs and RGD/NLS-AuNPs. The flow cytometry cell cycle 
results are shown in Figure 3.6 (see Appendix A, Figure A.3 for cell cycle histograms).  
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Figure 3.6. (top) M phase (mitosis phase of cell division) accumulation of cancer cells in 
the presence of 0.4 nM nuclear-targeting gold nanoparticles (RGD/NLS-AuNPs) suggests 
complete cell division (cytokinesis) has not taken place. (bottom) Data for normal cells. 
Nocodazole synchronization and release techniques were used in this experiment (see 
Experimental section) and the cell cycle was measured at different times of release (120 
and 360 min). 
 
 
 In the absence of AuNPs, 90% of the cancer cell population was synchronized in the 
M phase at time zero. At 120 min, more than 75% of the cell population had exited 
mitosis. Finally, at 360 min, more than 90% of the cell population was at the G1 phase. In 
the presence of 0.1 nM RGD/NLS-AuNPs, the process of cell division was slightly 
disrupted, as indicated by the dynamics compared with the untreated cancer cells, but 
more than 80% of the cell population was able to go through mitosis and enter the G1 
phase. in contrast, in the presence of 0.4 nM RGD/NLS-AuNPs, 60% of the cell 
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population was at the M phase after 120 min, suggesting mitotic delay. At 360 min, 35% 
of the cell population was still arrested at the M phase, indicating that the cancer cells 
were unable to proceed through mitosis. As for the normal cells, all of the AuNP-treated 
groups showed no contrast to the untreated cells. Normal cells in all cases were able to 
proceed through mitosis. 
 As the last step of cell division, cytokinesis is very complex and highly regulated.[24] 
Errors in the cytokinesis process could potentially cause apoptosis. To further investigate 
the result of the observed cytokinesis arrest, a complete cell cycle analysis via flow 
cytometry and subsequent identification of a subG1 cell population (apoptotic cells) was 
carried out and is shown in Figure 3.7 (see Appendix A, Figure A.4 for cell cycle 
histograms). 
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Figure 3.7. percentages of cells in each phase of the cell cycle show the appearance of a 
DNA-deficient cell population (subG1, yellow) for cancer cells in the presence of 0.4 nM 
nuclear-targeting gold nanoparticles (RGD/NLS-AuNPs), suggesting apoptosis. 
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 Cancer cells and normal cells were grown in the presence of different concentrations 
of RGD-AuNPs and RGD/NLS-AuNPs for 24 h before cell cycle analysis was carried out 
(see Experimental section for details). For cancer cells incubated with 0.4 nM RGD/NLS-
AuNPs, about 20% of the cell population was apoptotic (yellow in Figure 3.7). This 
particular attribute was not observed in the untreated cancer cells, the other AuNP-treated 
cancer cells, or any of the normal cell cases (treated or untreated). In the normal cell 
group, cells treated with a 0.4 nM concentration of AuNPs showed accumulation of cells 
at the G1 phase, indicating a disruption of the G1-to-S transition in the cell cycle, but the 
AuNPs did not cause apoptosis, as indicated by the absence of a subG1 cell population. 
In control groups treated with free peptides, neither M-phase arrest nor G1 disruption 
were observed (see Appendix A, Figure A.5). 
 Upon observation of an apoptotic cell population, absolute cell numbers were counted 
under each condition, shown in Figure 3.8 below. 
 
 
Figure 3.8. Number of normal cells (left) and cancer cells (right) counted using flow 
cytometry after incubation of cells with different AuNPs for 24 h. 
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 The cancer cell number did not significantly change with AuNPs in the cytoplasm 
(RGD-AuNPs), but a significant decrease in the cell number (30%) was observed in the 
presence of 0.4 nM RGD/NLS-AuNPs. The normal cell number did not significantly 
change upon treatment with AuNPs. Here, both the subG1 cell population (20%) and cell 
number decrease (30%) were observed in only the cancer cells treated with 0.4 nM 
RGD/NLS-AuNPs. These results clearly show that the cytokinesis arrest observed in the 
live-cell imaging and synchronized cell flow cytometry for cancer cells in the presence of 
0.4 nM RGD/NLS-AuNPs results in apoptosis. 
 
3.1.4. Conclusions and Future Outlook 
In conclusion, we have demonstrated that nuclear targeting of gold nanoparticles in 
cancer cells causes cytokinesis arrest, leading to the failure to complete cell division and 
thereby resulting in apoptosis. This work shows evidence that nanomaterials localized at 
the cell nucleus can specifically affect cellular function. A detailed mechanism has not 
been established, yet the results shown here are still significant. These observations have 
implications in understanding the basic interactions between nanomaterials and live 
systems and have a huge impact on the fields of nanomedicine and nanobiology. These 
results might even propose a new method by which AuNPs can be used alone as an 
anticancer therapeutic material if conjugated to the proper nuclear-targeting ligands. The 
cytokinesis arrest observed here could be a general effect for other types of nanoparticles 
that can selectively target the nuclei of cancer cells. 
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3.2. Inducing Cancer Cell Death by Targeting its Nucleus: Solid Gold 
Nanospheres versus Hollow Gold Nanocages [1] 
 
Recently, we have shown that targeting the cancer cell nucleus with solid gold 
nanospheres, using a cancer cell penetrating/pro-apoptotic peptide (RGD) and a nuclear 
localization sequence peptide (NLS), inhibits cell division, thus leading to apoptosis. In 
the present work, flow cytometric analysis revealed an increase in cell death, via 
apoptosis and necrosis, in HSC cells upon treatment with peptide-conjugated hollow gold 
nanocages, compared to those treated with the peptide-conjugated solid gold 
nanospheres. This is consistent with a G0/G1 phase accumulation, S phase depletion and 
G2/M phase depletion, as well as reduced ATP levels. Here, we investigate the possible 
causes for the observed enhanced cell death with the use of confocal microscopy. The 
fluorescence images of HSC cells treated with gold nanocages, indicate the presence of 
reactive oxygen species, known to cause apoptosis. The formation of reactive oxygen 
species observed is consistent with a mechanism involving the oxidation of metallic 
silver on the inner cavity of the nanocage (inherent to the synthesis of the gold 
nanocages), to silver oxide. This oxidation is confirmed by an observed redshift in the 
surface plasmon resonance of the gold nanocages in cell culture medium. The silver 
oxide, a semiconductor known to photochemically generate hydroxyl radicals, a form of 
reactive oxygen species, is proposed as a mechanism for the enhanced cell death caused 
by gold nanocages. Thus, the enhanced cell death, via apoptosis and necrosis, observed 
with peptide-conjugated hollow gold nanocage-treated cells is considered to be a result of 
the metallic composition (silver remaining on the inner cavity) of the nanocage. 
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3.2.1. Introduction 
Gold nanostructures and their interactions with biological systems are growing 
increasingly important, especially in biomedical research. Due to their unique optical 
properties, gold nanoparticles exhibit extrinsic activation as photothermal contrast agents, 
ultimately enabling the photothermal ablation of tumors by use of core-shell 
nanoparticles,[2, 3] gold nanorods,[4-6] gold nanocages,[7] and spherical gold 
nanoparticles.[6, 8] As our group has recently demonstrated, using peptide-conjugated 
gold and silver nanoparticles to target cancer cells in vitro,[9, 10] nanostructures also 
exhibit intrinsic antineoplastic capabilities. These targeted nanoparticles not only cause 
changes in the cell cycle and induce apoptosis, but their location in the cell can also be 
determined using plasmonic imaging, due to their high scattering cross-section, as was 
first demonstrated by El-Sayed and coworkers.[11] By utilizing polyethylene glycol 
(PEG) to minimize non-specific uptake, as well as an RGD (arginine-glycine-aspartic 
acid) sequence peptide and an NLS (nuclear localization sequence) peptide, nanoparticles 
are targeted to alpha v beta integrins on the cancer cell surface[12-15] and translocated to 
the nuclear pore complex,[16-18] respectively. Not only does the RGD peptide target 
integrins on the cell surface to serve as a cell penetration peptide, but it has also been 
characterized as a pro-apoptotic peptide, which induces rapid autoprocessing of the 
caspase-3 proenzyme, via interactions with an RGD-binding motif, causing subsequent 
caspase-3 activation.[19, 20] Previous reports of RGD and NLS peptides having the 
ability to target gold nanoparticles to the nucleus of cancer cells,[17, 21, 22] as well as 
the extensive studies done on the fundamental and applied properties of gold 
nanocages,[7, 23-26] provide an excellent platform for further investigation of the 
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antineoplastic properties of gold nanostructures, both solid gold nanospheres and hollow 
gold nanocages. One such property exhibited by gold nanostructures is the ability to 
modulate the cell cycle in malignant cells, which have characteristic sensitivities to cell 
cycle disruption, and, due to inherently compromised repair mechanisms, malignant cells 
can undergo subsequent apoptosis.[9, 10] 
In the present work, we compare the efficacy at which nuclear-targeting gold 
nanostructures, of different shapes, induce disruptions in the cellular functions of HSC 
(human oral squamous carcinoma) cells. We specifically detect cell cycle disruptions, 
ATP depletion, and apoptotic and necrotic cell populations induced by both solid gold 
nanospheres and hollow gold nanocages. We found that the gold nanocages are much 
more effective in disrupting cellular functions and causing cell death than the gold 
nanospheres. This is shown to result from the presence of reactive oxygen species (ROS) 
species, known to cause apoptosis in living cells.[27] From our previous work using gold 
nanocages for the destruction of pollutant azo dyes,[26] we concluded that the silver 
remaining on the inner cavity of the gold nanocages, inherent to their synthesis, is 
photochemically oxidized to silver oxide, which produces reactive oxygen species. 
Therefore, the different metallic compositions are proposed to be the cause of different 
cellular disruptions observed between the nanospheres and nanocages. 
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3.2.2. Experimental Methods 
3.2.2.1. Cell culture 
Human oral squamous cell carcinoma (HSC-3) cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Mediatech) supplemented with 10% v/v fetal bovine 
serum (FBS, Mediatech) and 1% v/v antimycotic solution (Mediatech) in a 37˚C, 5% 
CO2 humidified incubator.  
3.2.2.2. Nanoparticle synthesis and peptide conjugation 
Gold nanocages (AuNCs), with a 45 nm wall length and a 5 nm wall thickness, were 
prepared via galvanic replacement reaction with silver nanocubes as a template.[23] 
Silver nanocubes were prepared by a previously reported method.[25] Briefly, 70 mL of 
ethylene glycol (EG) was heated to 150˚C for 1 h, followed by the addition of polyvinyl 
pyrrolidone (PVP, MW 55,000; 0.82 g dissolved in 5 mL EG). While still at 150˚C, 0.7 
mL of a 3 mM sodium sulfide solution (in EG) was added, followed by slow injection of 
4 mL of a silver nitrate solution (0.48 g dissolved in 10 mL EG). [26, 28] The reaction 
was allowed to proceed to completion (10-15 min) resulting in the reduction of silver ions 
to silver nanocubes. The silver nanocubes were purified by adding a 1:2 acetone/water 
mixture at a volume two times that of the nanocube solution, centrifuging at 14,000 rpm 
for 5 min and redispersing the precipitate in 200 mL of water. The silver nanocube 
solution was brought to a boil under reflux, after which a 10 mg/L hydrogen 
tetrachloroaurate (HAuCl4) solution was slowly injected and the UV-Vis spectrum of the 
solution was monitored until the absorption maximum red-shifted and remained constant 
at about 720 nm.[28] The AuNCs were then purified by centrifugation at 14,000 rpm for 
5 min and redispersed in water. The surface plasmon absorption spectrum of the PVP-
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AuNCs can be found in Figure 3.9A (black). Transmission electron microscopy (TEM) 
reveals the AuNCs synthesized here are between 40 and 50 nm in wall length (Fig. 3.9C). 
Gold nanospheres (AuNSs), with a 35 nm diameter, were synthesized based on the 
method developed by Frens.[29] Briefly, 20 mL of a 1 mM HAuCl4 solution was brought 
to a boil, under reflux, while stirring, followed by addition of 0.5 mL of a 1% trisodium 
citrate solution. Reaction completion was determined by the color changing from clear to 
a deep red/purple. The UV-Vis spectrum of the solution showed the absorption maximum 
to be around 535 nm for the AuNSs. The AuNSs were then purified by centrifugation at 
6000 rpm for 15 min and redispersed in water. The surface plasmon absorption spectrum 
of the citrate-AuNSs can be found in Figure 3.9B (black). Transmission electron 
microscopy (TEM) reveals the AuNSs synthesized here are between 30 and 40 nm in 
diameter (Fig. 3.9D). 
Prior to peptide conjugation, the AuNCs and AuNSs were coated with thiol-
terminated polyethylene glycol (mPEG-SH 5000) through a Au-S bond. This was done in 
order to prevent nonspecific adsorption of proteins to the particles in a physiological 
environment. A 1 mM aqueous solution of PEG was added to AuNPs at 10
4
 molar 
excess, and left overnight. Particles were then purified by centrifugation at 6000 rpm for 
15 min and resuspended in water. The surface plasmon absorption spectrum of the PEG-
AuNCs and PEG-AuNSs can be found in Figure 3.13A,B (red), respectively. 
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Figure 3.9. UV-Vis absorption spectra of (A) PVP-AuNCs and (B) citrate-AuNSs before 
(black) and after (red) conjugation with PEG. Transmission electron micrograph of (C) 
45 nm PVP-AuNCs and (D) 35 nm citrate-AuNSs. 
 
After PEGylation the AuNCs and AuNSs were further conjugated with custom 
peptides purchased from GenScript USA, Inc. Specifically, an RGD 
(RGDRGDRGDRGDPGC) peptide and an NLS (CGGGPKKKRKVGG) peptide, both 
with C-terminal amidation, were used in this work. Conjugation of peptides was achieved 
by addition of a 5 mM aqueous solution of peptide to the PEG coated nanoparticles at 
1x10
4
 molar excess of NLS peptides/nanoparticle and 8x10
3
 molar excess of RGD 
peptides/nanoparticle for 24 h, after which the peptide conjugated nanoparticles were 
centrifuged at 6000 rpm for 15 min and redispersed in water to render RGD-AuNCs, 
RGD-AuNSs, NLS-AuNCs, NLS-AuNSs, RGD/NLS-AuNCs, and RGD/NLS-AuNCs. 
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The hydrodynamic diameter of the peptide-conjugated gold nanoparticles was determined 
using dynamic light scattering (DLS).  The hydrodynamic diameter of the PEG-
conjugated and peptide-conjugated AuNSs and AuNCs is drastically different although 
the actual gold nanoparticle size varies only by 10 nm. Upon conjugation with PEG, and 
RGD and NLS peptides, the hydrodynamic diameter of AuNCs increases to 96 nm while 
the RGD/NLS-AuNSs have a hydrodynamic diameter of 42 nm. The size increase to 
almost 100 nm observed in the case of the conjugated AuNCs is in agreement with the 
hydrodynamic diameter measurements previously observed, by Xia and coworkers[30], 
for PEG conjugated AuNCs. Further confirmation that the nanoparticle surface was 
modified during conjugation of PEG and peptides was achieved through zeta potential 
measurements, shown in Table 3.2. 
 
Table 3.2. Zeta potential measurements for functionalized AuNSs and AuNCs used 




The peptide conjugated AuNCs and AuNSs were further diluted in DMEM to 0.1 and 
0.4 nM, for treatment of HSC-3 cells. The gold nanoparticle concentrations were 
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determined using ε = 5.0x10
9
 (AuNCs), which was calculated based on ICP 
measurements, and ε = 5.3x10
9
 (AuNSs), which is based on previous reports.[31] ICP 
analysis was done by dissolving the AuNC solution in aqua regia (1 part HNO3 to 3 parts 
HCl).  
3.2.2.3. Gold nanoparticle internalization 
Two different methods were used to determine nanoparticle uptake by HSC-3 cells. 
First, to determine the percentage of nanoparticles taken up by HSC-3 cells, a previously 
utilized spectroscopic method was used[10]. Specifically, the cells were grown in 96-well 
tissue culture plates overnight. The growth media was then removed and replaced with 
growth media containing gold nanoparticles. After a 48 h incubation period with gold 
nanoparticles, the gold nanoparticle-containing media was removed and placed into a 
cell-free 96-well plate. The optical density was analyzed on a Biotek Synergy H4 multi-
mode plate reader at wavelengths of 723 and 538 nm (plasmon absorption for the AuNCs 
and AuNSs, respectively). In order to determine nanoparticle uptake, the recorded optical 
density was subtracted from the optical density of the gold nanoparticle-containing 
growth media initially added to the cell culture. This value was then converted to a 
percentage of what was initially added to the cell culture. Second, to visualize the 
nanoparticles inside HSC-3 cells by plasmonic dark field light scattering imaging, cells 
were grown on coverslips for 24 h, after which the culture medium was removed and 
replaced with nanoparticle-containing medium. HSC-3 cells were then grown in the 
presence of 0.4 nM peptide-conjugated gold nanoparticles for 48 h. The nanoparticle-
containing medium was removed and the cells were washed with PBS buffer. In order to 
remove nanoparticles that have not been internalized by the HSC-3 cells, a previously 
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developed etching method was used.[32] Briefly, 1 mL of an aqueous solution containing 
a 1:6 molar ratio mixture of I2 (0.34 mM) and KI was added to the cells and removed 
after 5 min. The coverslips were then washed with deionized water. The cells were then 
fixed with 4% paraformaldehyde. Dark field images were taken using an inverted 
Olympus IX70 microscope utilizing a dark field condenser (U-DCW) and a 100x/1.35 oil 
Iris objective (UPLANAPO).  
3.2.2.4. Nuclear localization of nanoparticles by confocal microscopy 
For FITC labeling, nanoparticles were conjugated with FITC-PEG-SH prior to 
peptide conjugation. After nanoparticle functionalization, HSC cells were prepared for 
confocal imaging. Briefly, HSC-3 cells were grown on coverslips overnight. The growth 
media was then removed and replaced with growth media containing FITC-PEG-
RGD/NLS-AuNCs and AuNSs. After a 24 h incubation period with gold nanoparticles, 
the gold nanoparticle-containing media was removed and the cells were washed with 
PBS. Cells were then fixed with 4% paraformaldehyde for 15 min, followed by nuclear 
staining with DAPI (4’6-Diamidino-2-phenylindole, Dihydrochloride, Invitrogen) and 
washing with water. Fluorescence images were taken by multiphoton confocal 
microscopy using the Zeiss LSM 510 NLS META with 785 (DAPI) and 488 nm (FITC) 
excitation sources. 
3.2.2.5. Flow cytometry cell cycle analysis 
HSC-3 cells were grown in 12-well tissue culture plates overnight. The growth media 
was then removed and replaced with growth media containing gold nanoparticles. After 
cells were treated with gold nanoparticles for 48 h, they were fixed in 70% ethanol, 
centrifuged, washed, and resuspended in phosphate buffered saline (PBS). Cells were 
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then treated with 10 μg/mL RNase (Sigma) at 37˚C for 30 min, after which they were 
stained with 100 μg/mL of propidium iodide (PI), fluorescent DNA stain, for 15 min at 
room temperature. Samples, consisting of 10,000 cells, in triplicate, were analyzed using 
the BD LSR II (BD Biosciences) with a 488 nm excitation. Using the flow cytometry 
analysis software, FlowJo, DNA content and subsequent cell cycle analyses were carried 
out.  
3.2.2.6. ATP assay 
HSC-3 cells were grown in white opaque-walled 96-well tissue culture plates 
overnight, after which the growth media was replaced with gold nanoparticle-containing 
media. Upon 48 h treatment with nanoparticles, the CellTiter-Glo® Luminescent Cell 
Viability Assay was used according to the manufacturer’s protocol. Briefly, the CellTiter-
Glo® Reagent was prepared by mixing the CellTiter-Glow® Buffer with the CellTiter-
Glo® Substrate. After 48 h gold nanoparticle treatment, the cells were rinsed with PBS, 
100 μL of fresh media was added, and the plate was allowed to equilibrate to room 
temperature. 100 μL of the CellTiter-Glo® Reagent was then added to the cells and the 
plate was mixed on an orbital shaker for 2 min to promote cell lysis. Luminescence was 
then recorded on a Biotek Synergy H4 multi-mode plate reader. This method provides a 
quantitative measurement of the amount of ATP in the cell culture, and can be used as a 
cell viability assay, as the luminescence signal is directly correlated to the number of 
metabolically active cells, based on their ATP production.[33] 
3.2.2.7. Flow cytometry analysis of apoptosis and necrosis 
HSC-3 cells were grown in 12-well tissue culture plates overnight, after which the 
growth media was removed and replaced with growth media containing gold 
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nanoparticles. After cells were treated with gold nanoparticles for 48 h, an Alexa Fluor 
488 annexin-V/Dead Cell Apoptosis kit for flow cytometry (Invitrogen) was used for the 
detection of apoptosis and necrosis. The standard protocol was optimized for our 
experimental conditions. Briefly, cells were centrifuged, washed, and resuspended in 1 
mL of 1X annexin-binding buffer. After which 5 μL of Alexa Fluor 488 annexin-V and 2 
μL of 100 mg/mL propidium iodide (PI) were added to the cell suspension and left to 
incubate at room temperature for 15 min. Upon completion of dye loading, 1 mL of 1X 
annexin-binding buffer was added. Cells were analyzed immediately using the BD LSR 
II (BD Biosciences) with a 488 nm excitation on 10,000 cells, in triplicate. Using the 
flow cytometry analysis software, FlowJo, the Alexa Fluor 488 and PI intensities were 
gated based on a negative control (HSC-3 cells in nanoparticle-free media) and a positive 
control for apoptosis (HSC-3 cells treated with 10 μM camptothecin for 4 h). 
3.2.2.8. Confocal acquisition of ROS 
HSC-3 cells were grown on coverslips overnight. The growth media was then 
removed and replaced with growth media containing gold nanoparticles. After a 24 h 
incubation period with gold nanoparticles, the gold nanoparticle-containing media was 
removed and the cells were washed with PBS, after which the cells were stained with a 
10 µM solution of H2DCFDA (6-carboxy-2’,7’-dichlorodihydrofluorescein diacetate, 
Invitrogen, C2938) and left to incubate at 37ºC for 30 min. After dye loading, the cells 
were washed with PBS and fixed with 4% paraformaldehyde for 15 min, followed by 
nuclear staining with DAPI (4’6-Diamidino-2-phenylindole, Dihydrochloride, Invitrogen) 
and washing with water. Fluorescence images were taken by multiphoton confocal 
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microscopy using the Zeiss LSM 510 NLS META with 785 (DAPI) and 488 nm (FITC) 
excitation sources.  
3.2.2.9. Statistical analysis 
All results are expressed as the mean + standard deviation of three independent 
experiments. Statistical significance (i.e. p-value) was calculated using a t-test calculator 
(GraphPad Software, Inc.) and the data is considered statistically significant (indicated by 
*) when p < 0.05.  
 
3.2.3. Results and Discussion 
HSC cells were treated with gold nanoparticles of different shape: solid gold 
nanospheres (AuNSs, ~35 nm diameter) and hollow gold nanocages (AuNCs, ~45 nm 
wall length) as shown in Figure 3.13. These two distinctly shaped gold nanoparticles 
were stabilized with polyethylene glycol thiol (mPEG-SH, MW 5000) in order to prevent 
any nonspecific interactions that might take place with these nanoparticles in the 
physiological environment. The PEGylated gold nanoparticles were then functionalized 
with specific peptides: an RGD (arginine-glycine-aspartic acid) sequence peptide and an 
NLS (nuclear localization sequence) peptide. The RGD peptide provides for receptor-
mediated uptake of nanoparticles by cancer cells, as it mimics extracellular matrix 
proteins and targets alpha v beta integrins that are overexpressed on the cell surface of 
HSC cells,[13, 34] while also exhibiting pro-apoptotic capabilities.[19, 20] The NLS 
peptide from the simian virus (SV) large T antigen, having a KKKRK (lysine-lysine-
lysine-arginine-lysine) sequence, provides for nuclear localization of nanoparticles, by 
binding importin alpha in the cytoplasm of the cell, which subsequently binds importin 
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beta located on the cytoplasmic side of the nuclear membrane.[35-39] Peptide 
conjugation was exploited to give rise to six different types of gold nanoparticles, RGD-
AuNSs NLS-AuNSs, RGD/NLS-AuNSs, RGD-AuNCs, NLS-AuNCs, and RGD/NLS-
AuNCs. Each nanoparticle type exhibited cellular internalization, with the NLS peptide-
conjugated nanoparticles showing subsequent nuclear localization. Cellular 
internalization (i.e. nanoparticle uptake) is shown in Figure 3.10A.  
 
 
Figure 3.10. Cellular internalization and nuclear localization of peptide-conjugated 
AuNPs by HSC cells after 48 h, determined as the percent uptake (A), as well as the with 
plasmonic dark field light scattering imaging (B) of internalized nanoparticles before and 
after etching of extracellular nanoparticles. Scale bar: 20 μm 
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Overall, each nanoparticle formulation exhibits about 50% uptake by HSC cells over 
48 h. In order to confirm the internalization of the nanoparticles, plasmonic dark field 
imaging and a previously developed etching technique were employed.[32] With this 
technique, it can be seen that the plasmonic dark field light scattering images, shown in 
Figure 3.10B, before and after the removal of extracellular nanoparticles by I2/KI etching, 
are the same, suggesting nanoparticle internalization by HSC cells has occurred. Also, 
these images suggest the nuclear localization of the nanoparticles conjugated with the 
NLS peptide, while those without appear to be more dispersed throughout the cytoplasm 
of the cell, as we have shown previously with similar nanoparticle formulations.[9] Co-
localization of the RGD/NLS-AuNSs and RGD/NLS-AuNCs with the nucleus was also 
confirmed with confocal imaging, as shown in Figure 3.11. 
 
 
Figure 3.11. Confocal microscopy images of FITC (green) labeled RGD/NLS-AuNCs 
(left) and AuNSs (right) co-localized with the nuclei (blue) of HSC cells. Scale bar: 20 
µm. 
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 Upon confirmation of nuclear and cytoplasmic localization, all nanoparticles were 
examined in terms of their effects on HSC cellular functions, as well as their ability to 
induce cell death via apoptosis and necrosis.  
3.2.3.1. Nanoparticle-induced disruption of cellular functions 
Cell cycle analysis was utilized in order to compare the dependence of cell cycle 
disruption on nanoparticle shape (solid sphere or hollow cage), as well as nanoparticle 
concentration (0.1 or 0.4 nM). The most significant changes seen for all of the 
nanoparticle formulations occur when HSC cells are treated with a 0.4 nM concentration. 
With this high concentration, HSC cells experience cell cycle disruptions that have been 
previously linked to apoptosis.[40] The cell cycle changes observed for the RGD/NLS-
AuNSs and RGD/NLS-AuNCs, as shown in Figure 3.12 (A and B, respectively), are an 
increased G0/G1 phase population (16% by AuNCs and 19% by AuNSs), a decreased S 
phase population (10% by AuNCs and 2% by AuNSs) and a decreased G2/M phase 
population (100% by both AuNCs and AuNSs).  
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Figure 3.12. Cell cycle changes induced by peptide-conjugated AuNPs, compared to 
control (HSC cells treated with nanoparticle-free culture medium). RGD/NLS-AuNSs 
(A), and RGD/NLS-AuNCs (B), at concentrations of 0.4 nM, both generate an increase in 
G0/G1 phase, a decrease in S phase and a decrease in G2/M phase populations when 
incubated with HSC cells for 48 h. Values expressed as mean + standard deviation of 
three independent experiments. Statistical significance, with respect to control, indicated 
by * (p < 0.05). 
 
Similar trends are seen with the RGD-conjugated and NLS-conjugated gold 
nanoparticles, shown in Appendix A, Figure A.5, except when HSC cells are treated with 
0.1 nM RGD-AuNCs. In this case, a prominent G2/M arrest is observed, which has been 
correlated to cytokinesis arrest and apoptosis.[9] The more common trend observed here, 
G0/G1 phase accumulation and subsequent S phase depletion, has been attributed to a 
decrease in cellular ATP, as demonstrated using mitochondrial function disrupting 
agents.[41] Therefore, a direct quantitative measure of the ATP in gold nanoparticle-
treated HSC cells was carried out. As shown in Figure 3.13, the amount of ATP present 
in cells is reduced with increased nanoparticle treatment concentrations for all 
nanoparticle formulations. 
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Figure 3.13. ATP depletion induced by peptide-conjugated AuNPs (0.1 and 0.4 nM), 
normalized to the control (HSC cells treated with nanoparticle-free medium) after 48 h. 
The combination of RGD and NLS peptides conjugated to the nanoparticles allows for 
the greatest reduction in ATP in the case of the AuNSs (A) and AuNCs (B). Values 
expressed as mean + standard deviation of three independent experiments. Statistical 
significance, with respect to control (0.0 nM), indicated by * (p < 0.05). 
 
The greatest reduction in ATP is observed with 0.4 nM RGD/NLS-AuNCs and 
RGD/NLS-AuNSs, as would be expected, based on the cell cycle changes observed for 
these two nanoparticle treatments (Fig. 3.12). When HSC cells are treated with 0.4 nM 
RGD/NLS-AuNCs, ATP production is reduced to about 38%, which is slightly lower 
than the 43% ATP production observed with 0.4 nM RGD/NLS-AuNS-treated cells. 
With previous evidence of the reduction of ATP leading to apoptosis[40], the sub G1 cell 
population observed in the cell cycle histograms (Appendix A, Figure A.6), and the 
efficacy at which these HSC cell nucleus targeting (RGD/NLS) nanoparticles reduce 
ATP in HSC cells, it is imperative to assess the fate of these physiological changes and to 
determine if the outcome (i.e. apoptosis  and/or necrosis) is dependent on the nanoparticle 
structure (i.e. solid sphere vs. hollow cage). In order to directly resolve whether or not the 
peptide-conjugated gold nanoparticles utilized in this study cause apoptosis and/or 
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necrosis, flow cytometric analysis of Alexa Fluor 488 conjugated annexin-V and 
propidium iodide (PI) in HSC cells was utilized. One of the earliest events that take place 
during apoptosis is the exposure of phosphatidylserine (PS) residues on the outer leaflet 
of the cell membrane. These PS residues have a high affinity for the phospholipid binding 
protein annexin-V. Therefore, by exposing cells to fluorescently labeled annexin-V, 
apoptosis can be quantified by the fluorescence intensity measured using flow 
cytometry.[42] The apoptotic population can be distinguished from the necrotic 
population with the addition of PI, which binds nucleic acids in cells only once the 
membrane becomes permeable (i.e. necrosis).  
HSC cells were treated with 0.1 and 0.4 nM concentrations of peptide-conjugated 
gold nanoparticles and the percentages of apoptotic and necrotic cells were determined. 
The RGD/NLS-conjugated nanoparticles induce greater overall cell death than those 
conjugated with only RGD or only NLS (Appendix A, Figure A.7), which correlates well 
with the observed decrease in ATP for these nanoparticle formulations in particular. As 
shown in Figure 3.14, the AuNCs significantly induce more apoptosis (Fig. 3.14A) and 
necrosis (Fig. 3.14B) than the AuNSs. At higher treatment concentrations, the 
RGD/NLS-AuNCs induce apoptosis in HSC cells two times greater than RGD/NLS-
AuNSs.  
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Figure 3.14. Cell death, via apoptosis (A) and necrosis (B), induced in HSC cells after 48 
h treatment with 0, 0.1, and 0.4 nM peptide-conjugated AuNSs (purple) and AuNCs 
(blue). The RGD/NLS-AuNCs, at 0.4 nM treatment concentrations, induce the greatest 
amount of cell death. Values expressed as mean + standard deviation of three 
independent experiments. Statistical significance, with respect to control (above each bar) 
and between AuNSs and AuNSs (above each line) indicated by * (p < 0.05). 
 
At higher concentrations, the RGD/NLS-AuNCs induce thirty times more necrosis 
than RGD/NLS-AuNSs. It is also important to note that these nanoparticles induce 
minimal cell death in a control (HaCat) cell line (Appendix A, Figure A.8), as these cells 
do not overexpress alpha beta integrins[43] and thereby are not effectively targeted with 
the RGD conjugated nanoparticle. The drastic differences in which the peptide-
conjugated nanoparticles, solid gold spheres and hollow gold cages, induce cell death in 
HSC cells prompt an explanation for how two different gold nanoparticle formulations 
could have such different effects on these cells. 
3.2.3.2. Possible mechanism for enhanced nanoparticle-induced cell death by the 
nanocages 
Since it has been shown previously that nanoparticle conjugates exhibit enhanced 
cellular effects compared to the free ligands in solution,[44, 45] we therefore propose that 
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the RGD and NLS peptides conjugated to the nanoparticles are more effective than when 
free in solution.  HSC cells were treated with the same concentration of NLS and RGD 
peptides as that which was added to the nanoparticles during conjugation (4 and 3.2 μM, 
respectively). The free NLS and RGD peptides induce much lower levels of apoptosis 




Figure 3.15. Cell death induced, via apoptosis (yellow) and necrosis (grey), in HSC cells 
after 48 h treatment with varying concentrations AgNO3 (i.e. Ag
+
 ions), as well as free 
peptides in culture medium (3.2 µM RGD and 4 µM NLS). Values expressed as mean + 
standard deviation of three independent experiments. Statistical significance, with respect 
to control, indicated by * (p < 0.05). 
 
 
This is possibly due to an RGD-dependent pathway. As was previously suggested by 
Salmon and coworkers, the RGD peptide activates pro-caspase-3, a pro-apoptotic protein, 
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via interactions with an RGD-binding motif and subsequent conformational changes in 
the protein.[19, 20] It is possible that multivalency (i.e. localized RGD peptides bound to 
the gold nanoparticle surface) can enhance the overall effect of RGD on the cell.  
Another mechanism is proposed based on the confirmation that the RGD/NLS-
AuNCs reduce ATP and induce apoptosis and necrosis in HSC cells to a greater extent 
than RGD/NLS-AuNSs. As expected, based on the method of AuNC synthesis (see 
Experimental section 3.3.2.2), ICP results show a 10% silver atom content in the metallic 
composition of the AuNCs used in this study. Therefore, we consider the possibility that 
there could be Ag
+
 ions present in the nanoparticle solution used for the treatment of 
HSC cells. In order to quantify the amount of Ag
+
 ions, NaCl was added to the 0.4 nM 
RGD/NLS-AuNC solution, such that the NaCl concentration is slightly below its Ksp. 
Upon dissolution of NaCl in the 0.4 nM RGD/NLS-AuNC solution, no AgCl white 
precipitate was observed, indicating that the concentration of Ag
+
 in the AuNC solution 
must be below 0.0456 nM. Therefore, HSC cells were treated with 0.0456 nM AgNO3 to 
represent the maximum concentration of Ag
+
 ions that could be present in the 0.4 nM 
RGD/NLS-AuNC treatment, as well as 10 and 20 nM AgNO3, to represent the 
concentration of Ag
+
 ions that would be needed in order to observe high levels of 
apoptosis or necrosis. Figure 3.15 displays the apoptotic and necrotic populations for 
cells treated with increasing concentrations of AgNO3 (i.e. Ag
+
 ions). It is obvious here 
that 0.0456 nM Ag
+
 is not sufficient to induce apoptosis or necrosis to the extent at which 
the 0.4 nM RGD/NLS-AuNCs do. It is also apparent that the concentration of Ag
+
 would 
have to be on the order of 20 nM for there to be significant apoptosis in HSC cells. 
Although the Ag
+
 ions do not appear to induce apoptosis or necrosis, the residual silver 
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atoms remaining on the inner cavity of the AuNCs could possibly have been oxidized in 
the cell culture medium to silver oxide (Ag2O).[26, 46] To test this, AuNCs were left 
under physiological conditions, in cell culture medium, for 48 h, after which the UV-Vis 
spectrum was taken in order to detect any changes in the surface plasmon resonance of 
the AuNCs. Indeed, a 51 nm redshift in the AuNC surface plasmon resonance was 
observed after 48 h in cell culture medium, as shown in Figure 3.16, indicating the 
residual silver atoms on the inner cavity of the AuNC were oxidized to Ag2O.[47-49]  
 
 
Figure 3.16. UV-Vis spectra of AuNCs in water (left) and DMEM, cell culture medium 
(right). A 51 nm shift in the surface plasmon of the AuNCs in DMEM is observed after 
48 h at physiological conditions indicating the oxidation of silver atoms to Ag2O on the 
inner cavity of the AuNC. 
 
It has previously been shown, by Yen, et. al.,[26] that when Ag2O is formed on the 
inside of the gold nanocage, it has the ability to produce hydroxyl radicals (generally 
termed reactive oxygen species (ROS)). These ROS have shown to damage DNA, 
ultimately leading to apoptosis, especially when located near the DNA,[27] as would be 
expected with the nuclear-targeted AuNPs studied here. Therefore, it is important to 
consider the possibility that ROS are generated by the RGD/NLS-AuNCs, which might 
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be causing the observed enhanced apoptosis and necrosis[50] above that observed with 
RGD/NLS-AuNSs. Confocal imaging was performed to detect the presence of ROS in 
HSC cells treated with 0.4 nM RGD/NLS-AuNCs and AuNSs, as shown in Figure 3.17.  
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Figure 3.17. Reactive oxygen species (ROS) generation detected by confocal microscopy 
for 0.4 nM RGD/NLS-AuNSs and AuNCs. DAPI panel (left) shows the nuclei of HSC 
cells stained blue. FITC panel (middle) represents green fluorescence indicative of ROS 
generated inside cells. DAPI/FITC overlay (right) shows the combination of both nuclei 
and ROS. Control (cells treated with nanoparticle-free medium) exhibits minimal FITC 
fluorescence, along with the 0.4 nM RGD/NLS-AuNSs. 100 μM H2O2 shows high FITC 
fluorescence, used as a positive control for ROS generation. The 0.4 nM RGD/NLS-
AuNCs display FITC fluorescence, indicating ROS are generated in HSC cells with this 
nanoparticle treatment. Scale bar: 20 µm. 
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HSC cells were stained with H2DCFDA after treatment with nanoparticles and a 
green fluorescent (FITC) signal is generated when the acetate groups of H2DCFDA are 
removed during intracellular oxidation via the generation of ROS. The confocal images 
shown in Figure 3.17 show that there are indeed ROS in the RGD/NLS-AuNC-treated 
HSC cells, which is not seen with the RGD/NLS-AuNS treatment. The presence of ROS 
is also detected with other peptide-conjugated AuNCs, but not the AuNSs (Appendix A, 
Figure A.9). Although the ROS seen with the AuNCs is not as apparent as the ROS seen 
with a positive control (100 μM H2O2 for 3 h), it can still be concluded that the silver 
atom content on the inner cavity of the AuNCs has an impact on the enhanced apoptosis 
and necrosis observed for the RGD/NLS-AuNC-treated HSC cells. 
 
3.2.4. Conclusions and Future Outlook 
We have found here that hollow gold nanocages conjugated with nuclear targeting 
(NLS) and cancer cell penetration/pro-apoptotic (RGD) peptides induce apoptosis and 
necrosis in HSC cancer cells to a greater extent than solid gold nanospheres. The 
observed cell death is preceded by a number of different processes that also appear to be 
dependent on the concentration and shape/metallic composition of the peptide-conjugated 
gold nanoparticles. It is found that the 0.4 nM RGD/NLS-AuNCs and RGD/NLS-AuNSs 
induce cell cycle changes (i.e. G0/G1 phase accumulation, S phase depletion and G2/M 
phase depletion) (Fig. 3.12) and subsequently reduce ATP production in HSC cells (Fig. 
3.13). The outcome of these cell cycle changes and reduction in ATP is apoptosis and 
necrosis (Fig. 3.14), with the greatest degrees of apoptosis and necrosis occurring when 
HSC cells are treated with the hollow gold nanocages. The increased apoptosis and 
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necrosis seen with hollow gold nanocages can be explained based on the metallic 
composition of the gold nanocage. As a result of the synthesis, the gold nanocage has 
residual silver atoms on its inner cavity, which can be easily oxidized to Ag2O, as 
observed by a redshift in the AuNC surface plasmon resonance (Fig. 3.16),[47-49] which 
in turn produces ROS,[26, 50] as observed by confocal microsopy of HSC cells treated 
with 0.4 nM RGD/NLS-AuNCs (Fig. 3.17). In conclusion, it is clear here that the 
metallic composition and thus, the shape of gold nanoparticles have an impact on their 
intrinsic antineoplastic properties, which can possibly be exploited further in the 
treatment of cancer.  
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3.3.  Varying the Silver Content of Gold Nanocages Impacts Apoptosis and 
Necrosis Induced in Cancer Cells [1] 
 
We previously reported that cancer cell nucleus targeting gold nanocages (AuNCs) 
induce higher levels of apoptosis and necrosis than their gold nanosphere counterparts. 
We attributed this enhancement in cell death to the residual silver present on the inner 
cavity of the AuNC (inherent to its synthesis) being oxidized to Ag2O in the cell culture 
and subsequently generating toxic reactive oxygen species. Based on these observations, 
we have examined this mechanism further, in the present work, by comparing the 
apoptosis and necrosis induced in cancer cells by AuNC containing varying ratios of Ag 
to Au, which can be controlled through the galvanic replacement method of synthesis. 
First, three different AuNC were synthesized such that they contained increasing ratios of 
Ag to Au. Second, the three different AuNCs were functionalized with cancer cell 
targeting (RGD) and nuclear targeting (NLS) peptides (RGD/NLS-AuNCs). The extent 
of Ag oxidation was estimated based on the redshift of the surface plasmon peak position 
for each of the three different RGD/NLS-AuNCs, with the greatest redshift occurring for 
AuNCs with highest Ag to Au ratio. The RGD/NLS-AuNCs were then tested for their 
ability to induce apoptosis and necrosis in cancer cells. The highest levels of apoptosis 
and necrosis were observed for AuNCs with the highest Ag to Au ratio. These results 
indicate that these particles induce cell death in a particle composition-dependent manner. 
More importantly, these results stress how crucial it is to consider the morphology, 
composition, and even the synthesis of nanostructures when utilizing them in cancer 
therapeutics.  
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3.3.1. Introduction 
Gold nanostructures are becoming increasingly popular in the application of cancer 
therapeutics, either by utilizing them as contrast agents for photothermal therapy,[2-8] 
imaging contrast agents,[9-11] drug delivery vehicles[12, 13] or as intrinsic 
antineoplastic agents.[14-17] Specifically, gold nanocages (AuNCs) have received a great 
deal of attention with their ability to function in all of the above aspects of cancer 
therapeutics.[7, 17-19] In considering their growing popularity for use in nanomedicine, 
it is crucial to understand how the morphology and composition of these AuNCs might 
affect living cancer cells, specifically when targeted to the nucleus. We have already 
established that the synthesis of these nanostructures can impact how they interact with 
cells. This is mainly due to the presence of residual silver that remains on the inner cavity 
of the AuNC after synthesis via galvanic replacement.[20] The residual silver can be 
oxidized under certain conditions, such as in cell culture medium,[21] creating a layer of 
silver oxide on the inner cavity of the AuNC. Silver oxide is known to generate reactive 
oxygen species (ROS),[22] which are highly toxic to cells.[23, 24] Therefore, it is 
possible that the amount of Ag2O present on the inner cavity of the AuNC could 
potentially influence the levels of apoptosis and necrosis induced when targeted to the 
cancer cell nucleus. 
In the present work we synthesize three different AuNCs with varying Ag:Au ratios 
(i.e. varying amounts of silver) and functionalize them with peptides known to target 
alpha v beta integrins present on the cancer cell surface,[25-28] as well as nuclear 
targeting peptides to facilitate nuclear localization[29-31] of AuNCs within the cells of 
interest.[17] The extent of oxidation of the three different AuNCs, indicated by a redshift 
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in the surface plasmon peak position, is measured after a 48 h incubation period in cell-
free culture medium. Further studies are conducted, in the presence of cells, to correlate 
the Ag:Au ratio, and subsequent silver oxidation, of the AuNCs to the levels of apoptosis 
and necrosis induced when these particles are localized at the nucleus of cancer cells. 
 
3.3.2. Experimental Methods 
3.3.2.1. Cell Culture 
Human oral squamous cell carcinoma (HSC-3) cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Mediatech) supplemented with 10% v/v fetal bovine 
serum (FBS, Mediatech) and 1% v/v antimycotic solution (Mediatech) in a 37˚C, 5% 
CO2 humidified incubator. 
3.3.2.2. Gold Nanocage Synthesis and Peptide Conjugation 
Gold nanocages (AuNCs) are synthesized via galvanic replacement method using 
silver nanocubes as a template. The silver atoms of the silver nanocube template are 
oxidized by Au
3+
, which is subsequently reduced and deposited onto the surface of the 
template.[20] The silver nanocube template is prepared by a previously reported 
method.[32] Briefly, 70 mL of ethylene glycol (EG) is heated to 145°C for 1 h, followed 
by addition of polyvinyl pyrrolidone (PVP, MW 55,000; 0.82 g dissolved in 5 mL EG). 
The temperature is then raised to 150°C and 0.7 mL of a 3 mM sodium sulfide solution 
(in EG) is added, followed by slow injection of 4 mL of a silver nitrate solution (0.48 g 
dissolved in 10 mL EG). [22, 33] The silver nanocubes are then purified by adding a 1:2 
acetone:water mixture at a volume twice that of the nanocube solution, followed by 
centrifugation at 10,000 rpm for 5 min and redispersing the precipitate in 600 mL of DI 
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water. From the template of silver nanocubes, AuNCs of different morphologies (i.e. 
porosity) and Ag to Au ratios can be prepared. Briefly, the silver nanocube solution is 
brought to a boil and a 10 mg/L hydrogen tetrachloroaurate (HAuCl4·3H2O) solution is 
slowly injected until the surface plasmon resonance peak of the solution shifts from ca. 
442 nm (silver nanocubes) to ca. 600 nm (gold-silver nanoboxes). Upon initial peak shift, 
a 1 mg/L HAuCl4·3H2O solution is added drop wise until the peak shifts to ca. 650 nm 
(Fig. 3.18A, sample 1). A 200 mL volume of this solution is moved to another clean flask 
and left to cool to room temperature. The 1 mg/L HAuCl4·3H2O solution is further added 
to the remaining 400 mL of the nanoparticle solution until the peak shifts to ca. 700 nm 
(Fig. 3.18A, sample 2). A 200 mL volume is again removed and placed in another clean 
flask to cool to room temperature. Further addition of the 1 mg/L HAuCl4·3H2O solution 
to the remaining 200 mL until the peak shifts to ca. 760 nm (Fig. 3.18A, sample 3). These 
three different samples of AuNCs exhibit varying ratios of Ag to Au. The AuNCs are 
then purified by centrifugation at 10,000 rpm for 5 min and redispersed in DI water. TEM 
images revealed that the AuNCs synthesized here have a wall length of about 40 nm, as 
shown in Figure 3.18B-D. Because the amount of Ag present in each of the different 
AuNC samples can vary with the addition of Au salt, ICP analysis was done by 
dissolving 1 mL of a 1 nM solution of each sample in nitric acid. The Ag to Au ratio was 
then determined. 
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Figure 3.18. UV-Vis spectra (A) and TEM images of 40 nm AuNCs (B-D) synthesized 
with varying  ratios of Ag to Au. As more gold salt is deposited onto the silver nanocube 
template, the surface plasmon peak redshifts (A). Scale bar: 40 µm. 
 
 
Upon synthesis and purification of the various AuNCs, they were stabilized with 
polyethylene glycol (mPEG-SH, MW 5000, Laysan Bio, Inc.) by addition of a 1 mM 
aqueous solution of PEG to the AuNCs at 10
4
 molar excess and shaking overnight. The 
PEG-AuNCs were then purified by centrifugation at 6000 rpm for 15 min and redispersed 
in water. After PEGylation, the particles are conjugated with custom peptides purchased 
from Genscript USA, Inc. as previously described.[17] Specifically, aqueous solutions of 
both an RGD peptide (RGDRGDRGDRGDPGC) and an NLS peptide 
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(CGGGPKKKRKVGG) were added to the PEG-AuNCs at a 10
4
 molar excess and left on 
an orbital shaker overnight. The RGD/NLS-AuNCs were then purified by centrifugation 
at 6000 rpm for 15 min and redispersed in DI water. 
3.3.2.3. Flow Cytometry Analysis of Apoptosis and Necrosis 
Cell death, via apoptosis and necrosis, associated with the treatment of cells with the 
varying RGD/NLS-AuNCs, was quantified using the ApoTarget
TM
 Annexin-V FITC 
Apoptosis Kit (Invitrogen, Inc. Cat. #PHN1010). The standard protocol was optimized 
for our experimental conditions. Briefly, HSC cells were plated in a 12-well tissue culture 
plate. Cells were allowed to grow overnight, after which they were treated with 0.1 nM 
RGD/NLS-AuNCs (samples 1-3). Upon treatment of cells, they are washed with PBS and 
collected by trypsinization and centrifugation. The cells are then washed again with cold 
PBS and collected by centrifugation, after which, 500 µL of 1x Annexin binding buffer, 2 
µL of 100 µg/mL PI and 5 µL of Annexin-V-FITC are all mixed with the cells and left to 
incubate for 15 min at room temperature. Following cell staining with PI and Annexin-V-
FITC, the remaining volume of 1x Annexin binding buffer was added (493 µL) and the 
cell solution was passed through a 40 µm sterile filter. Cells are then analyzed on a BD 
LSR II (BD Biosciences) with a 488 nm excitation. Flow cytometry data is analyzed 
using the flow cytometry analysis software, FlowJo. Results are reported as the average 
% of cells + standard deviation. 
3.3.2.4. Statistical Analysis 
Statistical significance was determined with the t test calculator (GraphPad Software, 
Inc.). Data is considered statistically significant when p < 0.05 and is indicated by *. 
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3.3.3. Results and Discussion 
The presence of residual silver on the inner cavity of gold nanocages (AuNCs) is 
inherent to their synthesis via galvanic replacement.[34, 35] This method of synthesis 
begins with a silver nanocube template and, after oxidation of the silver atoms by Au
3+
 
ions, results in a hollow cage structure with porous faces and residual silver remaining on 
the inner cavity, as displayed by the reaction and schematic shown in Figure 3.19. 
 
 
Figure 3.19. Synthesis of AuNCs via galvanic replacement. Stoichiometrically, three Ag 
atoms of the Ag nanocube template are oxidized by one Au
3+
 ion of the Au salt, which is 
subsequently reduced and deposited onto the Ag template. This results in hollow cage 
structure with porous faces and residual Ag on the inner cavity. 
 
Using this method of synthesis, it is possible to vary the ratio of Ag to Au in the 
nanocage. Therefore, we have used this method to obtain three different samples of 
AuNCs, all having the same average wall length, but varying silver content. During the 
synthesis of AuNCs (see section 3.3.2.2), a redshift of the surface plasmon peak (Fig 
3.18A) with increasing amounts of gold salt is an indication of the decrease in silver 
content.[34, 35] The actual ratio of Ag to Au for each AuNC synthesized in this work 
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was determined and is shown in Table 3.3 and it is clear that as the surface plasmon peak 
of the AuNCs is redshifted as the amount of silver present is slightly increased. 
 
Table 3.2. Various AuNCs synthesized with different surface plasmon peak positions and 




With evidence that AuNC samples 1-3 have increasing Ag:Au ratios, it is important 
to assess the implications of these variations. It is especially important to determine how 
the change of structure and composition of AuNCs will affect how these nanoparticles 
function in a physiological environment. Therefore, we have investigated the oxidation of 
these AuNCs in cell culture medium, since it has been previously suggested that the 
silver, remaining on the inner cavity, of the AuNCs can be oxidized to silver oxide 
(Ag2O) under these conditions.[17, 21] The oxidation of Ag to Ag2O, in general, can be 
estimated by a redshift in the surface plasmon peak position, which has been previously 
demonstrated both theoretically and experimentally.[36] This has also been shown in the 
case of oxidizing AuNCs.[22] In order to estimate the oxidation of RGD/NLS-AuNCs in 
this work, a 0.2 nM concentration of particles in cell culture medium was placed at 37˚C 
in a 5% CO2 humidified incubator for up to 48 h. The surface plasmon peak position was 
determined for each of the samples at 0, 24, and 48 h. Figure 3.20 displays the peak shift 
observed for samples 1-3. It should be noted that the initial peak position (0 h) is shifted 
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with respect to that of the as-synthesized AuNCs, due to conjugation of peptides and 
dispersion in cell culture medium (i.e. change in dielectric of the medium surrounding the 
nanoparticle). 
  
  125 
 
 
Figure 3.20. Surface plasmon peak shifts observed for the oxidation of various 
RGD/NLS-AuNCs incubated in cell culture medium for up to 48 h. (A) Sample 1 (2.56 
Ag:Au) exhibits an 84 nm redshift after 48 h. (B) Sample 2 (2.34 Ag:Au) exhibits a 63 
nm redshift after 48 h. (C) Sample 3 (1.78 Ag:Au) exhibits a 37 nm redshift after 48 h. 
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The peak shifts observed for the various RGD/NLS-AuNCs indicate that these 
particles are indeed oxidized under cell culture conditions at 24 h and further oxidized 
when remaining under these conditions up to 48 h. Based on previous reports of Ag being 
oxidized to Ag2O,[36] it can be estimated that the greatest redshift in the plasmon peak 
position (sample 1, 2.56 Ag:Au, 84 nm redshift) would have the greatest amount of Ag2O 
present on the inner cavity of the AuNC after oxidation of Ag in cell culture medium. We 
have previously reported that the oxidation of Ag remaining on the inner cavity of 
RGD/NLS-AuNCs can specifically induce cell death in HSC cells, via apoptosis and 
necrosis.[17] Because it has been established that Ag2O causes the production of toxic 
reactive oxygen species (ROS) in cells,[22-24] the impact of varying the Ag content, and 
subsequent Ag2O presence, on cell death is therefore assessed utilizing flow cytometry 
for the detection of apoptosis and necrosis (see section 3.3.2.3). Figure 3.21 displays the 
populations of apoptotic and necrotic cells induced in HSC cells after a 48 h treatment 
with RGD/NLS-AuNCs having increasing Ag content. 
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Figure 3.21. Apoptosis and necrosis induced in HSC cells by 48 h treatment of 0.1 nM 
RGD/NLS-AuNCs with varying porosity and Ag content (Samples 1-3). All nanocage-
treated samples have statistically higher levels of apoptotic and necrotic cells (p < 0.05) 
than the untreated cells (control). Remaining data are considered statistically significant if 
p < 0.05, and is indicated by * above bars. 
 
It appears that the greatest amount of apoptosis (~17%) is observed when HSC cells 
are treated with RGD/NLS-AuNCs having the highest amount of Ag (sample 1, 2.56 
Ag:Au) and the difference between sample 1 and sample 2 (2.34 Ag:Au) is not 
significant. However, the RGD/NLS-AuNCs having the lowest amount of Ag (sample 3, 
1.78 Ag:Au) do exhibit the least amount of apoptotic cells (~8%) when compared to the 
other treatments. In terms of necrosis, the RGD/NLS-AuNCs with the highest levels of 
Ag (sample 1 and sample 2) both induce significantly more (~7% and ~9%, respectively) 
than the particles containing the smallest amount of Ag (only ~2% necrotic cells).  
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3.3.4. Conclusions and Future Outlook 
In conclusion, the specific targeting of AuNCs to the nucleus of HSC cells 
(RGD/NLS-AuNCs) induces apoptosis and necrosis in a silver content-dependent 
manner. We propose that the Ag remaining on the inner cavity of the AuNCs becomes 
oxidized to Ag2O during the 48 h treatment period when in cell culture medium. The 
RGD/NLS-AuNCs exhibit redshifts in their surface plasmon peak positions, such that 
greater extent of Ag oxidation to Ag2O is characterized by a larger redshift.[36] The 
extent to which Ag is oxidized to Ag2O is said to be the basis of the observed trend of 
apoptosis and necrosis increasing with increasing Ag:Au ratio. The actual oxidation state 
of Ag can possibly be quantified (i.e. determine actual extent of Ag oxidation to Ag2O) 
by X-Ray Photoelectron Spectroscopy (XPS), which should be the next step in assessing 
the effects of AuNC oxidation on cellular functions. These results have important 
implications in the use of these nanostructures in medicine, such that the amount of Ag 
present within the inner cavity of the AuNC must be taken into consideration before 
utilizing them as photothermal contrast agents or drug delivery vehicles. 
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We have previously shown that gold nanoparticles conjugated with nuclear-targeting 
and cytoplasm-targeting peptides (NLS and RGD, respectively) are capable of altering 
the cell cycle of human oral squamous carcinoma cells (HSC-3). In the present work, we 
show that this regulation of the cell cycle can be exploited to enhance the efficacy of a 
common chemotherapeutic agent, 5-Fluorouracil, by pre-treating cells with gold 
nanoparticles. Utilizing flow cytometry cell cycle analysis, we were able to quantify the 
5-Fluorouracil efficacy as an accumulation of cells in the S phase with a depletion of 
cells in the G2/M phase. Nuclear-targeted gold nanoparticles (NLS-AuNPs, 30 nm in 
diameter) showed the greatest 5-Fluorouracil efficacy enhancement when compared to 
smaller NLS-AuNPs (15 nm in diameter) and particles that were targeted to the 
cytoplasm (RGD-AuNPs, 30 nm in diameter). Not only were these particles best at 
enhancing 5-Fluorouracil efficacy via cell cycle regulation, but this was further 
confirmed by cytotoxicity measurements. When 5-Fluorouracil treatment (500 µM, 48 h) 
is preceded by a 24 h treatment with 30 nm NLS-AuNPs (0.4 nM), the cell viability is 
significantly reduced from 40% to 17%. In addition, modes of cell death induced by 5-
Fluorouracil, namely late apoptosis and necrosis, were shown to be enhanced by the pre-
treatment of cells with these 30 nm NLS-AuNPs. Overall, we show that nuclear-targeted 
30 nm gold nanoparticles enhance 5-Fluorouracil drug efficacy in HSC-3 cells via 
regulation of the cell cycle, a chemosensitization technique that could potentially be 
expanded to different cell lines and different chemotherapies.  
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3.4.1. Introduction 
Noble metal nanoparticles are becoming increasingly prominent in the treatment of 
disease due to their unique properties as both intrinsic antineoplastic agents[2-5] and 
extrinsic photothermal contrast agents.[6-12] Gold nanoparticles, in particular, are 
showing great promise as antineoplastic agents, especially with their ability to prohibit 
cell growth and regulate the cell cycle without external stimulation via radiation.[3, 5, 13-
15] Specifically, cell cycle regulation by gold nanoparticles has been utilized for the 
sensitization of malignant cells to radiation. For example, Roa, et.al.[15] previously 
showed that glucose-capped gold nanoparticles caused accumulation of prostate cancer 
cells (DU145) in the G2/M phase of the cell cycle and subsequent radiation sensitization 
of these cells, as cells in the G2/M phase are most vulnerable to radiation. Another group 
later showed that peptide-capped gold nanorods were capable of sensitizing melanoma 
cells (A375) to radiation, also through a G2/M arrest.[16] 
Cell cycle regulation by gold nanoparticles could also potentially be useful for 
sensitization of malignant cell lines to chemotherapeutic agents. For example, the 
antimetabolite drug 5-Fluorouracil (5-FU) specifically acts on cells present in the S phase 
of the cell cycle.[17] More specifically, a population of cells is resistant to 5-FU 
treatment when there is a depletion of cells in the S phase with an accumulation of cells 
in the G2/M phase.[18, 19] With the extensive research done on the use of 5-FU as a 
chemotherapeutic agent and its mode of action, it is possible to now enhance 5-FU 
chemosensitivity in cells, namely by regulating the cell cycle. 
In the present work, we show that gold nanoparticles, specifically conjugated with 
nuclear-targeting peptides, are capable of regulating the cell cycle, such that they induce 
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an S phase accumulation and G2/M phase depletion. Subsequently, these gold 
nanoparticles enhance the chemosensitivity of a human oral squamous carcinoma cell 
line to 5-FU treatment, as shown by a cell viability assay. Along with the cell viability 
results, the mode of cell death is assessed by flow cytometry analysis of apoptotic and 
necrotic cells. With these results, it is again apparent that the pre-treatment of cells with 
nuclear-targeting gold nanoparticles, can enhance cell death pathways already 
predominant with 5-FU treatment. The cell cycle regulation and subsequent enhancement 
of 5-FU efficacy seen with the gold nanoparticles investigated in this work is dependent 
upon both nanoparticle size (30 vs. 15 nm) and nanoparticle functionalization with RGD 
peptides versus NLS peptides (i.e. location of nanoparticles within cells). Also interesting 
is that the gold nanoparticles are not inherently cytotoxic to the cells, potentially 
minimizing toxicity issues commonly presented with combination chemotherapies. 
 
3.4.2. Experimental Methods 
3.4.2.1. Cell Culture 
Human oral squamous cell carcinoma (HSC-3) cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Mediatech) supplemented with 10% v/v fetal bovine 
serum (FBS, Mediatech) and 1% v/v antimycotic solution (Mediatech) in a 37˚C, 5% 
CO2 humidified incubator. 
3.4.2.2. Gold Nanoparticle Synthesis and Peptide Conjugation 
Gold nanoparticles (AuNPs) were synthesized via citrate reduction of chloroauric 
acid (HAuCl4), as developed by Frens[20] Briefly, 50 mL of a 0.01% (w/v) HAuCl4 
aqueous solution is brought to a boil, while stirring, followed by addition of a trisodium 
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citrate aqueous solution. The reaction is determined to reach completion when the 
solution color changes from clear to a deep red/purple. To obtain AuNPs with a 30 nm 
diameter (Figure 3.22A), 1 mL of 1% (w/v) trisodium citrate was added to the HAuCl4 
solution. To obtain AuNPs with a 15 nm diameter (Figure 3.22B) 1 mL of 2% trisodium 
citrate (w/v) was added. The AuNPs were then purified by centrifugation at 6000 rpm for 
15 min and redispersed in water. The core nanoparticle diameters were determined using 









, respectively) were based on previous reports.[21] 
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Figure 3.22. TEM images of AuNPs synthesized via citrate reduction of HAuCl4. (A) 
AuNPs with diameter of 29 + 4 nm, inset showing size distribution histogram. (B) 
AuNPs with diameter of 14 + 1 nm, inset showing size distribution histogram. 
 
The as-synthesized AuNPs are first stabilized with polyethylene glycol (mPEG-SH, 
MW 5000, Laysan Bio, Inc.) to prevent nonspecific adsorption of proteins and other 
biological components in the physiological environment. Stabilization with PEG was 
achieved through addition of a 1 mM aqueous solution of PEG to the AuNP solution at a 
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molar excess of 10
4
 and shaking on an orbital shaker overnight at room temperature. 
After PEG stabilization, the AuNPs were centrifuged at 6000 rpm for 15 min and 
redispersed in water. 
The now PEG-stabilized AuNPs were functionalized with custom peptides purchased 
from GenScript USA, Inc, as we have previously demonstrated.[5] Specifically, an NLS 
(nuclear localization sequence) peptide with the sequence CGGGPKKKRKVGG and an 
RGD (Arg-Gly-Asp) peptide with the sequence (RGD)4PGC were used throughout this 
work. Peptide conjugation was achieved through addition of a 5 mM aqueous solution of 
peptides to the PEG-AuNP solutions at a molar excess of 10
4
 and shaking on an orbital 
shaker overnight at room temperature. The peptide-conjugated AuNPs were then purified 
by centrifugation at 6000 rpm for 15 min and redispersed in water. Three different 
nanoparticle formulations were utilized in this study; 15 nm NLS-AuNPs, 30 nm NLS-
AuNPs and 30 nm RGD-AuNPs.  
In order to confirm nanoparticle functionalization, the hydrodynamic diameter (HD) 
and zeta potential were measured via dynamic light scattering (DLS). Table 3.4 displays 
the increasing HD and neutralization of zeta potential upon conjugation of citrate-capped 
AuNPs with PEG and peptides. 
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Table 3.3. Dynamic light scattering measurements of the hydrodynamic diameter and 




3.4.2.3. Treatment of Cells with AuNPs and 5-Fluorouracil 
HSC-3 cells were treated with both AuNPs and 5-Fluorouracil (5-FU). Briefly, after 
cells were grown overnight, a 0.4 nM concentration of AuNPs (in cell culture medium) 
was added to the cells. Cells were treated with AuNPs for 24 h, after which, they were 
washed with PBS and subsequently treated with various concentrations of 5-FU. Cells 
were treated with 5-FU for 48 h before performing analyses. The control samples in this 
work are treated with an appropriate concentration of DMSO in cell culture medium 
(0.2%) corresponding to the highest percentage of DMSO that is introduced to cells by 
the 5-FU treatment.  
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3.4.2.4. Flow Cytometry Cell Cycle Analysis 
In order to determine the percentages of cells that exist in specific phases of the cell 
cycle, flow cytometry cell cycle analysis was performed. Briefly, HSC cells were plated 
in a 12-well tissue culture plate. Cells were allowed to grow overnight after which 
treatment was administered according to method described in Section 3.4.2.3. Upon 
treatment of cells, they are washed with PBS, collected by trypsinization and 
centrifugation, and fixed in 70% ice cold ethanol and storage at -20 °C. For preparation 
of cells for flow cytometry cell cycle analysis, the fixed cell suspension is centrifuged 
and a cell pellet is obtained. The cells are then redispersed in PBS (750 uL) and 5 uL of 2 
mg/mL RNase is added and the cells are incubated at 37 °C for 30 min. After RNase 
treatment, cells are stained with 75 uL of the fluorescent nucleic acid dye, Propidium 
iodide (PI, 1 mg/mL). Cells are then incubated at room temperature for 15 min, after 
which they are passed through a 40 um sterile filter. Cells are then analyzed on a BD LSR 
II (BD Biosciences) with a 488 nm excitation. Flow cytometry data is analyzed using the 
flow cytometry analysis software, FlowJo. Results are reported as the average % of cells 
in each phase of the cell cycle + standard deviation. 
3.4.2.5. Cell Viability Assay 
In order to determine cell viability, an XTT assay (Biotium, Inc. Cat# 30007) was 
utilized. Briefly, HSC cells were plated in a 96-well tissue culture plate. Cells were 
allowed to grow overnight, after which, treatment was administered according to method 
described in Section 3.4.2.3. Upon treatment of cells, they are washed with PBS and then 
incubated with the activated XTT reagent (prepared according to manufacturer’s 
protocol) for 5 h. The cell viability is determined based on spectrophotometric 
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measurements of the XTT reagent with a Biotek Synergy H4 multi-mode plate reader. All 
treated groups are normalized to the control (HSC cells treated with 0.2% DMSO) and 
results are reported as the average % viability + % relative standard deviation. 
3.4.2.6. Apoptosis and Necrosis Detection via Flow Cytometry 
In order to quantify the various modes of cell death that are potentially involved with 
the combination treatment of AuNPs and 5-FU, the ApoTarget
TM
 Annexin-V FITC 
Apoptosis Kit (Invitrogen, Inc. Cat. #PHN1010) was utilized. The standard protocol was 
optimized for our experimental conditions. Briefly, HSC cells were plated in a 12-well 
tissue culture plate. Cells were allowed to grow overnight after which treatment was 
administered according to method described in Section 3.4.2.3. Upon treatment of cells, 
they are washed with PBS and collected by trypsinization and centrifugation. The cells 
are then washed again with cold PBS and collected by centrifugation, after which, 500 
µL of 1x Annexin binding buffer, 2 µL of 100 µg/mL PI and 5 µL of Annexin-V-FITC 
are all mixed with the cells and left to incubate for 15 min at room temperature. 
Following cell staining with PI and Annexin-V-FITC, the remaining volume of 1x 
Annexin binding buffer was added (493 µL) and the cell solution was passed through a 
40 µm sterile filter. Cells are then analyzed on a BD LSR II (BD Biosciences) with a 488 
nm excitation. Flow cytometry data is analyzed using the flow cytometry analysis 
software, FlowJo. Results are reported as the average % of cells + standard deviation. 
3.4.2.7. Statistical Analysis 
Statistical significance was determined with the t test calculator (GraphPad Software, 
Inc.). Data is considered statistically significant when p < 0.05 and is indicated by *. 
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3.4.3. Results and Discussion 
3.4.3.1. Gold Nanoparticle Induced Cell Cycle Regulation 
Cell cycle regulation can be advantageous, specifically for the sensitization of 
malignant cells to specific methods of cancer treatment.[15, 16] Particularly, some 
chemotherapeutic agents act on cells that are in a specific phase of the cell cycle (e.g. 
G0/G1, S, or G2/M). For example, 5-Fluorouracil (5-FU), a standard drug utilized in the 
clinical treatment of cancers of the head and neck,[22, 23] is most effective when cells 
are  in the S phase of the cell cycle, as it is associated with the incorporation of  
fluoronucleotides (e.g. fluorodeoxyuridine triphosphate, FdUTP)  in place of nucleotides 
(e.g. deoxyuridine triphosphate, dUTP) in the cell’s DNA.[17-19] Since we have shown 
previously that AuNPs conjugated with NLS and RGD peptides have the ability to alter 
the cell cycle of HSC-3 cells[3, 5], we took this further by testing their ability to 
chemosensitize HSC-3 cells to 5-FU treatment in vitro. In order to first estimate the 
efficacy by which these nanoparticles chemosensitize HSC-3 cells to 5-FU treatment, we 
performed cell cycle analysis on cells after a 24 h treatment with various AuNPs (0.4 
nM), as well as a subsequent treatment with 100 µM 5-FU. In order to compare cell cycle 
regulation between nanoparticle size, 15 and 30 nm NLS-AuNPs, known to localize at 
the nucleus of HSC-3 cells,[5] were tested. In order to compare between the location of 
nanoparticles within cells (i.e. AuNP surface functionalization), the 30 nm NLS-AuNPs 
were also compared to RGD-AuNPs, known to localize in the cytoplasm of HSC-3 
cells.[5] Figure 3.23 shows the cell cycle analysis of HSC-3 cells after various treatments. 
An interesting observation here is that all nanoparticles induce an increase in the S phase 
population and a decrease in the G2/M phase population of cells after a 24 h treatment.  
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Also shown by the cell cycle analysis is that 100 µM 5-FU itself induces an S phase 
accumulation with a G2/M phase depletion. The combination treatment of AuNPs and 5-
FU causes an S phase increase with a G2/M phase decrease, but only in the case of the 30 
and 15 nm NLS-AuNPs (Fig. 3.23A,B).  
 
Figure 3.23. Cell cycle analysis of HSC-3 cells after treatment with various AuNPs (0.4 
nM, 24 h) and 5-FU (100 µM, 48 h). Cells that were not treated (white), cells treated with 
AuNPs alone (yellow), cells treated with 5-FU alone (light gray) and cells treated with 
combination of AuNPs and 5-FU (dark gray). Comparison between AuNP size: (A) 30 
nm NLS-AuNPs versus (B) 15 nm NLS-AuNPs. Comparison between AuNP surface 
functionalization: (A) 30 nm NLS-AuNPs versus (C) 30 nm RGD-AuNPs. 
 
 
The cell cycle regulation observed for the combination of AuNPs and 5-FU suggests 
that the potency of 5-FU could be enhanced when administered after an initial 24 h 
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treatment with the AuNPs tested in this work. In order to assess this potency, we have 
calculated the 5-FU efficacy by dividing the S phase population by the G2/M phase 
population. This value is justified as the chemosensitivity factor since 5-FU itself causes 
an S phase accumulation with a G2/M phase depletion (Fig. 3.23), and previous reports 
have defined the resistance to 5-FU as a decrease in S phase with an increase in G2/M 
phase populations.[18] Figure 3.24 shows the 5-FU chemosensitivity factors for the 
various nanoparticle treatments alone (0.4 nM, 24 h), as well as in combination with 100 
µM 5-FU (48 h). The inherent 5-FU efficacy value for HSC-3 cells is around 1.6 and 
after treatment with 100 µM 5-FU, this value is increased to 5.8. In terms of the various 
nanoparticles tested here, the 30 nm NLS-AuNPs have the greatest impact on 5-FU 
efficacy, increasing the value to 21.4 and when combined with 100 µM 5-FU, the value is 
increased even more, to 29.8. The 15 nm NLS-AuNPs increase 5-FU efficacy to 2.5, and 
only up to 6.3 when combined with 5-FU. The 30 nm RGD-AuNPs increase 5-FU 
efficacy to 4.1, but only up to 6.9 when combined with 5-FU. It is clear here that 5-FU 
efficacy is influenced by AuNPs and is dependent on the size and location of 
nanoparticles within cells, with 30 nm nuclear-localized AuNPs being the most effective 
at enhancing 5-FU efficacy. 
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Figure 3.24. 5-FU efficacy in HSC-3 cells after treatment with various AuNPs (0.4 nM, 
24 h) and 5-FU (100 µM, 48 h). Control represents cells that were not treated with any 
AuNPs. Cells that were not treated with 5-FU (light gray) and cells that were treated with 
5-FU (red). 5-FU efficacy defined as % cells in S phase divided by % cells in G2/M 
phase of the cell cycle. 
 
 
3.4.3.2. Enhanced 5-Fluorouracil Chemosensitivity 
Utilizing the various AuNPs and their ability to regulate the cell cycle, as shown 
above, we can now assess whether these nanoparticles actually sensitize HSC-3 cells to 
5-FU treatment (i.e.chemosensitization). HSC-3 cells were initially treated with the 
different AuNPs (0.4 nM, 24 h) in order allow for accumulation of cells in the S phase 
and depletion of cells in the G2/M phase. Following AuNP treatment, 5-FU was 
introduced at increasing concentrations (10-500 µM, 48 h) and the cell viability was 
determined. Figure 3.25 displays the results of the cell viability analysis comparing 
between both AuNP size and AuNP surface functionalization (i.e. nanoparticle location 
  146 
 
within the cell). It should first be noted that none of the AuNP formulations shown here 
are inherently cytotoxic to the HSC-3 cells (no significant reduction in cell viability upon 
24 h treatment with 0.4 nM AuNPs), possibly alleviating common toxicity issues 
presented with combination chemotherapies. As one would expect, cell viability 
decreases with increasing concentrations of 5-FU. The lowest cell viability observed for 
the control (no AuNPs) is about 40% when the cells are treated with 500 µM 5-FU, but 
when pre-treated with 30 nm NLS-AuNPs (Fig. 3.25A), the cell viability is significantly 
reduced to 17%. In addition to the 500 µM 5-FU treatment being more effective, 
sensitivities to concentrations as low as 100 µM are also significantly enhanced by the 
pre-treatment of cells with the 30 nm NLS-AuNPs (Fig. 3.25A). When comparing AuNP 
size, the 15 nm NLS-AuNPs (Fig. 3.25B) do not appear to enhance the efficacy of 5-FU 
at any of the 5-FU treatment concentrations tested. In particular, at 5-FU concentrations 
of 10 and 100 µM, the cell viability is significantly enhanced by pre-treatment of cells 
with 15 nm NLS-AuNPs. At increasing concentrations of 5-FU (200-500 µM), pre-
treatment of cells with 15 nm NLS-AuNPs has no significant effect on 5-FU efficacy. 
Another comparison here is the different effects induced when the nanoparticles are 
localized in the cytoplasm of the cell (RGD-AuNPs) as opposed to at the nucleus of the 
cell (NLS-AuNPs). When cells are pre-treated with 30 nm RGD-AuNPs (Fig. 3.25C), the 
efficacy of 10 µM 5-FU is significantly enhanced (79% cell viability reduced to 43%). At 
higher 5-FU treatment concentrations (100-500 µM), the pre-treatment of cells with 30 
nm RGD-AuNPs does not have any significant effect on 5-FU efficacy. 
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Figure 3.25. Cell viability determined by an XTT assay of HSC-3 cells after treatment 
with various AuNPs (0.4 nM, 24 h) and 5-FU (10-500 µM, 48 h). Cells that were only 
treated with 5-FU (control, black) and cells treated with a combination of AuNPs and 5-
FU (red). Comparison between AuNP size: (A) 30 nm NLS-AuNPs versus (B) 15 nm 
NLS-AuNPs. Comparison between AuNP surface functionalization: (A) 30 nm NLS-
AuNPs versus (C) 30 nm RGD-AuNPs. Statistical significance between cells treated with 
only 5-FU and cells treated with combination of AuNPs and 5-FU is indicated by * (p < 
0.05). 
 
It is clear from the cell viability results shown in Figure 3.25 that there are definite 
differences in the 5-FU efficacy after cells are pre-treated with various AuNPs. The 30 
nm NLS-AuNPs appear to be the most effective at sensitizing HSC-3 cells to 5-FU 
treatment, which is also confirmed by the high 5-FU efficacy values determined by cell 
cycle analysis (Fig. 3.23), and no apparent increase in 5-FU uptake by the presence of 
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nanoparticles was observed in this case (see Appendix A, Figure A10). Smaller AuNPs 
(15 nm NLS-AuNPs) and AuNPs localized at the cytoplasm (30 nm RGD-AuNPs) do not 
consistently enhance the efficacy of 5-FU, which is also confirmed by the lower 5-FU 
efficacy values determined by cell cycle analysis (Fig. 3.24). 
In order to further assess the mode by which the 30 nm NLS-AuNPs chemosensitize 
HSC-3 cells to 5-FU, cell death was investigated by flow cytometry analysis of cells 
labeled with the nucleic acid dye, propidium iodide (necrotic cells), cells stained with a 
phosphatidylserine label, Annexin-V-FITC (early apoptotic cells), cells labeled with both 
(late apoptotic), and cells that are unlabeled (live cells). Figure 3.26 displays percentages 
of necrotic (red), late apoptotic (dark blue), early apoptotic (light blue) and live (green) 
cells after treatment with 0.4 nM 30 nm NLS-AuNPs alone (24 h), 150 µM 5-FU alone 
(48 h), as well as 150 µM 5-FU (48 h) after pre-treatment with 30 nm NLS-AuNPs (0.4 
nM, 24 h). The primary mode of cell death upon treatment with 5-FU appears to be via 
early apoptosis.  Interestingly, the 30 nm NLS-AuNP treatment also exhibits a higher 
degree of early apoptosis, compared to necrosis or late apoptosis. Although early 
apoptosis is the predominant mode of cell death, late apoptosis and necrosis also occur to 
a significant degree. In terms of late apoptosis, when cells are treated with the 
combination of 30 nm NLS-AuNPs (0.4 nM, 24 h) and 150 µM 5-FU (48 h), the 
population is significantly enhanced compared to either treatment alone. In terms of 
necrosis, the population is also significantly enhanced for the combination treatment, 
compared to treatment with only 30 nm NLS-AuNPs or only 5-FU. In looking at the early 
apoptotic populations, which appear to be the dominant mode of cell death for both 
individual treatments, the pre-treatment with 30 nm NLS-AuNPs does not enhance the 
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amount of early apoptotic cells. It is interesting to note that this is the only population of 
dead cells in which this trend is observed, possibly due to the fact that the 30 nm NLS-
AuNPs alone exhibit a smaller population of early apoptotic cells than the 5-FU alone, 
therefore not providing any enhancement in this mode of cell death. 
  




Figure 3.26. Flow cytometry analysis of HSC-3 cell death after treatment with 0.4 nM 
NLS-AuNPs (24 h), 150 µM 5-FU (48 h) or 0.4 nM NLS-AuNPs (24 h) followed by 150 
µM 5-FU (48 h). Right panel shows necrotic cells (red), late apoptotic cells (dark blue), 
early apoptotic cells (light blue) and live cells (green) for cells that were untreated (c), 
treated with 150 µM 5-FU for 48 h (5-FU), treated with 0.4 nM 30 nm AuNPs for 24 h 
(Au) and treated with 150 µM 5-FU (48 h) after 24 h pre-treatment with 0.4 nM 30 nm 
NLS-AuNPs (Au + 5-FU). Statistical significance with respect to the control is indicated 
by * (p < 0.05) within the bars of the graph. Statistical significance with respect to 
different treatment groups indicated by * (p < 0.05) above graph. 
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3.4.4. Conclusions and Future Outlook 
In conclusion, we have shown that nuclear-targeted gold nanoparticles (NLS-AuNPs), 
specifically 30 nm in diameter, regulate the cell cycle of HSC-3 cells by inducing an 
accumulation of cells in the S phase with a depletion of cells in the G2/M phase. The S 
phase accumulation and G2/M phase depletion can be used to quantify the efficacy of a 
common chemotherapeutic agent, 5-Fluorouracil (5-FU). Of all the nanoparticles tested 
in this work, the 5-FU efficacy value is highest when cells are treated with 30 nm NLS-
AuNPs (0.4 nM, 24 h), compared with 15 nm NLS-AuNPs or 30 nm RGD-AuNPs 
(cytoplasm localized AuNPs). This high 5-FU efficacy value is made more apparent 
when testing the cytotoxicity of 5-FU after pre-treatment with the various AuNPs. The 
cell viability of 5-FU treated cells is significantly reduced when the cells are pre-treated 
with 30 nm NLS-AuNPs (0.4 nM, 24 h), compared with cells pre-treated with the smaller 
NLS-AuNPs or the RGD-AuNPs. More detailed analyses of the modes of cell death 
involved with 5-FU treatment revealed that these 30 nm NLS-AuNPs also enhance levels 
of late apoptosis and necrosis when introduced to the cells 24 h prior to 5-FU treatment. 
It is clear that cell cycle regulation plays a major role in enhancing drug efficacy in 
malignant cells. A detailed mechanism by which gold nanoparticles are capable of doing 
this will be essential. Once the molecular mechanisms involved in AuNP-induced cell 
cycle alterations are determined, chemosensitization via AuNPs can be exploited as a 
new technique for the treatment of various cancers with various chemotherapies. 
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EXTRINSIC PROPERTIES OF GOLD NANOPARTICLE CONJUGATES 
 
 
4.1.  The Most Effective Gold Nanorod Size for Plasmonic Photothermal 
Therapy: Theory and Experiment [1] 
 
 
The development of new and improved photothermal contrast agents for the 
successful treatment of cancer via plasmonic photothermal therapy (PPTT) is a crucial 
part of the application of nanotechnology in medicine. It is well established that as the 
size of a plasmonic nanoparticle decreases, the percentage of its extinction cross section 
that is converted to heat increases. But it is also known that the extinction cross section 
itself decreases as the size of the nanoparticle decreases.  Taking these two factors into 
consideration, one expects that there is a gold nanorod (AuNR) with an optimum size that 
is most efficient in heat production when exposed to near-infrared (NIR) laser irradiation 
for the treatment of cancer via PPTT. In the present work, we utilize theoretical 
calculations as well as experimental techniques to determine this optimum AuNR size, by 
comparing plasmonic properties and the efficacy as photothermal contrast agents of three 
different sizes of AuNRs. The more conventional AuNRs used in PPTT are synthesized 
via seed-mediated growth, having dimensions of 38 x 11 nm. The smaller, less 
conventional, AuNRs are synthesized by a seedless growth method, described previously 
by our group, having dimensions of 28 x 8 nm and 17 x 5 nm. Our theoretical 
calculations showed that the absorbance:scattering ratio of the 28 x 8 nm AuNRs is 3 
times greater than that of the commonly used larger (38 x 11 nm) AuNRs. We confirmed 
this experimentally in solution, by near-infrared (NIR) cw laser irradiation, where the 
optical density of the 38 x 11 nm AuNRs had to be 3 times that of the 28 x 8 nm AuNRs 
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in order to achieve an equivalent temperature increase. More theoretical calculations were 
carried out in order to determine the electromagnetic field intensity around the different 
AuNRs. The maximum field intensity for the 28 x 8 nm AuNRs is 1.5 times greater than 
that of the 38 x 11 nm AuNRs. We further confirmed this experimentally, by determining 
a parameter termed the photothermal heat conversion factor per particle. This value was 
found to be 1.4 greater for the 28 x 8 nm AuNRs than that of the 38 x 11 nm AuNRs. We 
also found that the field of the 17 x 5 nm AuNR extends a much shorter distance from its 
surface than that of the larger AuNRs, making it much less efficient at generated heat in 
solution. These results encouraged us to carry out in vitro experiments to compare the 
PPTT efficacy of the different sized AuNRs. The 28 x 8 nm AuNRs were found to the 
most effective in PPTT of human oral squamous cell carcinoma because the cancer cell 
death induced by the plasmonic AuNR-induced hyperthermia is greatest when this size 
AuNR is used as the photothermal contrast agent.  
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4.1.1. Introduction 
Plasmonic photothermal therapy (PPTT) for the treatment of cancer has received a 
great deal of attention in recent years, especially with the advent of new photothermal 
contrast agents.[2] In the past decade, specifically, there has been much progress in the 
development of plasmonic nanoparticles for photothermal therapy applications due to 
their unique optical properties, namely their localized surface plasmon resonance 
(LSPR),[3, 4] as well as their inherently low toxicities.[5-7] The unique plasmonic 
properties of the nanoparticles can be exploited in photothermal therapy by coherently 
photo-exciting their conduction electrons to induce surface plasmon oscillations. Upon 
surface plasmon formation, non-radiative relaxation occurs through electron-phonon and 
phonon-phonon coupling, efficiently generating localized heat that can be transferred to 
the surrounding environment.[4, 8, 9] This conversion of photon energy to thermal 
energy is useful in biomedical applications, such as plasmonic photothermal therapy of 
cancer.[10-14]  
In PPTT, thermal energy generated can induce temperature increases of more than 
20°C (i.e. hyperthermia), which can thereby induce tumor tissue ablation.[11, 12, 15-21] 
This was first demonstrated in vitro, by Lin and coworkers in 2003, using antibody-
conjugated spherical gold nanoparticle-labeled lymphocytes and a nanosecond pulsed 
visible laser.[22] A few years later, El-Sayed and coworkers also used visible light and 
antibody-conjugated spherical gold nanoparticles for the selective photothermal ablation 
of epithelial carcinoma cells in vitro.[10] Although visible light is successful in 
destroying cells labeled with spherical gold nanoparticles, the need for radiation to 
penetrate deep into tissues, with minimal attenuation by water and hemoglobin, is desired 
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for the practical application of PPTT. Near-infrared (NIR) external radiation is capable of 
achieving this, such that it can penetrate up to 10 cm in soft tissues (termed the NIR 
tissue transmission window, 650-900 nm).[23] By changing the shape and composition of 
the nanoparticle, the surface plasmon absorption can be shifted into the NIR transmission 
window.[24-29] With this in mind, gold nanoparticles (AuNPs) that absorb in the NIR 
tissue transmission window were developed by Halas and coworkers (silica-gold core-
shell nanoparticles),[12, 30] El-Sayed and coworkers (rod-shaped AuNPs),[13, 31] as 
well as Xia and coworkers (gold nanocages).[32] When comparing the different 
nanoparticle structures in terms of their application in PPTT, the most important 
plasmonic properties to consider are the absorption cross section, absorption efficiency, 
and thermal transduction per particle. Of all the plasmonic AuNPs developed, the rod-
shaped AuNPs, or gold nanorods (AuNRs), exhibit the most ideal NIR absorption cross 
section[33] and demonstrate extremely efficient NIR photothermal heat conversion.[19] 
The most common size of AuNR utilized for use in successful PPTT now is around 40 
nm in length and 10 nm in diameter, with a longitudinal plasmon resonance around 800 
nm. Investigating various AuNR sizes, specifically those that have smaller dimensions, 
and their efficacy as photothermal contrast agents has important implications in the 
clinical applications of AuNRs in PPTT, especially since the accumulation and toxicity of 
smaller AuNRs in the tumor interstitium and the organs of the reticuloendothelial system 
(RES) could be more ideal than that of the larger AuNRs. Also, as previously shown 
theoretically by Jain et.al., plasmonic absorption becomes dominant as the nanoparticle 
size is decreased.[34, 35] More specifically, the extinction of the AuNRs increases with 
the size of the AuNRs, while the contribution of scattering also increases, essentially 
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decreasing the absorbance:scattering ratio as the AuNR size increases. This ultimately 
suggests that as the particle size decreases, the absorbance:scattering ratio increases, 
allowing for greater photothermal heat conversion and therefore potentially enhancing 
PPTT efficacy with decreased particle size. Another plasmonic property associated with 
photothermal heat conversion is the electric field around the AuNRs. It has previously 
been shown that excitation at the plasmon wavelength creates very strong 
electromagnetic fields,[36, 37] and the field strength trends with absorbance, not 
scattering or extinction.[38] Since the field strength is derived from absorbance, not 
scattering, greater absorbance with smaller AuNRs would indicate a stronger field, which 
in turn would result in greater photothermal heat conversion and, again, enhanced PPTT 
efficacy. 
In this work, we present both theoretical and experimental results, ultimately 
comparing AuNRs commonly used for PPTT (about 38 x 11 nm) and new, smaller 
AuNRs[39] (about 28 x 8 nm and 17 x 5 nm), in order to determine which would be the 
most effective photothermal contrast agent. The discrete dipole approximation (DDA), a 
theoretical technique for modeling the spectral properties of varying nanoparticle shapes, 
was utilized for the theoretical portion of this work. DDA has the advantage of being able 
to model particles of arbitrary shape.[34, 37, 40-43] In this method, the particle is 
represented by a three-dimensional finite lattice of point dipoles that is excited by an 
external field. The response of the point dipoles to the external field and to one another is 
solved self-consistently using Maxwell’s equations. The DDSCAT 6.1 code offered 
publicly by Draine and Flatau[44] allows for the calculation of the absorbance and 
scattering spectra separately, enabling the assessment of the contributions from each to 
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the extinction spectra, which is ideal for comparing the absorbance:scattering ratio of the 
two different sizes of AuNRs. Furthermore, with modifications to the code by 
Goodman[45] and Schatz,[46] it is possible to calculate the electric field enhancement 
contours and the individual dipole orientations at a specific wavelength, allowing for the 
theoretical estimation of the potential heat generated by the different-sized AuNRs upon 
exposure to NIR radiation. Theoretical results show that the electromagnetic field around 
the particle and the absorbance:scattering ratio both increase with decreasing AuNR size, 
as expected. Experimental AuNR heating quantitatively agrees with the theoretical 
calculations for the 28 x 8 and 38 x 11 nm AuNRs, while the 17 x 5 nm particles do not 
experimentally trend with the theoretical results. We suggest that this is due to the fact 
that although the 17 x 5 nm AuNRs have the highest absorbance:scattering ratio and the 
most intense electromagnetic field, the field decays from the surface of the nanoparticle 
to a very short distance, suggesting that effective experimental heating of the solution, 
when exposed to NIR radiation, would be less likely. 
We take our theoretical and experimental results a bit further by determining the 
efficacy of the different sized AuNRs as photothermal contrast agents, using an in vitro 
malignant cell model. The 28 x 8 nm AuNRs showed the greatest efficacy, exhibiting 
greater cell death upon NIR laser irradiation compared to the more conventional AuNRs 
(38 x 11 nm) as well as the smallest AuNRs (17 x 5 nm). These results suggest that the 
most ideal AuNR for the plasmonic photothermal treatment of disease is that of a median 
size (e.g. 28 x 8 nm). 
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4.1.2. Experimental Methods 
4.1.2.1. Gold Nanorod (AuNR) synthesis and PEG conjugation 
The large AuNRs were synthesized via the seed-mediated growth method.[47] 
Briefly, a seed solution consisting of 7.5 mL of 0.2 M CTAB, 2.5 mL of 1.0 mM HAuCl4 
and 600 uL 0.01 M NaBH4 is prepared, followed by a growth solution containing 100 mL 
of 1.0 mM HAuCl4, 100 mL of 0.2 M CTAB, 5 mL of 4.0 mM silver nitrate and 1.4 mL 
of 78.8 mM ascorbic acid. A 240 uL volume of the seed solution is added to the growth 
solution, producing AuNRs approximately 38 nm in length and 11 nm in width, as 
displayed in Figure 4.1A. The surface plasmon resonance (SPR) of these AuNRs is 
around 740 nm. 
Two different, smaller, AuNRs were synthesized by a seedless growth method.[39] In 
this method, the growth solution was kept at an acidic pH and sodium borohydride was 
added instead of a seed solution, for simultaneous seed formation and AuNR growth. To 
obtain AuNRs approximately 28 nm in length and 8 nm in width (Fig. 4.1B), 300 μL of 
0.01 M NaBH4 was prepared and added to an acidic growth solution containing 160 μL 
of 37% HCl, 100 mL of 1.0 mM HAuCl4, 100 mL of 0.2 M CTAB, 5 mL of 4.0 mM 
silver nitrate and 1.4 mL of 78.8 mM ascorbic acid. The SPR of these AuNRs is around 
770 nm. To obtain AuNRs approximately 17 nm  in length and 5 nm in width (Fig. 4.1C), 
150 μL of 0.01 M NaBH4 was prepared and added to an acidic growth solution 
containing 160 μL of 37% HCl, 50 mL of 1.0 mM HAuCl4, 100 mL of 0.2 M CTAB, 5 
mL of 4.0 mM silver nitrate and 700 uL of 78.8 mM ascorbic acid. The SPR of these 
AuNRs is around 755 nm. All CTAB-stabilized AuNRs were also purified by 
centrifugation and redispersed in dI H2O. 




Figure 4.1. UV-Vis spectra of AuNRs (black) as well as the NIR cw laser spectrum (red) 
(with corresponding TEM images, scale bar: 60 nm). (A) 38 x 11 nm AuNRs with 
longitudinal plasmon resonance at 740 nm. (B) 28 x 8 nm AuNRs with longitudinal 
plasmon resonance at 770 nm (C) 14 x 5 nm AuNRs with longitudinal plasmon resonance 
at 755 nm.  
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After purification, the various AuNRs were functionalized with polyethylene glycol 
(mPEG-SH, MW 5000, Laysan Bio, Inc.) and left on a shaker overnight, after which, 
they were centrifuged and redispersed in dI H2O. 
4.1.2.2. Photothermal heating of AuNRs in solution  
The as-synthesized (i.e. CTAB capped) AuNRs were diluted in dI H2O, such that the 
three AuNR solutions had either the same concentration of particles or the same optical 
density (OD). The AuNR concentrations were calculated based on the previously 
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A 500 uL volume of AuNRs, in a microcentrifuge tube, was exposed to a near-infrared 
(NIR) cw laser (808 nm) at 5.8 W/cm
2
 (spot size around 5.6 mm) at increasing irradiation 
times. The temperature increase of the solution was measured by placing a 33 gauge 
hypodermic thermocouple (Omega) directly into the AuNR solution. A 500 uL solution 
of dI H2O was also measured and the temperature increase of the H2O was subtracted 
from that of the AuNR solutions in order to account for any heat generated from the laser 
itself. For normalization purposes, all initial temperatures were 24 + 1 ºC. TEM images 
and UV-Vis spectra indicate that photothermal heating did not alter the structure or 
spectra of the AuNRs (data not shown). 
4.1.2.3. AuNR heating in cell culture and cell viability assay 
Human oral squamous cell carcinoma (HSC-3) cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Mediatech) supplemented with 10% v/v fetal bovine 
serum (FBS, Mediatech) and 1% v/v antimycotic solution (Mediatech). The cell culture 
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was kept in a 37ºC, 5% CO2, humidified incubator. HSC-3 cells were grown in 96-well 
tissue culture plates overnight. After which, the growth media was removed and replaced 
with growth media containing PEG-AuNRs at optical densities of 0.5 (17 x 5, 28 x 8 and 
38 x 11 nm AuNRs) and 1.5 (38 x 11 nm AuNRs). After a 2 h incubation time, the cells 
were exposed to a NIR cw laser (808 nm) at 5.8 W/cm
2
 (spot size around 5.6 mm) at 
increasing irradiation times. The temperature increase was measured by placing a 33 
gauge hypodermic thermocouple (Omega) directly into the culture medium. For 
normalization purposes, all initial temperatures were 32 + 1 ºC. The cell viability was 
determined via an XTT cell viability assay kit (Biotium, Inc), according to the 
manufacturer’s protocol. 
4.1.2.4. Statistical analysis 
Results are expressed as the mean + standard deviations of three independent 
experiments. Statistical significance (i.e. p-value) was calculated by a t-test calculator 
(GraphPad Software, Inc.). Statistically significant data is indicated by * (p-value < 0.05). 
4.1.2.5. DDA calculations 
The optical response of a gold nanorod with varying dimensions (38 x 10 nm, 25 x 7 
nm, and 18 x 4 nm) was calculated using the DDA method with the DDSCAT 6.1 code 
offered publicly by Draine and Flatau[44] with modifications by Goodman[45] and 
Schatz.[46] The dielectric values for gold reported by Johnson and Christy[49] were 
used. The incident light is always polarized along the length of the particle (i.e. 
longitudinal mode) in this report, and the medium surrounding the particle was 
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represented as water with a refractive index of 1.333. The nanorods were modeled as 
cylinders with hemispherical end caps. 
 
4.1.3. Results and Discussion 
4.1.3.1. Size-Dependent Photothermal Heat Conversion: Experiment 
Gold nanorods (AuNRs) were synthesized with lengths of around 38 nm (Fig. 4.1A), 
28 nm (Fig. 4.1B) and 17 nm (Fig. 4.1C). The longitudinal plasmon resonances of the 
different AuNRs are around 740, 770 and 755 nm, respectively. With the knowledge that 
plasmonic absorption dominates as nanoparticle size is decreased,[34, 35] we expect that 
the smaller AuNRs would generate more heat than the larger AuNRs when exposed to 
near-infrared (NIR) cw laser irradiation (808 nm). Therefore, we determined the 
photothermal heat conversion factor, per particle, in order to directly compare the 
difference in heat generated by the different AuNRs upon NIR irradiation at increasing 
time intervals. This was done by preparing 10 nM solutions of the three different AuNRs 
(see Experimental Methods for details). The solutions were each then exposed to NIR 
radiation at 5.8 W/cm
2
 (spot size around 5.6 mm).  Upon determining the increase in 
temperature for the AuNR solutions, the change in temperature per AuNR was calculated 
and multiplied by a factor (10
11
) in order to simplify the values being compared. Figure 
4.2 compares the photothermal heat conversion factor of each different AuNR tested in 
this work. As the NIR laser irradiation time is increased, the photothermal heat 
conversion factor increases, especially for AuNRs that are 28 nm in length. At an 
exposure time of 2 min, the photothermal heat conversion factor for the 17, 28 and 38 nm 
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AuNRs is 1.21, 2.48 and 1.77, respectively. This indicates that the 28 nm AuNRs exhibit 
the greatest photothermal heat conversion, which was unexpected since we predicted that 
the smaller the AuNRs would generate more heat upon NIR laser irradiation. Therefore, a 
thorough investigation of the plasmonic properties of these three different nanoparticles, 




Figure 4.2. Photothermal heat conversion factor determined, per particle, for 17 x 5 nm 
AuNRs (17 nm, blue), 28 x 8 nm AuNRs (28 nm, yellow) and 38 x 11 nm AuNRs (38 
nm, gray) at increasing NIR laser irradiation time. All initial temperatures were 24 + 1 
°C. Statistical significance (p< 0.05) indicated by *. 
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4.1.3.2. Size-Dependent Electromagnetic Field: Theory 
Since the experimental photothermal heat conversion factor per particle could 
potentially be related to the field enhancement around the particle, the Discrete Dipole 
Approximation (DDA) was used to generate field contour plots for three different AuNRs 
(38 x 10 nm, 25 x 7 nm and 18 x 4 nm) shown in Figure 4.3. The laser wavelength (808 
nm) used for experimental heating did not exactly correspond to the plasmon resonances 
of the AuNRs, therefore in the DDA calculations the AuNRs were similarly excited off 
resonance. We also compared the field enhancement values for the three AuNRs (38 x 
10, 25 x 7 and 18 x 4 nm) on resonance, at their respective resonance wavelengths (786, 
757 and 865 nm), which can be seen in Figure B.1 of Appendix B. Experimentally, the 
particles were excited at 808 nm (i.e. off resonance), at which point the extinction value 
of the AuNRs was decreased by 15% (18 x 4 nm), 6% (25 x 7 nm) and 46% (38 x 10 
nm), compared to their maximum value (Fig. 4.1). In order to account for this 
theoretically, we calculated the electromagnetic field contours at 804 nm for the 38 x 10 
nm AuNR, 761 nm for the 25 x 7 nm AuNR and 875 nm for the 18 x 4 nm AuNR, which 
are the wavelengths where the DDA calculated extinction decreased by 46%, 6% and 
15% from its maximum value, respectively. As shown in Figure 4.3, the maximum fields 
generated are 3500, 5220 and 5480 for the 38 x 10, 25 x 7 and 18 x 4 nm AuNRs, 
respectively. It should also be noted that the field maximum for the 25 x 7 nm AuNRs is 
1.5 times that of the 38 x 10 nm AuNRs, which is consistent with their experimentally 
determined photothermal heat conversion factor being 1.4 times greater than that of the 
38 nm AuNRs. 
 




Figure 4.3. Field contour plots for the longitudinal mode of the different AuNRs, with 
particle dimensions indicated and the field decaying to 1.25 at the extremities of each 
plot. (A) The field maximum of the 38 x 10 nm AuNR (calculated at 804 nm) is 3500. 
(B) The field maximum of the 25 x 7 nm AuNR (calculated at 761 nm) is 5220. (C) The 
field maximum of the 18 x 4 nm AuNR (calculated at 875 nm) is 5480. 
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This trend of increasing electromagnetic field with decreasing particle size is 
expected, but does not necessarily correlate with what was seen experimentally for the 
photothermal heat conversion factor (Figure 4.2). The smallest AuNRs had the smallest 
photothermal heat conversion factor, suggesting that they would have the weakest 
electromagnetic field, but they in fact have the strongest field according to our 
calculations. Therefore, another factor involved in the photothermal heat conversion 
could be the distance at which the field decays. In order to achieve overall heating of the 
surrounding medium, as opposed to local heating around the particle, the field needs to 
extend a certain distance away from the particle surface. Because the field decays 
exponentially from the particle surface, both the maximum field enhancement value and 
particle size play a role in how far the enhanced field extends away from the particle. 
Therefore, also shown in Figure 4.3 are the distances at which the field has decayed to a 
value of 1.25. The smallest AuNR (18 x 4 nm) does indeed have the strongest field, but it 
only extends 15.17 nm from the nanoparticle surface before it has decayed to a value of 
1.25, while the 25 x 7 nm AuNR has a slightly weaker field maximum, but the field 
extends out to 24.66 nm from the nanoparticle surface. The largest AuNR (38 x 10 nm) 
has the weakest field maximum, but has the largest distance at which the field decays to 
1.25 (39.28 nm). 
The distance at which the field decays is relevant in terms of the experimental 
photothermal heat conversion determined for these AuNRs, such that although the 
smallest AuNR (18 x 4 nm) has the strongest field, it does not extend far enough from the 
nanoparticle surface to achieve sufficient overall experimental heating of the 10 nM 
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AuNR solution. The concentration of the smallest AuNRs must be at least 20 nM in order 
for the solution temperature to reach that which is comparable to the other AuNRs at 10 
nM concentrations (see Appendix B, Table B.1). The necessity for this prohibitively high 
concentration of the smallest AuNRs renders these particles impractical for applications 
in which overall heating of a solution is desired. 
4.1.3.3. Size-Dependent Absorbance:Scattering Ratio: Theory 
To further investigate the plasmonic properties of the different sized AuNRs, which 
influence their differences in photothermal heat conversion, DDA calculations were done 
to determine the contributions of absorbance and scattering to the total extinction of the 
particles. In Figure 4.4, the DDA spectra show that the plasmon resonance for the 
longitudinal mode of the 38, 25 and 18 nm AuNRs are at 786, 757 and 865 nm, 
respectively. Additionally, the total extinction decreases with increasing particle size, 
with the contribution from scattering also decreasing with particle size, as expected.[34, 
35] The absorbance:scattering ratio for the 38, 25 and 18 nm is 63.8, 204 and 921, 
respectively. Therefore, comparing the smaller AuNRs to the 38 nm AuNRs, the 
absorbance:scattering ratio is 3.2 times greater for the 25 nm AuNRs and 14.4 times 
greater for the 18 nm AuNRs. This suggests that the experimental photothermal heating 
of AuNR solutions would be equivalent when the optical density of 38 nm AuNRs is 
about 3 times that of the 28 nm AuNRs and about 14 times that of the 17 nm AuNRs. 





Figure 4.4. DDA extinction (black dots), absorption (red line) and scattering (green line, 
and shown in inset) spectra for the longitudinal mode of the different AuNRs in water. 
(A) The 38 x 10 nm AuNR has an absorbance:scattering ratio of 63.8. (B) The 25 x 7 nm 
AuNR has an absorbance:scattering ratio of 204. (C) The 18 x 4 nm AuNR has an 
absorbance:scattering ratio of 921. 
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4.1.3.4. Size-Dependent Absorbance:Scattering Ratio: Experiment 
In order to experimentally correlate the calculated absorbance:scattering ratio to 
photothermal heat conversion, we looked at the NIR photothermal heating of the different 
sized AuNRs at varying extinctions (optical densities). Specifically, as shown in Figure 
4.5, the smaller AuNRs (17 and 28 nm) with an OD of 0.5 demonstrate statistically 
significant enhanced photothermal heating (increase by 15 °C) compared to that of the 38 
nm AuNRs at OD 0.5 after 2 min of NIR laser exposure. Interestingly, the small AuNRs 
(17 and 28 nm) at OD 0.5 and the large AuNRs (38 nm) with OD 1.5, exhibit about the 
same change in temperature after 2 min of NIR laser exposure. This shows that a 3-fold 
increase in the optical density, the same difference in the absorbance:scattering ratio 
predicted by DDA, was needed to achieve the same temperature increase. Again, the 28 x 
8 and 38 x 11 nm AuNRs experimentally agree with the theoretical calculations for the 
25 x7 nm and 38 x 10 nm AuNRs, while the 17 x 4 nm AuNRs do not experimentally 
correlate with the theoretical predictions, since they are limited by a threshold solution 
concentration of 20 nM (OD 1.6) for sufficient overall experimental heating to be 
observed (see Appendix B, Table B.1). 
  





Figure 4.5. Temperature change induced by plasmonic photothermal heating of different 
AuNRs (17, 29=8 and 38 nm in length) at different optical densities (0.5 and 1.5) and 
increasing NIR laser irradiation times. All initial temperatures were 24 + 1 °C. Statistical 
significance between different sized AuNRs and optical densities at 2 min laser 
irradiation (p < 0.5) is indicated by *. 
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4.1.3.5. Size-Dependent in vitro Plasmonic Photothermal Efficacy in HSC-3 Cancer 
Cells 
The enhanced photothermal heat conversion observed with the 28 nm AuNRs 
suggests that these nanoparticles would have great potential as photothermal contrast 
agents in Plasmonic Photothermal Therapy (PPTT). Therefore, we used HSC-3 cells (oral 
squamous cell carcinoma), in vitro, to compare the efficacy of the three different PEG-
AuNRs for photothermal ablation. Our in vitro experiments essentially represent a 
situation in which the malignant cells are surrounded by a solution containing the 
photothermal contrast agents (i.e. PEG-AuNRs). These in vitro results can perhaps be 
expanded to the in vivo regime, in which a tumor is directly injected with AuNRs. HSC-3 
cells were treated with the three different PEG-AuNRs for 2 h before exposure to NIR 
radiation. The cells were irradiated at 5.8 W/cm
2
 for 0.5, 1 and 2 min, and the 
temperature increase was directly measured in the cell culture using a hypodermic 
thermocouple. The change in temperature observed for the different PEG-AuNRs in the 
cell culture is shown in Figure 4.6.  
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Figure 4.6. Temperature change of cell culture medium containing different AuNRs. 
AuNRs 38 nm in length at OD 0.5 (light gray), AuNRs 28 nm in length at OD 0.5 
(yellow), AuNRs 17 nm in length at OD 0.5 (blue) and AuNRs 38 nm in length at OD 1.5 
(dark gray) were all exposed to upon NIR laser irradiation at increasing lengths of time. 
All initial temperatures were 32 + 1 °C. . Statistical significance between different sized 
AuNRs and optical densities (p < 0.5) is indicated by * above bars. 
  176 
 
It is clear that at the same OD, the temperature increase is greater for the smaller 
PEG-AuNRs (17 and 28 nm) than for the large PEG-AuNRs (38 nm). When the optical 
density of the large PEG-AuNRs was made to be 3 times that of the smaller PEG-AuNRs, 
as suggested by the absorbance:scattering ratios determined with DDA (Fig. 4.4) and the 
photothermal heating in solution (Fig. 4.5), the temperature increase was similar to that of 
both smaller PEG-AuNRs. These temperature increases indicate hyperthermia, which is a 
well-established mode of tumor tissue ablation.[11-13] Therefore, it is important to assess 
the outcome of these temperature increases by determining the cell death associated with 
the AuNR-induced plasmonic photothermal hyperthermia. As shown in Figure 4.7, the 
cell viability decreases with increasing NIR laser irradiation times, as would be expected. 
Also interesting here is that the greatest amount of cell death, at any exposure time, is 
observed for the 28 nm PEG-AuNRs with an OD of 0.5. The 17 nm PEG-AuNRs with an 
optical density of 0.5 and the 38 nm PEG-AuNRs with an optical density of 1.5 show a 
higher cell viability, but not statistically significant enough to claim it as different from 
that of the 28 nm PEG-AuNRs (OD 0.5). The 38 nm PEG-AuNRs at OD 0.5 do not show 
any significant change in cell viability upon NIR laser exposure at any of the exposure 
times tested here.  
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Figure 4.7. Cell viability determined for HSC cells treated with different AuNRs and 
subjected to PPTT via NIR laser irradiation. Cells treated with AuNRs 38 nm in length at 
OD 0.5 shown in light gray, AuNRs 28 nm in length at OD 0.5 shown in yellow, AuNRs 
17 nm in length at OD 0.5 shown in blue and AuNRs 38 nm in length at OD 1.5 shown in 
dark gray. Statistical significance (p< 0.05) indicated by *. Statistical significance with 
respect to control (no AuNRs) indicated inside bars. Statistical significance between 




4.1.4. Conclusions and Future Outlook 
We have clearly shown, both theoretically and experimentally, that there are 
limitations in the AuNR size when choosing the best photothermal contrast agent for use 
in Plasmonic Photothermal Therapy (PPTT). It is clear from the agreement between 
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experimental and theoretical results presented above, that the 28 nm AuNR are capable of 
producing more heat via NIR cw laser irradiation than the larger more conventional (38 
nm) AuNRs. The disagreement between theory and experiment for the smallest AuNR 
investigated (17 nm) suggests that there is a lower limit in the size of the AuNR needed 
to achieve sufficient experimental photothermal heating. With AuNRs having dimensions 
around 17 x 5 nm, the particle is so small that although it has an extremely intense 
electromagnetic field at its surface, this field does not extend far enough from the surface 
to allow for overall experimental heating of a solution. With AuNRs having dimensions 
around 38 x 11 nm, the particle is so large that although it exhibits a high extinction 
cross-section, the majority of the extinction comes from scattering instead of absorption, 
thus less heat is generated upon experimental NIR laser irradiation. The AuNR having 
dimensions of around 28 x 8 nm exhibits the most ideal size for its application as a 
photothermal contrast agent. This size nanorod has an intense electromagnetic field that 
extends far enough from the particle surface in order to achieve sufficient experimental 
photothermal heating. This size nanorod, although having a low extinction cross-section, 
the majority of the extinction comes from absorption, allowing for high photothermal 
heat conversion upon experimental NIR laser irradiation. These theoretical and 
experimental observations lead to the conclusion, and is shown in our in vitro 
experiments, that the 28 x 8 nm AuNRs are more effective photothermal contrast agents 
than the 38 x 11 or 17 x 5 nm AuNRs, for the photothermal ablation of cancer cells. A 
full assessment of these newly investigated AuNRs should be done in order to determine 
their efficacy in vivo as well as their toxicity, compared with more conventional 
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photothermal contrast agents. This work has the potential to aid in the development of a 
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Plasmonic photothermal therapy (PPTT) is a non-invasive and highly effective 
method of cancer treatment. Optimizing current PPTT treatment methods by determining 
the most efficient photothermal contrast agents is important for transitioning from in vivo 
experiments to a clinical setting. We have previously shown by theoretical calculations 
and exprerimental evaluation in vitro, that the most efficient gold nanorod size for 
plasmonic photothermal heat conversion is around 28 nm in length and 8 nm in width. 
Therefore, in the present work, we determine how effective these gold nanorods are as 
photothermal contrast agents for the photothermal ablation of tumors in a mouse model. 
Since these particles are new for this type of application, we also determined their 
pharmacokinetic properties as well as their biodistribution profile, comparing between 
targeting (head and neck cancer) and non-targeting AuNRs (27 x 8 nm). These particles 
are stable in vivo, as demonstrated by their long blood circulation half-lives, and exhibit 
accumulation in organs of the reticuloendothelial system (RES), which is common to 
nanoparticle-based therapies. The targeting AuNRs do exhibit enhanced tumor 
accumulation in squamous cell carcinoma of the head and neck as well as dramatic tumor 
growth suppression upon exposure to laser radiation. These results suggest a new and 
improved AuNR-based photothermal contrast agent for tumor ablation via PPTT. 
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4.2.1. Introduction 
The plasmonic photothermal therapy (PPTT) treatment of cancer is a burgeoning field 
in medicine, especially with the use of noble metal nanoparticles, since they exhibit 
optical properties that can be exploited for their use as photothermal contrast agents.[1-4] 
The localized surface plasmon, associated with various gold nanostructures, especially 
gold nanorods (AuNRs),[1, 5] can be photo-excited by external radiation with coherent 
laser frequencies to generate local heating around the particle, which is transferred to the 
surrounding environment.[1, 5, 6] The heat generated by externally activating AuNRs is 
specifically useful in the treatment of cancer, since hyperthermia induces tumor tissue 
ablation. [2, 3, 7-14] 
In order for PPTT to be effective in vivo, external radiation must be able to penetrate 
deep into tissues. The most ideal radiation for this application is therefore in the near-
infrared (NIR) region (650-900 nm), where minimal attenuation of water and hemoglobin 
occurs.[3] Since the surface plasmon resonance of the photothermal contrast agent (i.e. 
AuNR) must be coherent with the laser radiation, its shape and composition can be tuned 
in order to achieve NIR surface plasmon resonance.[15-20]  
AuNRs have already shown to have high NIR absorption cross-sections as well as 
high photothermal heat conversion, [11, 21] but efficient PPTT for the suppression of 
tumor growth has mainly only been shown for AuNRs with dimensions of 40 x 10 nm.[9] 
Since we previously showed, both theoretically and experimentally in vitro (see Chapter 
4.1), that the ideal AuNR for the most efficient plasmonic photothermal heat conversion 
has dimensions of 28 x 8 nm, it is imperative that these particles are tested in their ability 
to suppress tumor growth in vivo via PPTT. Therefore, in the present work, we determine 
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the pharmacokinetics as well as the biodistribution of these smaller AuNRs in tumor-
bearing mice, comparing between particles that target cancer of the head and neck and 
non-targeting particles. After assessing their biocompatibility in vivo, the smaller AuNRs 
were utilized as photothermal contrast agents for us in PPTT and demonstrated dramatic 
tumor growth suppression.  
 
4.2.2. Experimental Methods 
4.2.2.1. Gold Nanorod Synthesis and Conjugation 
Relatively small gold nanorods (AuNRs) were synthesized by a seedless growth 
method.[22] In this method, the growth solution was kept at an acidic pH and sodium 
borohydride was added instead of a seed solution, for simultaneous seed formation and 
AuNR growth. To obtain AuNRs with a length of 27 + 4 nm and a width of 8 + 1 nm, as 
shown in Figure 4.8, 300 μL of 0.01 M NaBH4 was prepared and added to an acidic 
growth solution containing 160 μL of 37% HCl, 100 mL of 1.0 mM HAuCl4, 100 mL of 
0.2 M CTAB, 5 mL of 4.0 mM silver nitrate and 1.4 mL of 78.8 mM ascorbic acid. The 
surface plasmon resonance of these AuNRs is around 760 nm (Fig. 4.8). The CTAB-
stabilized AuNRs were purified by centrifugation and redispersed in dI H2O. The 






) is based on previous 
reports.[22] 




Figure 4.8. TEM image (A), size distribution (B), and UV-Vis spectrum (C) of AuNRs 
about 27 nm in length and 8 nm in width, with a surface plasmon resonance around 760 
nm. 
 
To obtain non-targeting AuNRs, the purified AuNRs were functionalized with 
polyethylene glycol (mPEG-SH, MW 5000, Laysan Bio, Inc.) by addition of a 1 mM 
aqueous solution of PEG to the AuNR solution at a ratio of 10,000 PEGs per AuNR and 
left on a shaker overnight, after which, they were centrifuged and redispersed in dI H2O. 
These particles are referred to as PEG-AuNRs. 
To obtain targeting AuNRs, the purified AuNRs were functionalized with PEG and a 
thiol-modified peptide (HNSCP, synthesized by the Oyelere Group at Georgia Tech), 
with a peptide sequence known to specifically target squamous cell carcinoma of the 
head and neck (SCCHN).[23] The peptide structure is shown in Figure 4.9 below. 
Functionalization of AuNRs with PEG and HNSCP was achieved by simultaneous 
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addition of a 1 mM aqueous solution of PEG, at 5000 PEGs per particle, and a 1 mM 
aqueous solution of HNSCP, at 5000 HNSCPs per particle. They were left to shake 
overnight, after which they were centrifuged and redispersed in DI H2O. These particles 
are referred to as HNSCP-AuNRs. 
 
 
Figure 4.9. Structure of HNSCP peptide conjugated to AuNRs for specific targeting of 
squamous cell carcinoma of the head and neck. Peptide provided by Raftery, E. and 
Sotimehin, A. (Georgia Tech). 
 
4.2.2.2. Circulation Half-Life and Biodistribution 
The animal experiments have been approved by the Institutional Animal Care and 
Use Committee (IACUC) of Emory University. The circulation half-life experiments 
were carried out on BALB/c mice, 6-7 weeks of age. The animals, 3 per group, were 
injected via the tail vein with a 200 µl solution of 2.5mg/kg AuNRs. A control group of 3 
mice received saline alone. At specified time points of 5 min, 10, 30 min, 2h, 4, 8, 12, 
24h and 72h, blood (10 µl) was collected from the tail vein in pre-weighed heparinized 
capillary tubes. The blood samples were dissolved with 70% nitric acid and assayed for 
Au mass using ICP-MS. The mass of Au in the blood at different time points was 
calculated, taking into consideration that the blood constitutes 7% of the body weight. 
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Blood circulation half-life was calculated based on a one phase decay model using 
GraphPad Prism Version 6.02 (GraphPad Software, Inc.). 
Biodistribution analysis was carried out on nude mice bearing human SCCHN 
tumors. Tu212 cells (1 х 10
6
) were injected subcutaneously into 4-6-week old nude mice, 
and when the tumors develop to about 150 mm
3
, mice were divided into groups at 
random (3 mice per group) and were then injected via the tail vein with a 200 µl solution 
of 2.5 mg/kg AuNRs. A control group of 3 mice received saline alone (200 µL). At 
specified time points mice (n = 3) were euthanized by pressurized CO2 asphyxiation. 
Blood samples (1000 µl) and other tissues (tumor, liver, spleen, kidney, lung, heart, 
brain, pancreas, stomach, intestine, bladder and muscle) were harvested for tissue 
distribution studies. The mass of Au in the various dried tissues was measured by ICP-
MS. 
4.2.2.3. Tumor Inoculation and Nanorod Injection 
Animal studies have been approved by the Institutional Animal Care and Use 
Committee (IACUC) of Emory University. Tumor inoculation was achieved by 
subcutaneously injecting 1 x 10
6
 Tu212 cells into 4-6 week old female nude mice. When 
the tumors reached about 200 mm
3
, the mice were divided into groups at random for each 
of the different treatment methods (n = 3). Intratumoral injection of either PBS (100 µL) 
or HNSCP-AuNRs (100 µL) was administered 2 min prior to laser exposure. The 
concentration of AuNRs injected into the tumor was adjusted according to the tumor 
volume, in order to achieve an overall AuNR concentration of 2.25 nM within the tumor, 
which was determined by preliminary experiments. 
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4.2.2.4. Near-Infrared (NIR) Laser Exposure 
After the intratumoral injection of HNSCP-AuNRs, or PBS, tumors were 
extracorporeally exposed to NIR cw laser radiation (5.8 W/cm
2
 for 2 min). The different 
treatment methods in this study are as follows: (1) control, 100 µL PBS only, (2) laser 
control, 100 µL PBS followed by 2 min NIR laser exposure, (3) HNSCP-AuNR control, 
100 µL HNSCP-AuNRs only, and (4) HNSCP-AuNR laser treatment, 100 µL HNSCP-
AuNRs followed by 2 min NIR laser exposure. After treatment, the tumor sizes were 
measured twice per week. The tumor volume was calculated using the formula V = 
(width)
2
 x (length/2). The data is displayed as the average tumor volume + standard 
deviation. 
 
4.2.3. Results and Discussion 
Based on our previous observations that the most effective gold nanorod (AuNR) size 
for plasmonic photothermal therapy (PPTT) is around 25 nm in length (see Chapter 4.1), 
we can now determine how effective this size AuNR is in a mouse model, particularly 
utilizing AuNRs that target SCCHN (Tu212 xenografts). In order to achieve targeting of 
SCCHN, AuNRs are conjugated with PEG and an HNSCP peptide (HNSCP-AuNRs) and 
non-targeting AuNRs are conjugated with PEG only (PEG-AuNRs). When transitioning 
from an in vitro model to an in vivo model, many more factors are involved, such as 
pharmacokinetic parameters, uptake of particles by the reticuloendothelial system (RES) 
and tumor accumulation/extravasation. The pharmacokinetic properties of the PEG-
AuNRs and HNSCP-AuNRs were determined by measuring the blood circulation half-
life of the particles in healthy mice. After tail vein injection of the particles, ICP-MS 
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measurements of Au content in the blood were taken at specified time points (0-24 h). 
The experimental data was fit to a one-phase decay. Figure 4.10 displays the blood 
circulation half-life for the PEG-AuNRs is 12.8 h (Fig. 4.10A) and for the HNSCP-
AuNRs is 8.5 h (Fig. 4.10B). 
 
Figure 4.10. Pharmacokinetic properties, in terms of the blood circulation half-life (t1/2) 
in healthy mice. (A) The t1/2 is 12.8 h for PEG-AuNRs and (B) 8.5 h for HNSCP-AuNRs, 
as calculated by fitting the data to a one-phase decay model. Conjugated particles were 
provided by Mackey, M.A. and Ali, M.R.K. (Georgia Tech). Circulation half-life 
measurements were provided by Peng, X. (Emory University). 
 
The decreased circulation half-life observed when functionalizing the AuNRs with 
HNSCP, indicate that blood clearance is increased when a targeting ligand is conjugated 
to the surface of the AuNR, which has been shown previously.[24-26] In addition to the 
circulation half-life, RES uptake and tumor accumulation are also important to assess 
before utilizing these AuNRs as photothermal contrast agents in vivo. Therefore, 
biodistribution in RES organs, as well as other tissues/organs were determined in nude 
  193 
 
mice bearing Tu212 xenografts. Figure 4.11 displays the biodistribution for both PEG-
AuNRs and HNSCP-AuNRs 24 h post tail vein injection.  
 
Figure 4.11. Biodistribution profile of PEG-AuNRs and HNSCP-AuNRs 24 h following 
iv injection to nude mice bearing Tu212 xenografts. (A) Accumulation of AuNRs in 
brain, heart, lung, kidney and tumor. (B) Uptake of AuNRs by RES (i.e. accumulation in 
the liver and spleen). Conjugated particles were provided by Mackey, M.A. and Ali, 
M.R.K. (Georgia Tech). Biodistribution profile was provided by Peng, X. (Emory 
University). 
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The HNSCP-AuNRs exhibit enhanced tumor accumulation when compared with the 
PEG-AuNRs (Fig. 4.11A), as expected. The surface functionalization (targeting vs.non-
targeting) also appears to have an effect on the accumulation of AuNRs in tissues such as 
brain, lung, kidney, and RES organs (liver and spleen). Specifically, the HNSCP-AuNRs 
exhibit a much lower accumulation in the spleen, compared to the PEG-AuNRs. The 
pharmacokinetic parameters and biodistribution profile of the targeting and non-targeting 
AuNRs suggests that the surface functionalization of the AuNRs has an impact on how 
these AuNRs behave in vivo.  
The HNSCP-AuNRs were chosen as the AuNR to be tested as a photothermal 
contrast agent in Tu212 tumor xenografts, due to their established targeting abilities, as 
shown in Figure 4.11. Optimal treatment conditions were established in preliminary 
studies. First, the tumor volume was measured and an HNSCP-AuNR solution (100 µL) 
was prepared from a concentrated stock solution of particles, such that the final 
concentration of these particles within the tumor volume is 2.25 nM. Second, the 
HNSCP-AuNRs were directly injected into the tumor. After 2 min, the tumors were 
extracorporeally exposed to NIR laser radiation at 5.8 W/cm
2
 for 2 min. After laser 
treatment, tumor volumes were measured twice per week for up to 33 days. Figure 4.12 
displays the tumor volume over the course of about 4 weeks, for the various treatments. It 
should be noted that the control, laser control, and HNSCP-AuNR control tumors could 
only be measured up to 16 days, due to tumor size reaching a limit at which animals had 
to be sacrificed. 
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Figure 4.12. Tumor volume measurements with respect to time after treatment of nude 
mice bearing Tu212 xenografts. Control (black) mice (n = 3) were directly injected with 
100 uL of PBS. Laser control (red) mice (n = 3) were directly injected with 100 uL of 
PBS and exposed to NIR radiation (5.8 W/cm
2
, 2 min). HNSCP-AuNR control (blue) 
mice (n = 3) were directly injected with 100 uL of HNSCP-AuNRs, such that final 
concentration in tumor was 2.25 nM. HNSCP-AuNR laser treatment (green) mice (n = 6) 
were directly injected with 100 uL of HNSCP-AuNRs, such that final concentration in 
tumor was 2.25 nM and exposed to NIR radiation (5.8 W/cm
2
, 2 min). Conjugated 
particles were provided by Mackey, M.A. and Ali, M.R.K. (Georgia Tech). Photothermal 
treatment and tumor size were provided by Mackey, M.A. (Georgia Tech) and Peng, X. 
(Emory University). 
  
It is clear from the tumor volume measurements that the HNSCP-AuNR laser 
treatment suppresses tumor growth, such that the tumors disappeared two weeks after 
treatment and complete resorption was observed for up to 33 days. The drastic decrease 
in tumor growth observed for the HNSCP-AuNR laser treatment group is attributed to 
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efficient PPTT-induced hyperthermia. This has been demonstrated in vitro for AuNRs of 
similar size and concentration (see Chapter 4.1), where a rapid increase in temperature 
(after 30 sec laser exposure) is observed. The hyperthermia induced by the 27 nm 
HNSCP-AuNRs after external NIR laser activation dramatically suppresses tumor growth 
by ablating tumor tissue through various disruptions of biochemical processes within in 
the tumor cells, as well as physical destruction of the tumor structure.[27-32] Dickerson, 
et.al. previously demonstrated tumor growth suppression of nude mice bearing HSC-3 
xenografts after PPTT with 40 nm PEG-AuNRs.[9] Specifically, 15 uL (10 nM, optical 
density 40) of 40 nm PEG-AuNRs were directly injected into tumors, followed by 10 min 
NIR laser radiation (1 W/cm
2
). Although in the present work, we irradiate tumors at 5.8 
W/cm
2
, we were able to decrease the laser exposure time to 2 min and still see complete 
tumor growth suppression, without causing severe skin burning, as well as observe tumor 
growth suppression for up to 1 month, as opposed to only 2 weeks. The decrease in laser 
irradiation time is possible, owing to the enhanced photothermal heat conversion 
exhibited by these 27 nm AuNRs, compared to that of the 40 nm AuNRs (see Chapter 
4.1). 
 
4.2.4. Conclusions and Future Outlook 
In conclusion, we have demonstrated the use of a new, smaller AuNR (27 x 8 nm) as 
an efficient photothermal contrast agent in PPTT. These smaller AuNRs can be 
conjugated with non-targeting ligands (PEG-AuNRs) as well as peptides that specifically 
target squamous cell carcinoma of the head and neck (SCCHN) for Tu212 xenograft 
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targeting in vivo (HNSCP-AuNRs). Both PEG-AuNRs and HNSCP-AuNRs are stable in 
vivo, as shown by the 12.8 and 8.5 h blood circulation half-lives, respectively. The two 
different AuNRs exhibit different tumor accumulation and biodistribution profiles, such 
that the HNSCP-AuNRs show higher tumor accumulation and are distributed in the RES 
organs (liver and spleen) differently (higher liver accumulation, lower spleen 
accumulation) than the PEG-AuNRs. Although HNSCP-AuNRs accumulate in the liver 
and spleen after 24 h, they still remain in the circulation long enough to allow for the 
accumulation in the tumor. With the ability for these HNSCP-AuNRs to target Tu212 
xenograft tumors in mice, as well as their size being the most efficient for photothermal 
heat conversion via NIR laser irradiation (see Chapter 4.1), they were tested for their 
efficacy as photothermal contrast agents for the suppression of tumor growth. About 16 
days after directly injecting HNSCP-AuNRs into the tumor and extracorporeally 
irradiating with a NIR cw laser for 2 min (5.8 W/cm
2
), tumors were almost completely 
resorbed, while control tumors continued to increase in volume. Up to 1 month after 
HNSCP-AuNR laser treatment, complete tumor resorption was still evident. Since these 
smaller AuNRs demonstrate such great potential as photothermal contrast agents for the 
clinical photothermal treatment of head and neck cancer, further examination of their 
long-term toxicity within the RES organs should be carried out and compared with the 
toxicity associated with the larger, more conventional AuNRs (40 x 10 nm).  
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APPENDIX A 




Figure A.1. Real time imaging of cancer cells incubated with 0.4 nM cytoplasm targeting 
gold nanoparticles (RGD-AuNPs) (a) and 0.1 nM nuclear targeting gold nanoparticles 
(RGD/NLS-AuNPs) (b) show no apparent cytokinesis arrest. 
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Figure A.2. Cell cycle time of cancer cells and normal cells with treatment of AuNPs. 
The cell cycle of cancer cells was extended by about 4 h with treatment of 0.1 nM 
RGD/NLS-AuNPs; but no changes with RGD-AuNPs treatment. The cell cycle time of 
normal cells have no change under both RGD-AuNPs and RGD/NLS-AuNPs. For cancer 
cells, 0.4 nM RGD/NLS-AuNPs induced cell cycle arrest, which make the whole cell 
cycle observation unavailable. The cell cycle time here is defined from the division of 
parent cells to the division of 2
nd
 generation cells (daughter cells). Four individual cell 
cases were taken for each data point to obtain an average value. The * indicates p < 0.05 
and NS indicates not significant. 
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Figure A.3. Release dynamics of cancer cells (left) and normal cells (right) initially 
synchronized at prometaphase. Cells are synchronized to prometaphase with nocodazole 
and then released in fresh medium. At different time points of release, DNA content was 
measured using flow cytometry. 
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Figure A.4. Apoptosis induced by the presence of AuNPs at the nucleus of cancer cells. 
Cells were incubated with AuNPs for 24 h before analysis. The red box indicates sample 
with subG1 cell population (i.e. apoptotic cells). 






Figure A.5. Cell cycle changes induced by 0.1 and 0.4 nM peptide-conjugated gold 
nanoparticles in HSC cells after 48 h treatment with RGD-AuNSs (A), NLS-AuNSs (B), 
RGD-AuNCs (C) and NLS-AuNCs (D). Values expressed as mean + standard deviation 
of three independent experiments. Statistical significance, with respect to control, 
indicated by * (p < 0.05). 
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Figure A.6. Raw data obtained from flow cytometry cell cycle analysis for all 
nanoparticle treatments tested in this work. Cell cycle histograms, not filled in, represent 
the raw data, including the subG1 population, indicative of an apoptotic population. 
SubG1 populations appear in HSC cells treated with 0.1 nM RGD-AuNC, 0.4 nM RGD-
AuNC, 0.4 nM RGD-AuNS, 0.4 nM NLS-AuNS, 0.4 nM RGD/NLS-AuNS, and the 
greatest subG1 population in 0.4 nM RGD/NLS-AuNC. Cell cycle histograms, filled in, 
represent how the data was fit, after gating single cells and eliminating the subG1 
populations, to obtain G0/G1 (green), S (yellow) and G2/M (blue) phase populations. 
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Figure A.7. Peptide-conjugated gold nanoparticle-induced cell death, via apoptosis (A) 
and necrosis (B), in HSC cells after 48 h treatment with RGD-AuNSs, RGD-AuNCs, 
NLS-AuNSs, and NLS-AuNCs. Values expressed as mean + standard deviation of three 
independent experiments. Statistical significance, with respect to control, indicated by * 






Figure A.8. HaCat cell death via apoptosis (left) and necrosis (right) induced by all 
nanoparticle formulations. All nanoparticle formulations induce minimal cell death in the 
HaCat cells compared with the HSC cells. This was expected, as the HaCat cells do not 
overexpress the alpha beta integrins on their surface.
1
 Values expressed as mean + 
standard deviation of three independent experiments. Statistical significance, with respect 
to control, indicated by * (p < 0.05). 






Figure A.9. ROS generation detected by confocal microscopy for 0.4 nM RGD-AuNCs, 
RGD-AuNSs, NLS-AuNCs, and NLS-AuNSs. DAPI panel (left) shows the nuclei of 
HSC cells stained blue. FITC panel (middle) represents green fluorescence indicative of 
ROS generated inside cells. DAPI/FITC overlay (right) shows the combination of both 
nuclei and ROS. The 0.4 nM RGD-AuNCs and NLS-AuNCs display FITC fluorescence, 











Figure A.10. Uptake analysis of 5-Fluorouracil (5-FU) in HSC-3 cells after cells were 
pre-treated with 15 nm NLS-AuNPs (light gray) or 30 nm NLS-AuNPs (dark gray). 5-FU 
uptake was determined by measuring the optical density (OD) of cell culture medium 
containing 5-FU, after 48 h treatment, with a Biotek Synergy H4 multi-mode plate reader. 





 (determined by measuring various concentrations of 5-FU in 
cell culture medium). This concentration was then subtracted from the treatment 
concentration initially added to cells. Pre-treatment with NLS-AuNPs does not appear to 
enhance the uptake of 5-FU by HSC-3 cells. 
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CHAPTER 4 ADDITIONAL FIGURES 
 
 









Figure B.1. Field contour plots at the resonance wavelength for the longitudinal mode of 
(A) a 38 x 10 nm AuNR at a wavelength of 786.  The field maximum is 5560. (B)A 25 x 
7 nm AuNR at a wavelength of 757 nm.  The field maximum is 5320. (C) An 18 x 4 nm 
AuNR at a wavelength of 865 nm,  The field maximum is 5760.  For all cases, the 
particle dimensions are indicated on the axes and the field has decayed to a value of 1.25 
at the extremities of the plot.  At the resonance condition, there is less than 10% 
difference between the maximum field enhancement values for the different sized AuNR, 
not corresponding to the experimental results. 




MEGAN A. MACKEY 
 
EDUCATION   
 
Georgia Institute of Technology, Atlanta             
Dissertation Completed: August 2013 
PhD, Chemistry and Biochemistry                                                                       
GPA: 3.20 
             
State University of New York at New Paltz, New Paltz, NY                                              
May 2007 
B.A., Chemistry, Minors in Biochemistry and Mathematics                                                    





Georgia Institute of Technology, Atlanta, GA                                            
11/2007-8/2013 
Research Assistant to Dr. Mostafa A. El-Sayed 
 
Nanoparticle synthesis, functionalization and characterization 
 Mastered the synthesis of spherical gold nanoparticles via citrate reduction 
method and rod-shaped gold nanoparticles via seed-mediated growth. 
 Established and carried out methods for functionalizing gold nanoparticles with 
various ligands. 
 Trained and qualified to use TEM, SERS, DLS and optical spectrometers for the 
use of nanoparticle characterization. 
 Served in supervisory roles, including mentoring graduate and undergraduate 
students, visiting scholars and high school students through 
 Training in various laboratory techniques 
 Designing detailed experiment plans 
 
Fundamental studies of the use of various gold nanoparticles in cancer treatment 
 Developed protocols for the testing of gold nanoparticles as anticancer agents. 
 Established a dark-field microscopy method for live-cell imaging of gold 
nanoparticles in cells. 
 Mastered flow cytometry cell cycle analysis to assess the potency of various gold 
nanoparticle cancer treatments. 
 Performed bioassays to detect apoptosis, cytotoxicity and metabolic changes in 
cells upon treatment with various gold nanoparticle composites. 
 Developed, designed, and carried out in vivo studies for the use of gold 
nanoparticles in photothermal therapy. 
  213 
 
 Liased with fellow scientists and medical doctors to assess and enhance clinical 
applications of gold nanoparticles. 
 
State University of New York at New Paltz, New Paltz, NY                                   
05/2005-05/2007 
Undergraduate Research Assistant to Dr. Pamela St. John 
 
 Optimized gel electrophoresis protocols for structural studies of DNA hairpin 
structures. 
 
James Madison University, Harrisonburg, VA                                                          
05/2006-08/2006 
Summer Research Assistant (NSF-REU) to Dr. Debra L. Mohler  
 
 Optimized agarose gel electrophoresis methods to determine DNA cleavage 





General Chemistry Teaching Assistant, Georgia Tech, Atlanta, GA                                       
08/2007-05/2008 
 
 Trained students in analytical techniques and communicated advanced chemical 
concepts. 
 Designed lesson plans for pre-lab and recitation lectures. 
 Assessed student progress through grading laboratory reports. 
 
Physical Chemistry Teaching Assistant, SUNY New Paltz, New Paltz, NY                          
01/2007-05/2007 
  





Women in Chemistry Executive Board, Georgia Tech, Atlanta, GA                                         
01/2011-Present 
 Served an administrative role and mentored female graduate students. 
 Initiated new procedures and policies for the organization through writing the 
Women in Chemistry handbook. 
 Organized a faculty advisory board for the organization to gain support and 
advice from faculty members in the School of Chemistry and Biochemistry. 
 Established a professional development seminar series for graduate and 
undergraduate students.  
  214 
 
 Designed and organized a travel grant fellowship to be awarded to two students in 
the School of Chemistry and Biochemistry each semester. 
 
Graduate Student Forum, Georgia Tech, Atlanta, GA                                                              
05/2008-05/2009 
 
 Organized seminars and various graduate student-specific events for the School of 




15. “Varying the Silver Content of Gold Nanocages Impacts Apoptosis and Necrosis 
Induced in Cancer Cells.” Mackey, Megan A.; Bordley, J.; Mahmoud, M.A.; El-Sayed, 
M.A., in preparation. 
 
14. “Gold Nanoparticle-Sensitized 5-Fluorouracil Treatment of Cancer by Regulation 
of the Cell Cycle.” Mackey, Megan A.; El-Sayed, Mostafa A., in preparation, Cancer 
Letters, 2013. 
 
13. “The Most Effective Gold Nanorod Size for Plasmonic Photothermal Therapy: 
Theory and Experiment.” Mackey, Megan A.; Ali, Moustafa R.K.; Austin, Lauren A.; 
Near, Rachel D.; El-Sayed, Mostafa A., submitted to Journal of Physical Chemistry B, 
2013. 
 
12.  “Antimicrobial Activity of Some Novel Water Soluble Phenazines.” Hayden, 
Steven C.; Bryant, Jonny B.; Mackey, Megan A.; Hofer, Katharina; Lindner, Benjamin; 
Nguyen, Vanessa P.; Jaschke, Andres; Bunz, Uwe H.F., submitted to JACS, 2013. 
 
11. “Surface Enhanced Raman Spectroscopy for the Real Time Monitoring of 
Molecular Events Associated with Reactive Oxygen Species-Induced DNA Damage and 
its Prevention by Platinum Nanocages.” Panikkanvalappil, Sajanlal; Mackey, Megan 
A.*; Mahmoud, Mahmoud A.*; El-Sayed, Mostafa A., under review, ACS Nano, 2013.  
*equal contributions 
 
10. “XAV939: From a Small Inhibitor to a Potent Drug Bioconjugate When 
Delivered by Gold Nanoparticles.” Afifi, Marwa A.; Mackey, Megan A.*; Austin, 
Lauren A.*; El-Sayed, Mostafa A., under review, Bioconjugate Chemistry, 2013. 
*equal contributions 
 
9.  “Inducing Cancer Cell Death by Targeting Its Nucleus: Solid Gold Nanospheres 
versus Hollow Gold Nanocages.” Mackey, Megan A.; Farhat Saira; Mahmoud, 
Mahmoud A.; El-Sayed, Mostafa A., Bioconjugate Chemistry, 2013, 24, 897-906. 
 
8. “Probing the Unique Dehydration-Induced Structural Modifications in Cancer 
Cell DNA using Surface Enhanced Raman Spectroscopy.” Panikkanvalappil, Sajanlal; 
  215 
 
Mackey, Megan A; El-Sayed, Mostafa A., JACS Communications, 2013, 135, 4815-
4821. 
 
7. “Size Matters: Gold Nanoparticles in Targeted Cancer Drug Delivery”. Dreaden, 
Erik C.; Austin, Lauren A.; Mackey, Megan A.; El-Sayed, Mostafa A. Therapeutic 
Delivery, 2012, 3, 457-478. 
 
6. “Remote Triggered Release of Doxorubicin in Tumors by Synergistic Application 
of Thermosensitive Liposomes and Gold Nanorods.” Agarwal, Abhiruchi; Mackey, 
Megan A.; El-Sayed, Mostafa A.; Bellamkonda, Ravi V. ACS Nano, 2011, 5, 4919-4926. 
 
5. “Beating Cancer in Multiple Ways Using Nanogold.” Dreaden, Erik C.; Mackey, 
Megan A.; Huang, Xiaohua; Kang, Bin; El-Sayed, Mostafa A. Chemical Society 
Reviews, 2011, 40, 3391-3404. 
 
4. “A comparative study of photothermolysis of cancer cells with nuclear-localized 
or cytoplasm-distributed gold nanoparticles: Continuous wave or pulsed lasers.” Huang, 
Xiaohua; Kang, Bin; Qian, Wei; Mackey, Megan A.; Chen, Po; Oyelere, Adegboyega; 
El-Sayed, Ivan; El-Sayed, Mostafa A. Journal of Biomedical Optics, 2010, 15 (5). 
 
3. “Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, 
causing cytokinesis arrest and apoptosis.” Mackey, Megan A.*; Kang, Bin*; El-Sayed, 
Mostafa A. JACS Communications, 2010, 132, 1517-1519. 
*equal contributions 
 
2. “Formal DNA Hydrolysis by Mono- and Dinuclear Iron Complexes.” Shell, 
Thomas A.; Glass, Jessica E.; Mackey, Megan A.; Layman, Kathryn A.; Mohler, Debra 
L. Inorganic Chemistry, 2007, 46, 8120-8122. 
 
1. “Increase in Hybridization Rates with Oligodeoxyribonucleotides Containing 
Locked Nucleic Acids.” Ormond, Thomas K.; Spear, Daniel; Stoll, Jacqueline; Mackey, 
Megan A.; St. John, Pamela M.   Journal of Biomolecular Structure and Dynamics, 




8. “Gold Nanoparticle-Induced Cell Death: Solid Gold Nanospheres versus Hollow 
Gold Nanocages.” American Chemical Society National Meeting (April 2013) New 
Orleans, Louisiana. 
 
7. “The Effects of Size and Surface Coating of Gold Nanorods on Biodistribution 
and Associated Toxicity in Mouse Models.” National Cancer Institute Alliance for 
Nanotechnology in Cancer Meeting (November 2012) Houston, Texas. 
 
  216 
 
6. “Biodistribution and Antitumor Efficacy of Tumor-Targeted Gold Nanorods in a 
Mouse Model.” National Cancer Instititute Alliance for Nanotechnology in Cancer 
Meeting (November 2012) Houston, Texas. 
 
5. “Gold Nanoparticle-Induced Apoptosis in Cancer: Nanoparticle Shape 
Dependence.” Georgia Life Sciences Summit (September 2011) Atlanta, Georgia. 
 
4. “Inducing Programmed Cancer Cell Death with Nuclear-Localizing Gold 
Nanoparticles: Nanoparticle Shape Dependence.” American Chemical Society National 
Meeting (August 2011) Denver, Colorado. 
 
3. “Potential for Nuclear Localization of Gold Nanoparticles in Cancer Therapy.” 
Georgia Life Sciences Summit (October 2010) Atlanta, Georgia. 
 
2.  “Nuclear Targeting of Gold Nanoparticles in Cancer Cells.” Invited talk. State 
University of New York (April 2010) New Paltz, New York. 
 
1. “Nuclear Targeting of Gold Nanoparticles in Cancer Cells Induces DNA Damage, 
Causing Cytokinesis Arrest and Apoptosis.” Integrative BioSystems Institute (IBSI) 





American Chemical Society                                        
08/2011-Present 






Mammalian Cell Culture                  Microplate Assay Techniques                                                                                       
Flow Cytometry                  Laser Scanning Confocal Fluorescence Microscopy 
SDS PAGE                                            Agarose gel electrophoresis 
In vitro and in vivo Laser-Ablative Therapeutics 
                       
 
Colloidal Noble Metal Nanoparticle Synthesis                                      Optical Microscopy                                                                                 
Colloidal Bio-Conjugation Techniques                                              UV-Vis Spectroscopy                                  
Surface-Enhanced Raman Spectroscopy                                             Raman Spectroscopy 
Dynamic Light Scattering                                              Transmission Electron Microscopy 
     
 
 
